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Abstract	  The	   endothelial	   to	   hematopoietic	   transition	   (EHT)	   is	   a	   key	   developmental	   event	  leading	   to	   the	   formation	   of	   blood	   stem	   and	   progenitor	   cells	   during	   embryogenesis.	   A	  small	   subset	   of	   cells	   called	   hemogenic	   endothelial	   cells	   (HE)	   undergoes	   the	   EHT	   by	  becoming	   pre-­‐hematopoietic	   stem	   and	   progenitor	   cells	   (Pre-­‐HSPC).	   Eventually	   after	  losing	  all	  their	  endothelial	  characteristics	  they	  become	  HSPC.	  Despite	  extensive	  studies	  on	   this	   process,	   there	   are	   several	   questions	   remaining:	   What	   are	   the	   differences	  between	   hemogenic	   and	   non	   hemogenic	   endothelial	   cells?	   How	   different	   is	   the	   EHT	  process	   in	   the	   aorta-­‐gonad-­‐mesonephros	   (AGM)	   generating	   mostly	   blood	   stem	   cells	  (self-­‐renewing	   and	   generating	   all	   cell	   types)	   and	   the	   yolk	   sac	   (YS)	   producing	   mostly	  blood	  progenitors	  (non	  self-­‐renewing	  and	  generating	  only	  a	  few	  cell	  types)?	  To	  address	  these	  questions,	  I	  used	  single	  cell	  transcriptomics	  because	  of	  the	  scarcity	  of	  the	  HE	  and	  the	  Pre-­‐HSPC	  within	  the	  endothelial	  population	  in	  the	  AGM	  and	  YS.	  I	  examined	  the	  cells	  isolated	  at	  E9.0,	  E10.5	  and	  E11.0	  mouse	  embryos.	   I	  showed	  that	   the	  major	  endothelial	  population	  of	  AGM	  and	  YS	  is	  different	  from	  each	  other,	  which	  might	  be	  linked	  with	  their	  distinct	   hematopoietic	   program.	   I	   showed	   that	   the	   pre-­‐HSPC	   in	   AGM	   and	   YS	   are	  transcriptionally	   alike	   suggesting	   that	   the	   different	   hematopoietic	   program	   between	  AGM	   and	   YS	   could	   be	   due	   to	   the	   microenvironment.	   Additionally,	   I	   identified	   a	   new	  population	  detected	  only	  in	  YS	  at	  E10.5	  co-­‐expressing	  endothelial	  and	  erythroid	  genes.	  
The	   molecular	   mechanism	   of	   the	   EHT	   is	   still	   not	   understood.	   Since	   the	   TGFβ	  signaling	   triggers	   a	   similar	   event	   during	   heart	   development	   called	   endothelial	   to	  mesenchymal	   transition	   (EndMT),	   we	   hypothesized	   that	   TGFβ	   activity	   may	   play	   a	  similar	   role	   in	   EHT.	  When	   I	   activated	   the	   TGFβ	   signaling	   by	   adding	   TGFβ2	   during	   in	  vitro	  EHT	  differentiation,	  I	  observed	  surprisingly	  a	  complete	  block	  of	  the	  hematopoiesis.	  When	   I	   inhibited	   it	   by	   adding	   the	   Tgfbr1	   inhibitor,	   it	   enhanced	   blood	   development.	  	  Additionally,	   the	  mRNA	  profile	  of	   the	   treated	  cells	   confirmed	   that	   inhibition	  of	  Alk5	   is	  promoting	  the	  EHT,	  while	  the	  TGFβ	  activation	  results	  in	  cells	  with	  a	  phenotype	  closer	  to	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Zusammenfassung	  Die	  endotheliale-­‐hämatopoetische	  Transition	  (EHT)	   ist	  ein	  Schlüsselereignis	   in	  der	  Embryonalentwicklung,	  das	  zur	  Bildung	  von	  Blutstamm-­‐und	  Vorläuferzellen	  führt.	  Eine	  kleine	  Gruppe	  von	  Zellen,	  hämogene	  Endothelzellen	  (HE),	  durchläuft	  die	  EHT,	  in	  der	  sie	  sich	   zu	   prä-­‐hämatopoetischen	   Stamm-­‐und	   Vorläuferzellen	   (prä-­‐HSVZ)	   entwickeln.	  Nachdem	   sie	   alle	   Endotheleigenschaften	   verloren	   haben,	   gehen	   aus	   diesen	   Zellen	  schließlich	  die	  HSVZ	  hervor.	  Trotz	  intensiven	  Arbeiten	  auf	  diesem	  Gebiet	  sind	  noch	  viele	  Fragen	   offen.	   Was	   sind	   die	   Unterschiede	   zwischen	   den	   hämogenen	   und	   nicht	  hämogenen	   Endothelzellen?	   Wie	   unterscheidet	   sich	   die	   EHT	   in	   der	   Aorta-­‐Gonade-­‐Mesonephros	  Region	   (AGM-­‐Region),	   die	  hauptsächlich	  Blutstammzellen	   generiert,	   von	  der	  im	  Dottersack,	  die	  überwiegend	  Blutvorläuferzellen	  hervorbringt?	  Um	  diese	  Fragen	  zu	   beantworten	   wurden	   die	   Transkriptome	   einzelner	   Endothelzellen	   aus	   der	   AGM-­‐Region	   sowie	  des	   	  Dottersacks	  untersucht.	  Diese	  Zellen	  wurden	  vorher	   aus	  9-­‐11	  Tage	  alten	  Mausembryonen	   isoliert.	  Mit	   dieser	   Arbeit	   konnte	   gezeigt	  werden,	   dass	   sich	   die	  Endothelpopulationen	   der	   AGM-­‐Region	   und	   des	   Dottersacks	   unterscheiden,	   was	   mit	  dem	   unterschiedlichen	   hämatopoetischen	   Programm	   in	   Verbindung	   gebracht	   werden	  könnte.	   Dagegen	   sind	   prä-­‐HSVZ	   aus	   der	   AGM-­‐Region	   und	   vom	   Dottersack	  transkriptionell	   ähnlich,	   was	   darauf	   hinweist,	   dass	   die	   unterschiedlichen	   Programme	  der	   Zellen	   zwischen	   der	   AGM-­‐Region	   und	   des	   Dottersacks	   auf	   einen	   Effekt	   der	  Mikroumgebung	   zurückzuführen	   sein	   könnte.	   Darüber	   hinaus	   konnte	   eine	   neue	  Zellpopulation	   identifiziert	   werden,	   die	   nur	   im	   Dottersack	   von	   10,5	   Tage	   alten	  Embryonen	  zu	  finden	  ist	  und	  endotheliale	  sowie	  erythroide	  Gene	  co-­‐exprimiert.	  	  
Der	  molekulare	  Mechanismus	  der	  EHT	  ist	  noch	  nicht	  geklärt.	  Da	  der	  TGFβ	  Signalweg	  einen	   ähnlichen	   Vorgang	  während	   der	  Herzentwicklung,	   die	   sogenannte	   endotheliale-­‐mesenchymale	   Transition	   (EndMT)	   steuert,	   haben	   wir	   eine	   vergleichbare	   Rolle	   von	  TGFβ	   in	   der	   EHT	   vermutet.	   Jedoch	   führte	   die	   Aktivierung	   des	   TGFβ	   Signalweges	   in	  einem	   in	   vitro	   EHT	   Modell	   überraschenderweise	   zu	   einer	   kompletten	   Hemmung	   der	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Hämatopoese.	   Die	   Inhibition	   dagegen	   begünstigte	   die	   Blutbildung.	   Das	   Transkriptom	  der	   behandelten	   Zellen	   bestätigte	   zusätzlich,	   dass	   die	   Inhibition	   von	   Alk5	   die	   EHT	  fördert,	   wohingegen	   die	   Aktivierung	   TGFβ	   Signalweges	   in	   Zellen	   resultiert,	   deren	  Phänotyp	  denen	  von	  Herz-­‐	  und	  mesenchymalen	  Zellen	  ähnelt.	  Obwohl	  EndMT	  und	  EHT	  zu	  einem	  Verlust	  der	  Endothelzellidentität	  und	  der	  Bildung	  von	  mobilen	  Zellen	  führen,	  zeigt	  unsere	  Studie	  somit,	  dass	  die	  zu	  Grunde	  liegenden	  Signalprozesse	  unterschiedlich	  voneinander	  sind.	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Chapter1:	  Introduction	  
1. Why	  studying	  blood	  cell	  development	  is	  important	  A	  single	  cell	  needs	  to	  have	  continuous	  uptake	  of	  nutrients	  and	  export	  of	  metabolites.	  For	  organisms	  like	  Hydra,	  with	  simple	  two	  cell	  layers,	  nutrient	  transportation	  does	  not	  require	  a	  specialized	  circulatory	  system.	  However,	  for	  bilateria	  animals	  with	  three	  germ	  layers	   (tripoblastic)	   and	   complex	   tissue	   structure,	   osmosis	   would	   not	   be	   enough	   to	  support	   each	   and	   every	   cell’s	   needs.	   Development	   of	   blood	   system	   in	   vertebrates	  fulfilled	  the	  need	  of	  each	  cell	  regardless	  of	  the	  organism	  size	  and	  complexity.	  
The	   development	   of	   vertebrates	   begins	   with	   the	   fertilization	   of	   egg	   with	   sperm,	  forming	  the	  first	  totipotent	  cell,	  the	  zygote.	  The	  zygote	  goes	  through	  consecutive	  mitotic	  divisions,	  which	   is	   followed	  by	  the	  organization	  of	  cells	   to	   form	  tissues.	  As	  a	  cluster	  of	  cells	  at	  the	  blastocyst	  stage,	  each	  cell	  can	  uptake	  their	  nutrients	  from	  the	  environment,	  so	  would	  not	  need	  a	  blood	  system.	  Later	  during	  embryogenesis,	  where	  the	  cell	  number	  increase	  dramatically	  in	  a	  short	  time	  and	  the	  inside	  of	  embryo	  is	  hypoxic,	  how	  does	  the	  each	   cell	   of	   a	   developing	   organism	   take	   the	   nutrients	   and	   oxygen	   inside?	   Before	  development	  of	  any	  other	  organ	  systems,	  to	  fulfill	  the	  nutrient	  and	  oxygen	  need	  of	  every	  cell,	  the	  development	  of	  blood	  system	  is	  required.	  
Regarding	  the	  vital	  role	  of	  blood	  system	  in	  sustaining	  vertebrate	  organism	  since	  the	  beginning	  of	  its	  development,	  any	  kind	  of	  defect	  or	  absence	  of	  blood	  cell	  leads	  to	  mostly	  deadly	   diseases	   in	   human.	   Answering	   how	   blood	   cells	   are	   generated	   is	   not	   only	  important	   for	   general	  developmental	   biology	  knowledge	  but	   also	  bears	  keys	   to	  use	   in	  treatments	  of	  hematopoietic	  disorders.	  Current	  technology	  is	  facilitating	  the	  production	  of	  various	  cell	  types,	  such	  as	  adipocytes,	  chondrocytes,	  myocytes	  in	  in	  vitro	  conditions,	  ultimately	   aiming	   at	   using	   them	   for	   therapeutic	   transplantation	   into	   humans.	  Knowledge	  about	  mouse	  embryonic	  hematopoiesis	  would	  have	  enormous	  contributions	  to	   the	   improvement	   of	   in	   vitro	   production	   of	   blood	   cells.	   Particularly	   in	   vitro	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hematopoietic	  stem	  cell	  (HSC)	  production	  by	  using	  someone’s	  own	  cell	  would	  open	  a	  big	  window	  by	  eliminating	  search	  for	  a	  matching	  donor.	  
2. Ontogeny	  of	  blood	  system:	  Where	  does	  the	  first	  blood	  cell	  come	  from?	  
2.1. First	  observations	  and	  hemangioblast	  hypothesis	  Where	   are	   the	   first	   blood	   cells	   generated?	   The	   answer	   to	   that	   question	   came	   in	  1920s,	   from	  the	  first	  observation	  made	  in	  chick	  embryos.	  Florence	  Sabin	  hypothesized	  the	   presence	   of	   a	   mesoderm	   origin,	   common	   precursor	   for	   blood	   and	   vascular	  endothelial	  lineages	  (Sabin,	  1921).	  	  She	  named	  that	  precursor	  cell	  	  ‘angioblast’.	  In	  1932,	  P.	   Murray	   cultured	   ex	   vivo	   the	   sections	   of	   primitive	   streak	   of	   chick	   embryos	   and	  supported	  Sabin’s	  hypothesis,	  by	  renaming	  the	  common	  progenitor	  of	  blood	  vessels	  and	  primitive	  blood	  cells	  as	  ‘hemangioblasts’	  for	  the	  first	  time	  (Murray,	  1932).	  	  
Inactivation	   of	   one	   gene	   in	   mouse	   development	   is	   a	   powerful	   technique	   to	  understand	  the	  function	  of	  that	  gene.	  Regarding	  the	  questions	  about	  the	  cellular	  origins	  of	  hematopoietic	  system,	  several	  gene	  knockout	  mice	  with	  both	  defective	  vascular	  and	  hematopoietic	   system	  phenotype	   took	   attention.	   If	   a	   disruption	  of	   one	   gene	   results	   in	  malformation	  of	  two	  distinct	  cell	  types,	  it	  may	  mean	  that	  these	  two	  cell	  types	  are	  used	  to	  share	   a	   common	   precursor	   cell.	   There	   are	   several	   examples	   of	   such	   gene	   knockout	  studies.	  As	   an	  example	   inactivation	  Flk-­‐1,	   as	   a	   gene	  used	   to	  be	   considered	  endothelial	  specific,	   it	   surprisingly	   leads	   to	   failure	   in	  hematopoiesis	  as	  well	  as	  vasculogenesis	  and	  embryonic	  lethality	  at	  E8.5-­‐9.5	  (Shalaby	  et	  al.,	  1995).	  Similarly,	  Scl/Tal1	  mutation	  leads	  to	   embryonic	   lethality	   at	   E9.5-­‐10.5	   due	   to	   disruption	   of	   both	   endothelial	   and	  hematopoietic	   lineages	   (Robb	  et	  al.,	  1995;	  Shivdasani,	  Mayer,	  &	  Orkin,	  1995).	  Another	  study	  showed	  that	  the	  lack	  of	  Tal1	  in	  the	  endothelium	  leads	  to	  the	  ectopic	  activation	  of	  the	  cardiac	  program	  in	  endothelial	  cells	  (Van	  Handel	  et	  al.,	  2012).	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2.2. Advances	  in	  mouse	  embryonic	  stem	  cell	  techniques	  Although	   there	   were	   several	   observations	   supporting	   the	   existence	   of	  hemangioblasts,	   direct	   experiment	   on	   those	   cells	  were	   technically	   challenging.	   Firstly,	  there	   was	   no	   marker	   to	   locate	   a	   hemangioblast	   cell	   within	   mesoderm	   layer	   during	  embryonic	   development.	   Secondly,	   even	   if	   it	   would	   be	   possible	   to	   identify	  hemangioblasts	   among	   all	   the	   other	   mesodermal	   cells,	   studying	   their	   in	   vivo	  differentiation	  steps	  would	  be	  difficult	  due	  to	  the	   limited	   imaging	  techniques	  available	  for	  mouse	  embryogenesis	  at	  that	  time.	  Nevertheless	  these	  challenges	  were	  overtaken	  by	  the	  embryonic	  stem	  cell	  differentiation	  system.	  
2.2.1. mES	  cell	  differentiation	  system	  as	  in	  vitro	  model	  of	  hematopoiesis	  
2.2.1.1. Use	  of	  mouse	  ES	  cells	  as	  a	  technique	  to	  study	  development	  At	   the	   blastocyst	   stage	   of	   mouse	   embryo	   the	   inner	   cell	   mass	   cells	   is	   shown	   to	  generate	  teratocarcinoma,	  a	  type	  of	  tumor	  composed	  of	  cells	  from	  mesoderm,	  endoderm	  and	  ectoderm	  origin	  cells(Stevens,	  1970).	  The	  potential	  of	  this	  cell	  to	  differentiate	  into	  three	   germ	   layers	   is	   called	   pluripotency,	   which	   took	   immediate	   attention	   for	   in	   vitro	  differentiation	   studies	   to	   produce	   tissues	   and	   organs	   in	   culture	   conditions.	   The	   big	  obstacle	  was	  to	  expand	  those	  pluripotent	  cells	  derived	  from	  blastocyst,	  while	  preserving	  their	  pluripotency	  and	  prevent	   their	  differentiation	   towards	  any	   lineage.	   In	  1981,	   two	  groups	   almost	   simultaneously	   published	   two	   papers,	   describing	   how	   to	   culture	  blastocyst	   derived	   mouse	   embryonic	   stem	   cells	   (mESCs)	   (Evans	   &	   Kaufman,	   1981;	  Martin,	  1981).	  Afterwards	  the	  first	  successful	  attempt	  to	  create	  chimeric	  mouse	  by	  using	  these	   mESCs	   demonstrated	   the	   capacity	   of	   these	   cells	   to	   contribute	   to	   the	   germ	   line	  (Bradley,	  Evans,	  Kaufman,	  &	  Robertson,	  1984).	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2.2.1.2. Establishment	  of	  hematopoiesis	  differentiation	  protocol	  
development	  In	   vitro	   mESC	   culture	   and	   differentiation	   towards	   several	   cell	   fates	   become	   an	  epoch-­‐making	  technique	  for	  developmental	  biology	  and	  yet	  provided	  an	  ideal	  method	  to	  study	   hematopoietic	   lineage	   tracing.	   In	   general	   three	   types	   of	   in	   vitro	   differentiation	  protocols	  towards	  mesoderm	  were	  developed:	  differentiation	  in	  embryoid	  bodies	  (EBs),	  differentiation	   on	   stromal	   cell	   line,	   or	   differentiation	   on	   a	   plate	   coated	   with	   ECM	  proteins	   (G.	   M.	   Keller,	   1995;	   Smith,	   2001).	   Especially	   with	   embryoid	   body	   culture	  appearance	  of	  hemoglobinized	  red	  blood	  cells	  (erythrocytes)	  at	  day	  5	  of	  EB	  culture	  was	  evident	   (Doetschman,	   Eistetter,	   Katz,	   Schmidt,	   &	   Kemler,	   1985).	   Several	   groups	   also	  study	  hematopoietic	  differentiation	  in	  culture	  condition	  (Burkert,	  von	  Rüden,	  &	  Wagner,	  1991;	  G.	  Keller,	  Kennedy,	  Papayannopoulou,	  &	  Wiles,	  1993;	  Nakano,	  Kodama,	  &	  Honjo,	  1994;	   Schmitt,	   Bruyns,	  &	   Snodgrass,	   1991;	  Wiles	  &	  Keller,	   1991).	   The	   embryoid	  body	  culture	   and	   other	   in	   vitro	   differentiation	   techniques	   were	   further	   refined	   to	   enhance	  hematopoietic	  lineage	  choice	  (Faloon	  et	  al.,	  2000;	  G.	  Keller	  et	  al.,	  1993).	  
2.3. Identifying	  hemangioblast	  in	  vitro	  and	  in	  vivo	  
2.3.1. Hemangioblast	  like	  cells	  found	  in	  in	  vitro	  differentiation	  Several	  decades	  after	  Florence	  Sabin’s	  observations,	  with	  the	  advancement	  of	  mESC	  in	  vitro	  differentiation	  system,	  the	  presence	  of	  hemangioblast	  cells	  was	  investigated.	  At	  day4	  of	  EB	  differentiation,	  primitive	  erythroid	  cells	  are	  generated	  (G.	  Keller	  et	  al.,	  1993).	  When	  the	  precursor	  of	  these	  primitive	  erythroid	  cells	  are	  isolated	  from	  EBs	  at	  day3,	  it	  is	  found	  to	  be	  giving	  rise	  to	  definitive	  erythroid,	  myeloid	  and	  multi-­‐lineage	  progenitors.	  This	  gives	  the	  first	  results	  to	  support	  a	  common	  precursor	  (blast	  colony	  forming	  cells	  BL-­‐CFC)	  idea	  for	  both	  primitive	  and	  definitive	  hematopoiesis	  (Kennedy	  et	  al.,	  1997).	  Further	  study	  with	  the	  same	  BL-­‐CFCs	  isolated	  from	  EBs,	  suggested	  that	  they	  might	  be	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the	  hemangioblast	  cells,	  previously	  hypothesized	  (Choi,	  Kennedy,	  Kazarov,	  Papadimitriou,	  &	  Keller,	  1998).	  	  Development	  of	  Brachyury-­‐GFP	  ES	  cells	  enabled	  researchers	  to	  follow	  Brachyury+	  cells	  through	  its	  differentiation,	  and	  suggests	  Flk-­‐1+,	  Brachyury+	  cells	  can	  give	  rise	  to	  endothelial,	  hematopoietic	  cells,	  therefore	  Bra+,	  Flk-­‐1+	  can	  be	  the	  marker	  of	  BL-­‐CFC	  (Fehling	  et	  al.,	  2003).	  
2.3.2. Hemangioblast	  like	  cells	  found	  in	  vivo	  yolk	  sac	  The	  in	  vivo	  counterpart	  of	  BL-­‐CFC	  is	  soon	  identified	   in	  gastrulating	  mouse	  embryo	  as	   the	   mesodermal	   Flk-­‐1+,	   Brachyury+	   cells,	   which	   can	   differentiate	   to	   vascular	  endothelial	  and/or	  hematopoietic	  cells	   in	  vitro	  conditions.	  Hemangioblasts	  are	   located	  mostly	   at	   the	   posterior	   primitive	   streak	   of	   E7.5	   mouse	   embryos,	   which	   suggests	   a	  migration	   towards	   yolk	   sac	   and	   form	   the	   first	   blood	   cells	   surrounded	   by	   vascular	  endothelial	  cells,	  so	  called	  blood	   islands	  at	  stage	  E8	  (Huber,	  Kouskoff,	  Fehling,	  Palis,	  &	  Keller,	  2004).	  
2.4. Yolk	  Sac	  as	  the	  first	  hemogenic	  site	  
2.4.1. First	  observations	  of	  yolk	  sac	  hematopoiesis	  Alexander	  Maximow	  first	  observed	  the	  primitive	  blood	  cells	  characterized	  by	  their	  red	   color	   within	   chick	   embryos	   in	   1909	   and	   later	   by	   Florence	   Sabin	   in	   1921	   (Sabin,	  1921).	  	  	  They	  named	  that	  particular	  structure	  of	  the	  clusters	  of	  blood	  cells	  encapsulated	  by	   the	   vascular	   endothelial,	   as	   blood	   islands	   of	   yolk	   sac,	   although	  we	   currently	   know	  that	  it	  is	  more	  like	  a	  ring	  of	  vessel	  structure	  surrounding	  blood	  cells.	  
2.4.2. Stages	  of	  hematopoietic	  progenitors	  rising	  from	  YS	  Similar	  to	  chick,	  the	  first	  hematopoietic	  cells	  in	  mouse	  embryo	  are	  arising	  from	  yolk	  sac	  mesoderm	   at	   the	   neural	   plate	   stage	   of	  mouse	   embryo	   of	   E7.5	   (Haar	  &	  Ackerman,	  1971).	   These	   first	   hematopoietic	   cells	   were	   primitive	   erythrocytes	   with	   nucleus	   and	  expression	  of	  embryonic	  hemoglobin.	  However	  these	  primitive	  erythrocyte	  progenitors	  (EryP)	  are	  transient,	  only	  within	  E7	  and	  E9,	  cannot	  be	  detectable	  after	  E9.	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After	   the	   primitive	   erythrocytes,	   a	   precursor	   of	   definitive	   erythrocyte	   progenitors	  (BFU-­‐E)	  arises	  in	  the	  yolk	  sac.	  The	  definitive	  erythroid	  progenitors	  are	  found	  as	  early	  as	  E8.25	   of	   mouse	   embryos,	   before	   circulation.	   Unlike	   primitive	   erythroid	   progenitors,	  definitive	   erythroid	   progenitors	   give	   rise	   to	   enucleated,	   βmajor	   globin	   expressing	  erythrocytes.	  
The	   wave	   of	   definitive	   erythroid	   progenitors	   is	   followed	   by	   the	   emergence	   of	  myeloid/erythroid	   progenitors	   starting	   from	   E9.5	   of	   mouse	   embryo.	   Although	   the	  contractions	   of	   the	   heart	   started	   at	   E8.5	   (McGrath,	   Koniski,	  Malik,	   &	   Palis,	   2003)	   and	  some	   of	   these	   progenitors	   are	   detected	   in	   the	   blood	   stream	   and	   embryo	   proper,	   the	  majority	  of	  the	  progenitors	  are	  in	  the	  yolk	  sac	  at	  E9.5.	  Those	  progenitors	  later	  give	  rise	  to	  definitive	  erythrocytes,	  macrophages,	  mast	  cells,	  and	  granulocytes.	  
Despite	   early	   argument	   about	   incapability	   of	   yolk	   sac	   derived	   hematopoietic	  progenitor	   to	   differentiate	   into	   lymphoid	   cells,	   recent	   studies	   proves	   that	   argument	  wrong.	  When	   the	   hematopoietic	   progenitors	   from	   yolk	   sac	   are	   pulse	   labeled	   at	   E7.5,	  before	   the	   intra-­‐embryonic	   hematopoiesis	   start	   and	   traced	   afterwards,	   the	   lymphoid	  progenitors	   derived	   from	   yolk	   sac	   is	   detected	   in	   the	   fetal	   liver	   and	   adult	   mouse	  (Samokhvalov,	  Samokhvalova,	  &	  Nishikawa,	  2007).	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Figure	  1.0.1	  The	  YS	  hematopoiesis	  starting	  at	  E7.5.	  The	  top	  left	  image	  depicts	  the	  series	  of	  cell	  
differentiation	  events	  with	  regards	  to	  cell	  locations	  and	  their	  direction	  of	  migration	  during	  
differentiation.	  The	  cells	  shown	  below	  is	  to	  give	  the	  detailed	  cell	  identity	  and	  markers,	  found	  based	  
on	  the	  mESC	  and	  mouse	  YS	  studies.	  The	  differentiation	  scheme	  is	  drawn	  based	  on	  the	  model	  
(Lancrin	  et	  al.,	  2010)	  	  
2.5. Aorta	  Gonad	  Mesonephros	  as	  the	  main	  intra-­‐embryonic	  hemogenic	  site	  
2.5.1. First	  experiments	  for	  intra-­‐embryonic	  origin	  of	  hematopoiesis	  While	   yolk	   sac	   is	   known	   to	  be	   the	   site	   of	   hematopoietic	   origin,	   that	  perspective	   is	  changed	  for	  the	  first	  time	  when	  F.	  Dieterlen-­‐lievre	  grafted	  embryo	  of	  quail	   into	  chick’s	  yolk	   sac	   and	   observed	   all	   adult	   hematopoietic	   cells	   were	   of	   quail	   origin	   (Dieterlen-­‐Lievre,	   1975).	   That	   experiment	   clearly	   shows	   the	   intra-­‐embryonic	   origin	   of	   the	   adult	  avian	   hematopoiesis.	   Further	   support	   to	   understand	   yolk	   sac	   and	   intra-­‐embryonic	  hematopoiesis	  came	  from	  the	  same	  group	  (Beaupain,	  Martin,	  &	  Dieterlen-­‐Lièvre,	  1979;	  Lassila,	   Martin,	   Toivanen,	   &	   Dieterlen-­‐Lièvre,	   1982).	   Studies	   of	   frog	   embryos	   also	  supported	   the	   two	   types	  of	  hematopoiesis	  depending	  on	   the	  site	   (Turpen,	  Knudson,	  &	  Hoefen,	  1981).	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The	   intra-­‐embryonic	   origin	   of	   hematopoiesis	   of	   zebrafish	   is	   identified	   at	   14hpf	   in	  posterior	   lateral	  mesoderm	  and	   the	  mouse	   equivalent	   of	   this	  would	  be	   the	  paraaortic	  splanchnopleura	   (PsP)	   at	  E8.5	   embryo.	  PsP	   is	  differentiating	   later	   in	   the	  development	  towards	  a	  region	  named	  as	  aorta-­‐gonad	  mesonephros	  (AGM)	  due	  to	  its	  differentiation	  to	  form	  the	  dorsal	  aorta	  and	  the	  urogenital	  system.	  
2.5.2. Hematopoietic	  Stem	  Cell	  emergence	  from	  AGM	  Hematopoietic	  stem	  cell	  (HSC),	  by	  definition,	  is	  a	  cell,	  which	  can	  generate	  itself	  and	  at	   the	   same	   time	   differentiate	   into	   all	   erythroid,	  myeloid	   and	   lymphoid	   blood	   cells	   to	  produce	  the	  complete	  blood	  system	  throughout	  the	  life	  of	  a	  mouse.	  To	  test	  pluripotency	  capacity	   of	   an	   HSC,	   a	   classical	   but	   robust	   experiment	   is	   to	   inject	   the	   cells	   into	   an	  irradiated	   adult	   mouse	   and	   test	   the	   presence	   of	   donor	   origin	   cells	   in	   the	   mature	  differentiated	   blood	   cells,	   at	   least	   four	   months	   after	   transplantation.	   This	   type	   of	  experiment	   is	   called	   functional	   repopulation	   and	   become	   a	   keystone	   criterion	   for	  defining	  a	  HSC.	  
The	  studies	  with	  clonogenic	  hematopoietic	  progenitors	  found	  in	  the	  pre-­‐circulation	  yolk	   sac	   were	   not	   successful	   to	   show	   long	   term	   (more	   than	   4	   months)	   functional	  repopulation	   after	   the	   transplantation	   into	   adult	   mouse.	   Therefore,	   progenitors	  originated	   from	  pre-­‐circulation	  (before	  E8.25)	  yolk	  sac	  accepted	  as	   transient	  and	  does	  not	   remain	   until	   the	   adult	   hematopoiesis.	   On	   the	   other	   hand,	   the	   cells	   fitting	   the	  HSC	  criteria	  was	  found	  first	  in	  the	  AGM	  region	  at	  E10	  (A.	  L.	  Medvinsky,	  Samoylina,	  Müller,	  &	  Dzierzak,	   1993).	   Several	   studies	   claimed	   that	   definitive	   hematopoietic	   stem	   cells	   are	  originating	   only	   from	  AGM	   region	   of	   E10-­‐E12	   of	  mouse	   embryos	   (I.	   Godin,	   Dieterlen-­‐Lièvre,	   &	   Cumano,	   1995;	   I.	   E.	   Godin,	   Garcia-­‐Porrero,	   Coutinho,	   Dieterlen-­‐Lièvre,	   &	  Marcos,	  1993;	  A.	  L.	  Medvinsky	  et	  al.,	  1993)	  (Müller,	  Medvinsky,	  Strouboulis,	  Grosveld,	  &	  Dzierzak,	  1994).	  Although	  the	  yolk	  sac	  contribution	  to	  the	  AGM	  hematopoiesis	  is	  still	  a	  
	   	   	  28	  
big	  debate,	  several	  mouse,	  zebrafish,	  and	  chick	  studies	  confirm	  the	  formation	  of	  HSCs	  in	  the	  AGM.	  
The	   evidences	   from	  mouse	   studies	  were	   suggesting	  AGM	  origin	  HSCs.	   	   The	   use	   of	  transparent	  zebrafish	  embryos	  would	  be	  the	  ideal	  model	  to	  trace	  the	  HSCs	  from	  the	  time	  point	  they	  are	  generated.	  Several	  groups	  looked	  at	  AGM	  equivalent	  tissues	  in	  zebrafish	  and	   traced	   the	   cells	   expressing	   hematopoietic	   markers.	   Blood	   precursors	   expressing	  
CD41	  and	  gata1	  were	  first	  detected	  in	  the	  region	  between	  the	  dorsal	  aorta	  and	  the	  axial	  vein,	   called	   sub-­‐aortic	   mesenchyme.	   The	   definitive	   HSC	   characteristic	   of	   this	   CD41+,	  
gata1+	   cells	   is	   shown	   by	   their	   migration	   to	   caudal	   hematopoietic	   tissue	   and	   then	   to	  thymus	  and	  kidney	  (Murayama	  et	  al.,	  2006).	  Similar	  study	  confirms	  the	  HSC	  emergence	  at	   AGM	   of	   zebrafish	   (Bertrand,	   Kim,	   Teng,	   &	   Traver,	   2008).	   Later,	  CD41-­‐gfp	   zebrafish	  line	  was	  used	  to	  trace	  the	  HSC	  and	  clearly	  showed	  the	  CD41low	  cells	  emergence	  at	  the	  DP	  joint	  of	  AGM	  and	   later	  entrance	   into	  circulation	   through	  axial	  vein	  (Kissa	  et	  al.,	  2008).	  Unlike	   in	  mammals,	   in	   zebrafish	   the	   first	  HSPCs	  were	  not	  detected	   in	   the	  dorsal	  aorta	  but	   at	   the	  mesenchymal	   region	   underneath.	   Further	   information	   coming	   from	   several	  groups	  enlightened	  further	  the	  situation	  showing	  that	  actually	  dorsal	  aorta	  endothelial	  cells	  were	  giving	  rise	  to	  HSCs,	  but	  those	  HSCs	  reaches	  the	  axial	  vein	  after	  extravasation	  through	  the	  sub-­‐aortic	  mesenchyme	  (Bertrand	  et	  al.,	  2010;	  Kissa	  &	  Herbomel,	  2010;	  E	  Y	  N	  Lam,	  Hall,	  Crosier,	  Crosier,	  &	  Flores,	  2010).	  
2.5.3. Intra-­‐aortic	  clusters	  arisen	  from	  AGM	  During	  the	  examination	  of	  tissue	  sections	  of	  AGM	  region,	  hematopoietic	  progenitor	  cells	   are	  marked	   as	   cluster	   of	   cells	   located	   in	   the	   lumen	   of	   the	   aorta.	   These	   cells	   are	  called	   intra-­‐aortic	  clusters.	  Several	  studies	  point	  out	  the	  heterogeneity	  of	   those	  cluster	  of	   cells,	   in	   terms	   of	   number	   of	   cells	   in	   a	   cluster,	   expression	   of	   hematopoietic	   and	  endothelial	  markers,	   and	   their	   capacity	   to	   generate	  different	  hematopoietic	   cell	   types.	  The	   high	   resolution	   imaging	   techniques	   showed	   that	   an	   attached	   hematopoietic	   cell	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cluster	  has	  consistent	  distribution	  of	  cells	  in	  terms	  of	  its	  marker	  protein	  expression.	  The	  round	   cells	   closer	   to	   endothelial	   layer	   can	   be	   labeled	   with	   Flk-­‐1,	   CD31,	   C-­‐kit	   and	  sometimes	  CD41	  but	  no	  CD45.	  On	  the	  contrary,	  the	  cells	  closer	  to	  the	  aortic	  space	  can	  be	  labeled	   with	   CD45	   but	   not	   with	   Flk-­‐1	   (Yokomizo	   &	   Dzierzak,	   2010).	   Regarding	   the	  pluripotency	  capacity	  of	  hematopoietic	  cells	  present	   in	   intra-­‐aortic	  clusters,	  Alexander	  Medvinsky’s	   group	   put	   forward	   the	   idea	   of	   step-­‐wise	   maturation	   of	   HSCs.	   The	  hematopoietic	   cells	   with	   close	   contact	   with	   endothelial	   layer	   of	   dorsal	   aorta	   can	   be	  identified	   as	   VE-­‐Cadherin+,	   CD41lo,	   CD45-­‐	   and	   CD43+	   population,	  which	   is	   named	   as	  type	   I	   pre-­‐HSCs.	   The	  maturation	   of	   type	   I	   pre-­‐HSCs	   forms	   type	   II	   pre-­‐HSCs	   with	   VE-­‐Cadherin+,	  CD45+,	  CD43+	  marker	   identity	   (A.	  Medvinsky,	  Rybtsov,	  &	  Taoudi,	  2011).	  A	  recent	   study	   from	   Catherine	   Robin’s	   group	   confirmed	   that	   intra-­‐aortic	   clusters	   are	  harboring	   pre-­‐HSCs,	  which	  will	  mature	   later	   into	   fully	   functional	   HSCs	   (Boisset	   et	   al.,	  2014).	  
Figure	  1.0.2	  The	  AGM	  hematopoiesis	  at	  E10.5	  of	  embryo	  proper.	  The	  scheme	  is	  drawn	  based	  on	  the	  
information	  provided	  by	  Boisset	  et	  al.,	  2010,	  2014.	  Non-­‐hemogenic	  endothelium	  is	  shown	  in	  green,	  
hemogenic	  endothelium	  is	  shown	  in	  orange,	  hematopoietic	  cells	  are	  shown	  in	  red,	  intra-­‐aortic	  
hematopoietic	  clusters	  are	  composed	  of	  heterogeneous	  cell	  types	  including	  the	  HC	  and	  HE	  cells.	  IAHCs	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appear	  in	  every	  side	  of	  the	  aortic	  wall	  but	  HSC	  forming	  capacity	  is	  detected	  only	  in	  the	  IAHCs	  emerge	  
from	  the	  ventral	  wall	  of	  the	  dorsal	  aorta	  (Taoudi	  &	  Medvinsky,	  2007).	  
2.6. Other	  hemogenic	  sites	  
2.6.1. Placenta	  In	   avian	   embryos,	   the	   allantois	   is	   an	   appendage	   of	   mesodermal	   and	   endodermal	  origin.	  First	  in	  1998,	  its	  potential	  role	  in	  hematopoiesis	  was	  investigated	  by	  using	  quail-­‐chick	   chimeras.	   Both	   endothelial	   and	   hematopoietic	   precursor	   cells	   are	   shown	   to	  emerge	   from	   grafted	   quail	   and	   contributed	   into	   adult	   chicken	   bone	   marrow	   cells	   (A.	  Caprioli,	  Jaffredo,	  Gautier,	  Dubourg,	  &	  Dieterlen-­‐Lièvre,	  1998).	  Later	  by	  the	  same	  group,	  the	  origins	  of	  the	  hematopoietic	  cells	  emerging	  from	  allantois	  were	  investigated	  in	  chick	  embryos.	   Beginning	   from	   HH17	   stage	   chick	   the	   allantois	   shows	   the	   expression	   of	  
VEGFR2	   (FLK1,	   KDR),	   followed	   by	   expression	   of	   GATA2,	   SCL	   and	   GATA1,	   a	   gene	  expression	  change	  suggested	  to	  resemble	  the	  differentiation	  of	  hemangioblast	  towards	  hematopoietic	  cells.	  Then	  the	  observation	  of	  CD45+,	  hemoglobinized	  cells	  in	  structures	  similar	  to	  yolk	  sac	  blood	  islands	  further	  strengthens	  the	  argument	  of	  allantois	  as	  a	  site	  of	  hematopoietic	  differentiation	  from	  hemangioblast	  (	  Caprioli	  et	  al.,	  2001).	  
In	   mouse	   embryo,	   the	   allantois	   and	   chorion	   fuse	   and	   forms	   placenta	   at	   E8.0-­‐8.5	  stages.	  Placenta	  is	  an	  extraembryonic	  tissue	  composed	  of	  trophoblast	  and	  two	  types	  of	  mesoderm:	  allantoic	  and	  chorionic	  mesoderm	  (Adamson	  et	  al.,	  2002;	  Downs	  &	  Gardner,	  1995;	   Rossant	   &	   Cross,	   2001).	   Hemangioblast	   theory,	   which	   argues	   a	   mesoderm	  originating	   hematopoietic	   cells,	   took	   also	   attention	   for	   chorio-­‐allantoic	   mesoderm	   of	  murine	   placenta.	   The	   first	   clue	   for	   hematopoietic	   capacity	   of	   placenta	   came	   from	   the	  finding	  of	  fetal	  precursor	  B	  cells	  in	  the	  placenta	  (Melchers,	  1979).	  A	  few	  decades	  later,	  a	  comprehensive	  analysis	  of	  hematopoietic	  potential	  of	  the	  placenta	  was	  done	  by	  using	  an	  in	  vitro	  colony	  assay.	  Beginning	  with	  E9.5,	  placenta	  harbors	  CFU-­‐C	  and	  BFU-­‐E	  as	  much	  as	  caudal	  half	  of	  embryo.	  Later	  at	  E15	  and	  E17,	  placenta	  has	  the	  highest	  CFU-­‐C	  counts	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compared	   with	   yolk	   sac,	   caudal	   half	   of	   embryo	   and	   fetal	   liver.	   In	   addition,	   RT-­‐PCR	  analysis	  of	  placenta	  at	  late	  E9	  stage	  shows	  Runx1	  expression,	  consistent	  with	  the	  timing	  of	   progenitor	   detection	   (Alvarez-­‐Silva,	   Belo-­‐Diabangouaya,	   Salaün,	   &	   Dieterlen-­‐Lièvre,	  2003).	  Yet,	  this	  study	  does	  not	  provide	  enough	  information	  to	  conclude	  about	  placenta’s	  contribution	  to	  adult	  hematopoiesis.	  
In	  2005	  two	  groups	  took	  one	  step	  further	  from	  Alvarez-­‐Silva’s	  work	  and	  proved	  the	  presence	  of	  HSCs	  beginning	  from	  E10.5	  mouse	  embryo	  (Gekas,	  Dieterlen-­‐Lièvre,	  Orkin,	  &	  Mikkola,	  2005;	  Ottersbach	  &	  Dzierzak,	  2005).	  The	  placenta	  derived	  HSCs	  are	  shown	  to	  express	   CD34,	   C-­‐kit	   and	   can	   repopulate	  myeloid	   and	   lymphoid	   blood	   cells	   in	   primary	  and	  secondary	  adult	  mouse	  for	  longer	  then	  4	  months.	  This	  clearly	  shows	  the	  presence	  of	  definitive	   HSC	   with	   confirmed	   pluripotency	   and	   self-­‐renewal	   capacity.	   Although	   both	  studies	  underlie	  the	  fact	  that	  the	  HSCs	  found	  in	  placenta	  outnumbers	  the	  AGM,	  YS	  and	  FL,	   they	   have	   different	   reasoning	   for	   it.	   The	   group	   of	   Stuart	   Orkin	   emphasize	   the	  presence	   of	   more	   undifferentiated	   HSCs	   and	   less	   hematopoietic	   progenitors	   in	   the	  placenta;	   therefore	   placenta	   may	   serve	   as	   a	   niche	   for	   HSC	   expansion	   without	  differentiation	   (Gekas	   et	   al.,	   2005).	   On	   the	   other	   hand,	   Elaine	  Dzierzak’s	   group	   draws	  attention	   to	   the	  presence	  of	  endothelial	   cells	  expressing	  hematopoietic	  markers	  at	   the	  placenta	   labyrinth	   site	   and	   concludes	   that	   HSCs	   may	   originate	   from	   the	   hemogenic	  endothelial	  cells,	  similar	   to	  AGM	  and	  YS	  hematopoiesis	  (Ottersbach	  &	  Dzierzak,	  2005).	  Mouse	   placenta	   surprisingly	   harbors	  HSCs	   but	   is	   it	   because	   placenta	   is	   a	   site	   for	  HSC	  expansion	  or	  placenta	  is	  a	  site	  for	  de	  novo	  hematopoiesis?	  
Another	   study	   came	   from	   Hanna	   Mikkola’s	   group	   to	   investigate	   de	   novo	  hematopoiesis	   capacity	   of	   mouse	   placenta	   (Rhodes	   et	   al.,	   2008).	   They	   found	  hematopoietic	  cells	  stained	  with	  CD41	  early	  hematopoietic	  marker	  on	  placenta	  of	  Ncx1	  -­‐
/-­‐	   mouse	   line	   (Koushik	   et	   al.,	   2001),	   which	   lacks	   heartbeat;	   therefore	   it	   has	   no	   blood	  circulation.	   Using	   that	  mouse	   line	   eliminates	   the	   idea	   of	   detecting	   hematopoietic	   cells	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generated	   in	   other	   regions.	   	   Isolated	   placenta	   of	   Ncx1-­‐/-­‐	   mouse	   is	   shown	   to	   generate	  myeloid,	   B	   and	  T	   lymphoid	   cell	   in	   vitro	   culture.	  However,	   the	   lack	   of	   adult	   functional	  repopulation	  assay	  of	  those	  cells,	  in	  my	  point	  of	  view	  prevents	  us	  to	  call	  those	  placenta	  originated	  hematopoietic	  cells	  HSCs.	  Altogether	  this	  study	  provides	  the	  first	  evidence	  for	  de	  novo	  hematopoiesis	  capacity	  of	  mouse	  placenta,	  yet	  doesn’t	  argue	  against	  its	  function	  for	  hematopoietic	  niche.	  
2.6.2. Vitelline	  and	  Umbilical	  Arteries	  
	  In	  mouse	   embryos	   at	  E8.0	   continuation	  of	   dorsal	   aorta	   forms	  omphalomesenteric	  artery,	   which	   then	   connects	   with	   allantoic	   bud.	   That	   connection	   is	   called	   umbilical	  vessel,	  while	  allantoic	  bud	   fuses	  with	  chorion	  and	   forms	  placenta	  at	  E8.5.	  After	  E9.5	   it	  makes	  another	  connection	  with	  the	  dorsal	  aorta	  and	  forms	  the	  vitelline	  artery.	  At	  E10.5	  the	  connection	  between	  vitelline	  and	  umbilical	  arteries	   is	   lost.	  The	  vitelline	  artery	  has	  the	  connection	  with	  yolk	  sac	  vasculature	  and	  dorsal	  aorta,	  while	  the	  umbilical	  artery	  is	  connected	   to	   chorio-­‐allantoic	   mesenchyme	   and	   placenta	   (Garcia-­‐Porrero,	   Godin,	   &	  Dieterlen-­‐Lièvre,	  1995).	  	  
Initial	  examinations	  of	  mouse	  embryo	  spotted	  first	  detection	  of	  hematopoietic	  cells	  at	   E9.5	   of	   vitelline	   artery	   and	   E10	   of	   umbilical	   artery	   (Garcia-­‐Porrero	   et	   al.,	   1995).	  Another	  mouse	  study	  with	  finely	  dissected	  vitelline	  and	  umbilical	  arteries	  was	  used	  to	  test	  for	  its	  functional	  repopulation	  capacity.	  Similar	  to	  dorsal	  aorta,	  before	  E10,	  no	  HSC	  with	   successful	   functional	   repopulation	   in	   irradiated	   host	  mouse	   is	   detected.	   Starting	  from	   E10.5,	   the	   dorsal	   aorta,	   umbilical	   artery	   and	   vitelline	   artery	   are	   proven	   to	   bear	  HSCs	  (M.	  F.	  de	  Bruijn,	  Speck,	  Peeters,	  &	  Dzierzak,	  2000).	  3	  dimensional	  imaging	  done	  by	  using	   hematopoietic	   and	   endothelial	   markers,	   also	   confirmed	   the	   presence	   of	  hematopoietic	   clusters	   in	   the	   major	   arteries	   (dorsal	   aorta,	   umbilical	   and	   vitelline	  arteries)	  at	  E10.5	  and	  E11.0	  mouse	  embryos	   (Yokomizo	  &	  Dzierzak,	  2010).	   In	  parallel	  with	   the	   timing	   of	   identified	   hematopoietic	   cells,	   Runx1,	   the	   major	   transcriptional	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regulator	   of	   definitive	   hematopoiesis,	   is	   shown	   to	   be	   expressed	   in	   the	   umbilical	   and	  vitelline	  arteries	  (T.	  North	  et	  al.,	  1999).	  
Since	  the	  heartbeat	  starts	  at	  E8.25,	  all	  produced	  hematopoietic	  cells	  are	  circulating	  around	  yolk	  sac,	  embryo	  proper,	  vitelline	  artery,	  umbilical	  artery	  and	  placenta.	  Because	  of	   that,	   the	   origin	   of	   hematopoietic	   cells	   found	   in	   a	   certain	   tissue	   at	   a	   certain	   time	   of	  embryo	  development	  is	  uncertain.	  It	  doesn’t	  give	  enough	  information	  about	  the	  de	  novo	  hematopoietic	  capacity	  of	  umbilical	  and	  vitelline	  arteries.	  When	  the	  heart	  does	  not	  beat	  in	  Ncx1	  mutant	  mouse,	  CD41	  expressing	  hematopoietic	  cells	  are	  observed	  to	  appear	  in	  the	  umbilical	  artery	   (Rhodes	  et	  al.,	  2008),	  yet	   the	   functional	  hematopoietic	  analysis	  of	  those	   cells	   are	   inadequate.	   Latest	   studies	   showed	   that	   umbilical	   and	   vitelline	   arteries	  bear	   hematopoietic	   cells	   that	   can	   generate	   HSCs	   upon	   IL3	   introduction	   (Gordon-­‐Keylock,	  Sobiesiak,	  Rybtsov,	  Moore,	  &	  Medvinsky,	  2013).	  Therefore	  it	  is	  highly	  probable	  that	   vitelline	   and	   umbilical	   artery	   originated	   cells	   may	   contribute	   to	   adult	  hematopoiesis.	  
2.7. Sites	  for	  colonization	  and	  expansion	  of	  hematopoietic	  progenitors	  
2.7.1. Fetal	  Liver	  By	  the	  time	  circulation	  starts	  at	  E8.5	  of	  mouse	  embryo,	  all	  the	  progenitors	  with	  yolk	  sac	  origin	  start	  to	  be	  found	  in	  the	  blood	  stream,	  embryo	  proper	  and	  fetal	  liver.	  Starting	  from	  E9.5,	  fetal	  liver	  becomes	  a	  site	  of	  colonization	  for	  the	  progenitors	  generated	  from	  other	  sites.	  Starting	  from	  E12.5	  of	  mouse	  embryo,	  among	  other	  hematopoietic	  sites,	  fetal	  liver	   has	   the	   highest	   number	   of	   colony	   forming	   progenitors	   and	   adult	   repopulating	  HSCs.	   The	   hematopoietic	   progenitors	   in	   fetal	   liver	   are	   dividing	   and	   committing	   to	  mature	  hematopoietic	  cells.	   In	   that	   term,	   fetal	   liver	   is	  more	  of	  a	  site	   for	  hematopoietic	  cell	   differentiation	   rather	   than	   the	   site	   of	   initiating	   hematopoietic	   program.	  Mobilized	  progenitor	   cells	   start	   to	   colonize	   in	   the	   fetal	   liver	   and	   differentiate	   to	   become	   fully	  committed	  hematopoietic	  cells,	  and	  then	  are	  released	  back	  to	  the	  circulation.	  Although	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the	   liver	   functions	   as	   hematopoietic	   site	   until	   2	   weeks	   after	   birth,	   the	   main	   site	   of	  residing	  hematopoietic	  progenitors	  is	  taken	  over	  gradually	  by	  bone	  marrow.	  
Definitive	   HSCs	   emerged	   from	   AGM	   of	   zebrafish	   embryos	   detected	   at	   the	   caudal	  hematopoietic	  tissue	  (CHT).	  The	  newly	  formed	  HSCs	  go	  through	  circulation	  and	  to	  CHT	  region	  while	  still	  expressing	  hematopoietic	  markers	  c-­‐myb	  and	  ikaros	  (Murayama	  et	  al.,	  2006).	   Afterwards	   it	   is	   shown	   to	   migrate	   to	   thymus	   and	   kidney	   to	   colonize	   and	  contribute	  to	  the	  adult	  hematopoiesis	  (Kissa	  et	  al.,	  2008).	  Regarding	  the	  role	  of	  CHT	  as	  a	  stop	   site	   before	   seeding	   the	   adult	   hematopoietic	   organs,	   CHT	  may	   serve	   as	   expansion	  and	  differentiation	  site	  like	  an	  equivalent	  of	  fetal	  liver	  in	  mammals.	  
2.7.2. Bone	  Marrow	  Bone	  marrow	  is	  the	  site	  of	  final	  destination	  of	  all	  hematopoietic	  stem	  and	  progenitor	  cells,	   which	  will	   stay	   along	   the	   adulthood.	   Circulating	   hematopoietic	   stem/progenitor	  cells	   (HSPCs)	   start	   to	   colonize	   in	   the	   bone	   marrow	   at	   E15	   stage	   of	   mouse	  embryo(Dzierzak	  &	   Speck,	   2008;	  A.	  Medvinsky	   et	   al.,	   2011)	   .Bone	  marrow	   consists	   of	  highly	  vascularized	  niche	  with	  stromal	  cells	  and	  osteoblast	   to	  support	  definitive	  HSC’s	  self-­‐renewal	  and	  differentiation	  towards	  all	  blood	  cell	  types.	  Different	  cytokines,	  which	  are	  secreted	  from	  nearby	  cells	  in	  the	  bone	  marrow	  niche	  trigger	  various	  programs	  in	  the	  HSPCs.	   The	   cell	   is	   either	   promoted	   to	   differentiate	   and	   form	  mature	   blood	   cells	   to	   be	  released	   into	   the	   circulation	  or	  kept	  quiescent	   to	   stay	   as	  HSC	   reservoir	   for	   the	   rest	   of	  organism’s	  life.	  Thanks	  to	  that	  highly	  specialized	  niche,	  HSCs	  are	  producing	  itself	  and	  all	  types	  of	  blood	  cells	  continuously.	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Figure	  1.0.3	  Embryonic	  hematopoiesis	  time	  line	  with	  their	  tissue	  origin.	  
3. Mechanism	  of	  blood	  cell	  emergence:	  How	  is	  it	  generated?	  
3.1. Hemogenic	  endothelial	  cells	  as	  ancestor	  of	  hematopoietic	  cells	  In	  chick	  and	  mouse	  embryos	  intra-­‐aortic	  cluster	  cells	  are	  always	  in	  close	  proximity	  with	   ventral	   part	   of	   the	   endothelial	   lining	   of	   dorsal	   aorta.	   	   Hematopoietic	   progenitor	  cells	   also	  observed	   to	  be	   juxtaposed	  with	  endothelial	   cells	  of	   the	  yolk	   sac	  vasculature.	  Wide	   range	   of	   organisms	   from	   avian	   to	   murine	   embryos,	   finding	   hematopoietic	  progenitor	   cells	   near	   the	   endothelial	   lining	   of	   vessels	   regardless	   of	   the	   site	   of	   origin	  indicates	   an	   evolutionarily	   conserved	   relation	   of	   endothelial	   and	   hematopoietic	   cells.	  The	  hypothesis	  of	  endothelial	  originating	  hematopoietic	  cells	  was	  proposed.	  
Supporting	   evidence	   comes	   from	   commonly	   expressed	   genes	   in	   both	   endothelial	  cells	  and	  hematopoietic	  cells.	  As	  an	  example	  CD34	  expression	  is	  detected	  at	  the	  vascular	  lining	   and	   in	   the	   hematopoietic	   cells	   of	   E9.0	   mouse	   yolk	   sac	   (Young,	   Baumhueter,	   &	  Lasky,	   1995).	   Similarly,	   in	   5	   weeks	   old	   human	   embryos,	   CD34	   is	   expressed	   in	   both	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endothelial	  lining	  of	  dorsal	  aorta	  and	  the	  intra-­‐aortic	  hematopoietic	  clusters	  (Tavian	  et	  al.,	   1996).	   Another	   gene	   SCL/Tal1	   is	   a	   transcription	   factor	   expressed	   in	   two	   types	   of	  cells,	  which	  is	  shown	  by	  studies	  done	  by	  chicken	  (Drake,	  Brandt,	  Trusk,	  &	  Little,	  1997),	  mouse	   embryos	   	   (Kallianpur,	   Jordan,	  &	  Brandt,	   1994)	   and	  human	  umbilical	   cord	   cells	  	  (Hwang,	   Siegelman,	   Davis,	   Oppenheimer-­‐Marks,	   &	   Baer,	   1993).	   The	   common	   gene	  expression	   studies	   indicate	   a	  developmental	   link	  between	  hematopoietic	   cells	   and	   the	  endothelial	   cells	   in	   the	   surrounding	   vessel.	   By	   these	   studies,	   the	   hypothesis	   of	   an	  endothelial	  precursor	  for	  hematopoietic	  cells	  is	  favored.	  
Emphasizing	   the	   nature	   of	   the	   cell	   phenotype	   change,	   the	   formation	   of	  hematopoietic	   cells	   from	   endothelial	   precursor	   is	   called	   endothelial	   to	   hematopoietic	  transition	  (EHT)	  and	  those	  precursor	  cells	  are	  called	  hemogenic	  endothelium.	  The	  EHT	  is	  highly	  regulated	  both	  temporally	  and	  spatially,	  that	  only	  rare	  hemogenic	  endothelial	  cells	  and	  for	  a	  short	  time	  window	  can	  go	  through	  the	  transition.	  EHT	  is	  now	  accepted	  as	  the	   birth	   of	   first	   blood	   precursors	   and	   reported	   in	   several	   vertebrate	   species	   (i.e.	  zebrafish,	   chick,	   quail,	   mouse,	   human).	   Such	   a	   strict	   regulation	   of	   EHT	   indicates	   a	  conserved	   mechanism,	   which	   is	   tightly	   controlled	   by	   series	   of	   intrinsic	   and	   extrinsic	  cellular	  mechanisms.	  	  
3.2. Endothelial	  to	  hematopoietic	  transition	  Time-­‐lapse	   imaging	   and	   live	   cell	   tracking	   technology	   shed	   more	   light	   on	   the	  complete	   process	   of	   EHT.	   At	   the	   beginning	   hemogenic	   endothelial	   cells	   seem	   not	  different	   then	   other	   endothelial	   cells	   of	   the	   vascular	   lining	   with	   flat,	   highly	   attached	  morphology.	  When	   the	   EHT	   program	   is	   initiated	   in	   hemogenic	   endothelial	   cells,	   they	  loose	   their	   attachment	   gradually	   and	   gain	   more	   round	   morphology.	   Afterwards	   they	  detach	  and	  bud	  off	  to	  the	  lumen.	  The	  morphology	  change	  happens	  in	  parallel	  with	  gene	  expression	   and	  marker	   protein	   synthesis	   change.	   The	   hemogenic	   endothelial	   cells	   are	  gradually	   losing	   their	   endothelial	   markers	   and	   gain	   hematopoietic	   markers.	   The	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complete	  process	  is	  a	  transition	  of	  one	  cell,	  rather	  then	  one	  asymmetrically	  dividing	  cell	  leading	  to	  two	  different	  daughter	  cells.	  
Our	   current	   knowledge	   about	   the	   EHT	   is	   based	   on	   several	   studies	   done	   by	   using	  chicken,	  quail,	  zebrafish,	  mouse	  and	  lastly	  the	  mES	  cell	  models.	  Since	  emergence	  of	  first	  hematopoietic	   progenitors	   from	   endothelial	   cells	   is	   observed	   among	   that	   variety	   of	  animals,	   we	   can	   conclude	   that	   EHT	   is	   a	   well-­‐conserved	   mechanism	   responsible	   of	  hematopoiesis	  in	  vertebrates.	  
3.2.1. Studies	  of	  EHT	  during	  development	  
3.2.1.1. In	  vivo	  avian	  studies	  The	  first	  observations	  of	  endothelial	  originating	  hematopoietic	  cells	  are	  done	  on	  the	  developing	  chick	  embryos.	  	  (Sabin,	  1921).	  Later	  with	  the	  usage	  of	  antibodies,	  endothelial	  marker	  proteins	  are	  used	  to	  trace	  hematopoietic	  origin.	  One	  of	   the	  endothelial	  marker	  KDR	  (a.k.a.	  VEGF-­‐R2/FLK-­‐1	  and	  Quek-­‐1	  in	  chicken)	  is	  used	  to	  sort	  endothelial	  cells	  from	  gastrulating	   chick	   embryo	   and	   found	   to	   give	   rise	   to	   hematopoietic	   and	   endothelial	  progenitors	   (Eichmann	   et	   al.,	   1997).	   Later	   Dieterlen-­‐Lievre’s	   group	   used	   both	  endothelial	   marker	   KDR	   and	   hematopoietic	   marker	   CD45	   to	   identify	   the	   relation	   of	  endothelial	  cells	  and	  hematopoietic	  intro-­‐aortic	  clusters	  in	  chick	  embryo.	  Dual	  staining	  marked	   endothelial	   cells	   as	   KDR+,	   CD45-­‐	   and	   intra-­‐aortic	   clusters	   as	   KDR-­‐,CD45+.	  Acetylated-­‐low	  density	  lipoprotein	  (Ac-­‐LDL)	  can	  be	  up	  taken	  by	  endothelial	  cells,	  which	  makes	  it	  very	  useful	  to	  trace	  endothelial	  lineage	  (Voyta,	  Via,	  Butterfield,	  &	  Zetter,	  1984).	  When	   they	   traced	   the	   endothelial	   cells	   with	   Ac	   LDL-­‐DiI,	   they	   observed	   some	  hematopoietic	  cells	  stained	  with	  AcLDL,	  proving	  the	  link	  of	  endothelial	  to	  hematopoietic	  transition	   in	  dorsal	  aorta	  of	  chicken	  embryo	  (Jaffredo,	  Gautier,	  Eichmann,	  &	  Dieterlen-­‐Lièvre,	  1998).	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3.2.1.2. In	  vivo	  zebrafish	  studies	  In	   parallel	   with	   avian	   and	   mouse	   studies,	   close	   relation	   of	   endothelial	   and	  hematopoietic	  lineage	  in	  zebrafish	  was	  investigated.	  The	  first	  evidence	  of	  developmental	  link	  between	  endothelial	  cells	  and	  hematopoietic	  cells	  came	  from	  mutant	  zebrafish	  lines.	  Mutation	   in	   the	   cloche	   gene	   is	   an	   example	   of	   such	   defective	   phenotype	   effecting	  expression	   of	   both	   vascular	   markers	   (Stainier,	   Weinstein,	   Detrich,	   Zon,	   &	   Fishman,	  1995)	  and	  definitive	  and	  primitive	  hematopoietic	  markers	  (Thompson	  et	  al.,	  1998).	  	  
Several	   studies	   detected	  definitive	  HSCs	  not	  within	   intra-­‐aortic	   clusters	   but	   at	   the	  sub-­‐aortic	  mesenchyme	  in	  AGM	  (Bertrand	  et	  al.,	  2008;	  Kissa	  et	  al.,	  2008;	  Murayama	  et	  al.,	   2006).	   A	   big	   advantage	   of	   zebrafish	   over	   mouse	   is	   that	   zebrafish	   embryos	   are	  transparent	  which	  facilitates	  in	  vivo	  live	  cell	  imaging	  and	  cell	  tracing	  with	  reporter	  lines.	  Considering	  that	  advantage	  of	  zebrafish	  model	  in	  hematopoiesis,	  three	  groups	  managed	  to	  trace	  HSCs	  back	  to	  their	  endothelial	  progenitor.	  	  
Philippe	  Herbomel	   and	  Karima	  Kissa	   have	   showed	   the	   endothelial	   origin	  HSCs	   by	  using	  zebrafish	  lines	  kdr:EGFP	  transgenic	  line	  for	  in	  vivo	  time-­‐lapse	  imaging	  from	  stage	  28hpf	   till	   100hpf.	   Their	  work	   became	   prominent	   by	   clearly	   showing	   at	   the	   single	   cell	  level	  the	  morphological	  changes	  that	  hemogenic	  endothelial	  cell	  is	  going	  through	  while	  becoming	   HSC.	   All	   endothelial	   cells	   are	   expressing	   Kdr	   but	   only	   a	   few	   have	  hematopoietic	  capacity.	  During	  EHT,	  the	  rare	  hemogenic	  endothelial	  cell	  bends	  towards	  the	  intra-­‐aortic	  space	  and	  form	  a	  round	  shape	  while	  the	  neighboring	  lateral	  endothelial	  cells	  are	  filling	  the	  space	  on	  the	  endothelial	  lining.	  After	  staying	  slightly	  attached	  to	  the	  endothelial	  layer,	  the	  round	  cell	  goes	  through	  the	  sub-­‐aortic	  mesenchyme	  and	  joins	  the	  circulation	   through	   the	   cardinal	   vein.	   They	   also	   showed	   that	   in	   Runx1	   morphant	  
kdr:EGFP	  embryos,	  EHT	  is	  initiated	  more	  rarely	  than	  normal	  ones	  and	  the	  rare	  emerging	  cells	   die	   afterwards.	   They	   conclude	   that	   Runx1	   is	   crucial	   for	   a	   successful	   EHT	   and	  formation	  of	  HSCs	  (Kissa	  &	  Herbomel,	  2010).	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David	   Traver’s	   group	   used	   double	   transgenic	   line	   with	   kdrl:mCherry	   to	   trace	  endothelial	  cells	  and	  c-­‐myb:eGFP	   line	  to	   trace	  hematopoietic	  cells.	  Fluorescent	   imaging	  clearly	   spots	   endothelial	   cells	   at	   the	   ventral	   wall	   of	   the	   dorsal	   aorta	   with	   Kdrl+	  expression	  has	  initially	  flat	  endothelial	  morphology,	  which	  then	  some	  of	  them	  express	  C-­‐myb	   and	   transform	   to	   a	   spherical	   shape.	   That	   Kdrl+,	   C-­‐myb+	   cells	   migrate	   towards	  ventral	   side	   and	   goes	   into	   the	   circulation	   via	   caudal	   vein.	   They	   also	   showed	   EHT	  transitions	   steps	   by	   combining	   markers	   they	   used	   to	   image	   and	   sort	   with	   qRT-­‐PCR	  analysis	   of	   important	   endothelial	   and	   hematopoietic	   markers.	   They	   define	   the	  hemogenic	   endothelial	   cells	   with	   isolated	   Kdrl+,	   C-­‐myb-­‐	   gate,	   expressing	   genes	   of	  endothelial	  markers	  cdh5	  and	  kdrl	  high,	  some	  hematopoietic	  regulators	  lmo2,	  runx1	  high	  and	  hematopoietic	  marker	  CD41,	  CD45	  low.	  It	  might	  indicate	  that	  hemogenic	  endothelial	  cells	   have	   already	   initiated	   EHT	   by	   expressing	   lmo2	   and	   runx1	   but	   not	   bearing	   the	  hematopoietic	   features	   yet.	   Lineage	   tracing	   of	   those	   endothelial	   origin	   HSCs	   confirm	  their	  long-­‐term	  repopulation	  and	  multi-­‐lineage	  commitment	  capacities	  (Bertrand	  et	  al.,	  2010).	  
A	  few	  months	  later,	  Maria	  Vega	  Flores’s	  group	  showed	  time-­‐lapse	  imaging	  of	  EHT	  by	  using	   runx1P2:EGFP	   transgenic	   zebrafish	   line,	   which	   is	   shown	   before	   to	   be	   marking	  definitive	  HSCs	  specifically	  (Enid	  Yi	  Ni	  Lam	  et	  al.,	  2009).	  Together	  with	  Runx1,	  to	  mark	  endothelial	  cells	  they	  crossed	  with	  kdrl:nls-­‐mCherry	  transgenic	  line	  and	  imaged	  from	  22	  to	   35	   hpf.	   The	   first	   co-­‐expressing	   Runx1	   and	   Kdrl	   cells	   are	   seen	   at	   25hpf	   at	   the	  endothelial	  lining	  of	  the	  ventral	  wall	  of	  the	  dorsal	  aorta.	  Approximately	  9	  hours	  after	  the	  co-­‐expression	   starts,	   the	   round	   shape	   replaces	   the	   flat	  morphology	  of	   endothelial	   cell.	  All	  Runx1	  positive	  round	  cells	  are	  expressing	  Kdrl,	  so	  the	  endothelial	  origin	  of	  HSCs	   is	  confirmed.	  The	  Runx1+	  Kdrl+	  cells	  are	  shown	  to	  enter	  the	  circulation	  via	  axial	  vein	  and	  seed	   thymus	   and	   kidney	   at	   5df,	   therefore	   HSC	   nature	   of	   the	   double	   positive	   cells	   are	  validated.	  Lastly	   they	  did	  morpholino	  study	  on	   the	  double	   transgenic	   line	  and	  showed	  that	  deficiency	  of	  Runx1	  activity,	  no	  blood	  flow	  or	  aberrant	  dorsal	  aorta	  can	  reduce	  the	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number	   of	   double	   positive	  HSCs.	   Therefore	   they	   conclude	   that	  Runx1,	   blood	   flow	   and	  vascular	  integrity	  are	  regulators	  of	  EHT	  (E	  Y	  N	  Lam	  et	  al.,	  2010).	  
3.2.1.3. Mouse	  studies	  The	   close	   relation	   between	   hematopoietic	   cells	   and	   the	   vasculature	   in	   the	  mouse	  embryo	  sections	  are	  observed	  in	  several	  studies	  (Garcia-­‐Porrero	  et	  al.,	  1995;	  I.	  Godin	  et	  al.,	   1995).	   In	   the	   mouse	   yolk	   sac	   at	   E8.25	   and	   E9.5	   embryos,	   isolated	   Tie2+,Flk-­‐1+	  endothelial	  cells	  are	  shown	  to	  give	  rise	  to	  CD41	  expressing	  hematopoietic	  cells	  as	  well	  as	  endothelial	  cells	  upon	  cultured	  in	  vitro	  (W.	  Li,	  Ferkowicz,	  Johnson,	  Shelley,	  &	  Yoder,	  2005)	  .	  
Only	  after	  the	  development	  of	  genetic	  cell	  tracing	  methods	  in	  mouse	  and	  knowledge	  of	   better	   cell	   type	   specific	   markers,	   the	   clonal	   link	   of	   developing	   hematopoietic	   cells	  from	  endothelial	  cells	  was	  established.	  Elaine	  Dzierzak’s	  lab	  showed	  the	  direct	  evidence	  of	   endothelial	   derived	   hematopoietic	   cell	   formation	   by	   using	   VE-­‐Cadherin	   reporter	  mouse	   line.	  Temporally	   labeled	   endothelial	   cells	   in	   the	   time	  window	  of	  E9.5	   to	  E12.5,	  forms	   long-­‐term	   HSCs	   and	   contribute	   to	   adult	   hematopoiesis	   (Zovein	   et	   al.,	   2008).	  Runx1	   is	   accepted	   as	   the	  major	   regulator	   of	   EHT	   so	   that	  Runx1	  KO	   leads	   to	   complete	  depletion	   definitive	   hematopoiesis	   and	   embryonic	   lethality	   (Okuda,	   van	   Deursen,	  Hiebert,	   Grosveld,	   &	   Downing,	   1996;	   Q	   Wang	   et	   al.,	   1996).	   Interestingly,	   the	   same	  phenotype	  occurs	  with	  no	  definitive	  hematopoiesis	  when	  Runx1	  is	  depleted	  only	  in	  VE-­‐Cadherin+	  endothelial	  cells	  (Chen,	  Yokomizo,	  Zeigler,	  Dzierzak,	  &	  Speck,	  2009).	  Thus,	  it	  emphasizes	   the	   endothelial	   origin	   of	   Runx1	   dependent	   definitive	   HSCs.	   Lastly,	   the	  concrete	  evidence	  for	  EHT	  in	  mouse	  came	  from	  ex	  vivo	  live	  cell	   imaging	  of	  endothelial	  cells	   of	   dorsal	   aorta	  while	   transiting	   into	   hematopoietic	   cells.	   Sagitally	   dissected	  AGM	  sections	   are	   stained	   with	   endothelial	   marker	   CD31,	   and	   hematopoietic	   marker	   Ly6A,	  and	  kept	  alive	  during	  time-­‐lapse	  imaging.	  Although	  it	  includes	  ex	  vivo	  culture	  of	  dorsal	  aorta	   sections	  without	   intact	   environment,	   a	   few	   hours	  were	   enough	   to	   capture	   very	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rare	  EHT	  events.	  Similar	  to	  chicken	  and	  zebrafish	  studies,	  this	  work	  shows	  that	  EHT	  in	  mouse	   is	  characterized	  with	  morphology	  change	   from	  flat	   to	  round	  cells,	  coupled	  with	  marker	   change	   from	   endothelial	   to	   hematopoietic	   (Ly6A,	   c-­‐kit,	   CD41)	   (Boisset	   et	   al.,	  2010).	  
3.2.1.4. In	  vitro	  differentiation	  studies	  In	  vivo	  studies	  on	  EHT	  are	  helpful	   to	  see	   the	   localization	  and	  timing	  of	  EHT	   inside	  the	   living	   embryo,	   however	   in	   vivo	   techniques	   are	   limited	   especially	   with	   mouse,	   to	  analyze	  the	  transition	  of	  each	  cell	  and	  characterization	  of	  the	  stages.	  Fortunately	  in	  vitro	  mES	  cell	  differentiation	  model	  passes	  over	  the	  technical	  obstacles	  of	  in	  vivo	  cell	  tracing	  and	  system	  manipulations.	  By	  using	  in	  vitro	  differentiation	  of	  mES	  cell	  techniques,	  two	  articles	   were	   published	   in	   2009,	   both	   present	   invaluable	   information	   about	   the	  identification	  of	  transiting	  cells	  and	  the	  stages	  of	  EHT.	  
Georges	  Lacaud’s	  group	  showed	  the	  hemangioblast	  cells	  can	  give	  rise	  to	  hemogenic	  endothelial	   cells	   and	   those	   cells	   are	   forming	   hematopoietic	   progenitors	   by	   going	  through	   EHT.	   Differentiated	   mES	   cells	   were	   harvested	   and	   hemangioblast	   equivalent	  Flk-­‐1	   expressing	   cells	   were	   put	   into	   blast	   colony	   assay	   for	   time-­‐lapse	   imaging.	   After	  approximately	   1.5	   days,	   tightly	   attached,	   flat	   cells	   appeared	   and	   some	   of	   them	   were	  forming	   semi-­‐adherent,	   round	   cells.	   FACS	   analysis	   of	   that	   stage	   suggest	   that	   Tie2hi,	   C-­‐kit+,	   CD41-­‐	   cells	   may	   further	   differentiate	   into	   CD41	   expressing	   round,	   non-­‐adherent	  hematopoietic	   cells.	   Those	   round	   hematopoietic	   progenitor	   cells	   eventually	   detached	  from	  the	  adherent	  cells	  and	  can	  give	  rise	  to	  committed	  blood	  cells.	  They	  also	  found	  that	  Scl	  deficient	  cell	  lines	  cannot	  produce	  Tie2hi,	  c-­‐kit+	  cells,	  therefore	  no	  hematopoietic	  cells	  are	  generated.	  When	  they	  tested	  Runx1	  deficient	  cells	  line,	  they	  found	  the	  formation	  of	  Tie2hi,	  C-­‐kit+	  cells	  but	  no	  CD41+	  cell	  emergence,	  which	  can	  be	  rescued	  by	  re-­‐introduction	  of	  Runx1.	  All	  together,	  in	  vitro	  differentiation	  experiment	  showed	  a	  stepwise	  generation	  of	   hematopoiesis.	   The	   first	   step	   is	   the	   differentiation	   of	   hemangioblast	   to	   hemogenic	  
	   	   	  42	  
endothelium,	   under	   the	   control	   of	   Scl	   then	   the	   second	   step	   is	   the	   differentiation	   of	  hemogenic	   endothelium	   to	   definitive	   hematopoietic	   progenitors,	   which	   is	   under	   the	  control	   of	   Runx1	   activity.	   Their	   study	   provides	   the	   first	   link	   between	   the	   theory	   of	  mesodermal	   hemangioblast	   cells	   as	   the	   common	   precursor	   for	   endothelial,	  hematopoietic	   and	   smooth	   muscle	   lineages	   with	   the	   recent	   findings	   of	   endothelial	  originating	  hematopoietic	  cells	  (Lancrin	  et	  al.,	  2009a).	  
In	   the	   same	   issue	   of	   Nature,	   there	  was	   another	   article	   from	   Shin-­‐Ichi	   Nishikawa’s	  and	  Tim	  Schroeder’s	  groups	  showing	   in	  vitro	  single	  cell	   imaging	  together	  with	  marker	  expressions	  of	   the	   cells	   going	   through	  EHT.	   Isolated	  Flk-­‐1	  positive	  hemangioblast-­‐like	  cells	  were	   grown	   on	   stromal	   cells	   and	   the	   formation	   of	   hemogenic	   endothelium,	   then	  hematopoietic	   progenitors	  was	   traced	   at	   the	   single	   cell	   level.	   Similar	   to	   findings	   from	  Lancrin	   et	   al.	   (2009)	   from	   single	   hemangioblast	   cell,	   formation	   of	   adherent,	   flat	   cells	  with	   endothelial	   specific	   labeled	   tight	   junctions	   (VE-­‐Cadherin::Venus-­‐claudin5)	   was	  observed	   and	   Ac-­‐LDL	   uptake	  was	   used	   to	  mark	   their	   endothelial	   phenotype.	   Some	   of	  those	  endothelial	  cells	  become	  semi-­‐adherent	  and	  round	  while	  gaining	  first	  CD41,	  early	  hematopoietic	  marker,	  expression	  then	  CD45,	   late	  hematopoietic	  commitment	  marker,	  expression.	   At	   last,	   CD41+CD45+	   round	   hematopoietic	   cells	   loose	   tight	   junctions,	  adherence	  to	  the	  other	  cells	  and	  start	  floating	  in	  the	  culture.	  The	  quantified	  data	  for	  all	  single	   cell	   tracing	   experiments	   showed	   that	   only	   1.5%	   of	   mesodermal	   colonies	   can	  generate	   hematopoietic	   cells	   and	   the	   timing	   for	   all	   EHT	   events	   are	   roughly	  synchronized.	   The	   same	   precise	   transition	   of	   adherent,	   endothelial	   cells	   to	   CD41	  expressing	  non-­‐adherent	  hematopoietic	  cells	  was	  observed	  also	  from	  the	  isolated	  Flk-­‐1+,	  VE-­‐Cadherin-­‐,	   CD41-­‐	   mesodermal	   cells	   from	   E7.5	   mouse	   embryos.	   In	   summary,	   this	  study	  confirms	  the	  presence	  of	  hemangioblast	  like	  cells	  and	  their	  capacity	  to	  give	  rise	  to	  rare	   hemogenic	   endothelial	   cells,	   while	   emphasizing	   a	   rare	   hemogenic	   endothelium	  population	  and	  time	  wise	  tight	  control	  of	  EHT	  (Eilken,	  Nishikawa,	  &	  Schroeder,	  2009a).	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3.2.2. Markers	  to	  study	  EHT	  	  EHT	  can	  be	  defined	  by	  the	  change	  from	  endothelial	  to	  hematopoietic	  morphology	  in	  parallel	  with	  change	  of	  marker	  protein	  expressions.	  Endothelial	  cells	  are	   forming	  tight	  adhesion	  within	  each	  other	  and	  have	  elongated	  phenotype.	  VE-­‐Cadherin	  (Cdh-­‐5),	  Flk-­‐1,	  Tie-­‐2,	  CD31	  are	  a	  few	  markers	  of	  vascular	  endothelial	  cells.	  While	  these	  endothelial	  cells	  in	   the	   vascular	   lining	   going	   through	   the	   EHT,	   they	   lose	   their	   attachments	   with	   the	  neighboring	  cells	  and	  express	   less	  endothelial	  markers.	  The	  transiting	  cell	  has	  a	  round	  shape	  with	   slight	   attachment	   to	   the	   endothelial	   layer	   and	   start	   to	   express	   some	   early	  hematopoietic	  markers	  like	  CD41	  and	  C-­‐kit.	  Later	  those	  cells	  detach	  completely	  from	  the	  endothelial	   lining	  of	   the	  vessel	   and	  express	   less	  or	  no	  endothelial	  markers,	   in	  parallel	  with	   late	   hematopoietic	   marker	   expression	   like	   CD45.	   As	   a	   result	   of	   the	   EHT,	   the	  hematopoietic	  progenitor	  cells	  with	  round	  shape	  and	  hematopoietic	  marker	  expression	  appear	  in	  the	  vessel	  space.	  
3.2.3. The	  important	  transcriptional	  regulators	  of	  EHT	  	  The	   compilation	  of	   abovementioned	   studies	   on	   chicken,	   zebrafish	   and	  mouse	  puts	  forward	  a	  clear	  notion	  of	  EHT	  as	  highly	  regulated	  and	  conserved	  event,	  which	  is	  vital	  for	  development	  of	  blood	  system.	  Exploring	  the	  regulatory	  mechanisms	  of	  EHT	  will	  open	  a	  gate	   to	   understand	   the	  basics	   of	   EHT	   and	  more	   importantly	   to	   use	   that	   knowledge	   to	  generate	   blood	   cells	   for	   therapeutical	   applications.	   Until	   now,	   researchers	   revealed	   a	  few	  transcription	  factors,	  which	  has	  regulatory	  functions	  on	  EHT.	  
Runt-­‐related	  transcription	  factor	  1,	  AML1/Runx1	  is	  one	  of	  the	  crucial	  genes	  for	  EHT.	  The	  mutant	  Runx1	  mice	  die	  at	  E11-­‐13,	  due	  to	  severe	  hemorrhage	   in	  the	  brain	  and	  the	  trunk	  (Okuda	  et	  al.,	  1996;	  Q	  Wang	  et	  al.,	  1996).	  In	  the	  Runx1	  mutant	  embryos	  primitive	  erythropoiesis	   in	   the	   yolk	   sac	   is	   not	   affected	   but	   the	   lack	   of	   lymphoid	   and	   myeloid	  progenitors	   and	   HSCs	   indicate	   the	   vital	   role	   of	   Runx1	   in	   definitive	   hematopoiesis.	  (Yokomizo	   et	   al.,	   2008).	   Cbfb,	   a	   binding	   partner	   of	   Runx1,	   also	   has	   similar	   defective	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hematopoietic	  phenotype	  when	  mutated	  (Qing	  Wang	  et	  al.,	  1996).	  Further	  studies	  with	  mES	  cells	  reveal	  that	  Runx1	  deficient	  EBs	  generate	  normal	  primitive	  erythroid	  colonies	  but	   less	   BL-­‐CFC	   colonies	   coupled	   with	   less	   committed	   myeloid	   and	   lymphoid	  progenitors.	   This	   indicates	   that	   primitive	   erythropoiesis	   is	   independent	   of	   Runx1	  activity,	   on	   the	   other	   hand,	   Runx1	   seems	   regulating	   hematopoietic	   commitment	   of	  hemangioblasts	  and	  also	  further	  at	  EHT	  (Lacaud	  et	  al.,	  2002).	  
Although	   the	  knockout	  Runx1	  mice	  have	   clearly	  hematopoietic	   and	   cardiovascular	  deficient	   phenotype,	   Runx1	   gene	   is	   not	   only	   expressed	   during	   hematopoietic	  commitment.	  It	  is	  also	  expressed	  in	  brain	  and	  hair	  follicle	  cells.	  This	  means	  differential	  functions.	   Regarding	   the	   importance	   of	   its	   expression	   to	   define	   hematopoietic	  commitment,	  the	  understanding	  of	  its	  gene	  expression	  regulation	  is	  the	  key	  to	  trace	  the	  hematopoietic	  program.	  Studies	  about	  its	  promoter	  and	  enhancer	  show	  that	  only	  distal	  promoter	  of	  Runx1	   can	  be	   related	  with	  definitive	  hematopoietic	  development.	   (Bee	  et	  al.,	   2009;	   Enid	   Yi	   Ni	   Lam	   et	   al.,	   2009;	   Nottingham	   et	   al.,	   2007).	   To	   use	   that	   specific	  function	   of	   distal	   Runx1	   promoter,	   a	   mouse	   reporter	   line	   is	   made	   with	   GFP	   on	   +23	  promoter/enhancer	   position	   of	   Runx1(Bee	   et	   al.,	   2010).	   Aiming	   at	   isolation	   of	  hemogenic	  endothelium,	  another	  reporter	  mouse	  ES	  cell	  line	  is	  generated	  by	  integration	  of	  human	  CD4	  gene	  into	  the	  distal	  promoter	  (Sroczynska,	  Lancrin,	  Kouskoff,	  &	  Lacaud,	  2009b).	  
Since	   Runx1	   is	   vital	   for	   EHT,	   downstream	   targets	   of	   Runx1	   took	   the	   interest	   of	  Christophe	  Lancrin	   for	   the	  potential	   to	  understand	   the	  mechanism	  of	  EHT.	  When	   they	  studied	   the	   transcriptome	  of	  Runx1	  mutant	  mES	  cell	   line	  by	  microarray	  analysis,	   they	  found	   that	  Gfi1	  and	  Gfi1b	  genes	  are	  up-­‐regulated	  by	  Runx1.	  Furthermore,	  ectopic	  Gfi1	  expression	  rescues	  the	  deficient	  EHT	  phenotype	  in	  Runx1-­‐/-­‐	  mESCs.	  Gfi1	  and	  Gfi1b	  are	  transcriptional	  repressors	  which	  are	  also	  found	  mutated	  in	  blood	  cancer	  cases(Grimes,	  Chan,	   Zweidler-­‐McKay,	   Tong,	   &	   Tsichlis,	   1996).	   Further	   assessment	   of	   Gfi1	   over-­‐
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expression	  suggested	  that	  the	  expression	  of	  Gfi1	  and	  Gfi1b	  at	  the	  early	  stages	  of	  EHT	  is	  responsible	  for	  the	  endothelial	  phenotype	  loss	  (Lancrin	  et	  al.,	  2012).	  	  
3.2.4. The	  important	  signaling	  pathways	  of	  EHT	  Hematopoietic	   clusters	   are	   found	   all	   around	   the	  main	   arteries	   of	   E10.5	   and	  E11.0	  embryos,	   but	   within	   dorsal	   aorta	   the	   hematopoietic	   clusters	   are	   reported	   to	   be	  dominantly	   at	   the	   ventral	  wall	   (Yokomizo	  &	  Dzierzak,	   2010).	   It	   has	   been	   argued	   that	  hematopoietic	  stem	  cells	  are	  originating	  only	  from	  the	  ventral	  wall	  endothelium	  (Taoudi	  &	  Medvinsky,	   2007).	   Previous	   studies	   on	   chicken	  may	   explain	   the	   dorsal-­‐ventral	   axis	  dependence	  of	  EHT	  with	  different	  growth	  factors	  secreted	  from	  dorsal	  and	  ventral	  part	  of	  the	  aorta.	  Hematopoiesis	  suppressor	  EGF	  is	  present	  in	  the	  dorsal	  while	  hematopoiesis	  enhancer	  BMP	  is	  present	  in	  the	  ventral	  part	  of	  the	  chicken	  AGM.	  Therefore,	  gradient	  of	  EGF	  versus	  BMP	  signals	   are	   formed	  at	   the	  dorsal-­‐ventral	   axis(Pardanaud	  &	  Dieterlen-­‐Lièvre,	   1999).	   Additionally,	   the	   ventrally	   expressed	   BMP4	   is	   shown	   to	   enhance	   HSC	  growth	  in	  AGM	  (Durand	  et	  al.,	  2007).	  
Not	   only	   the	   signaling	   molecules	   but	   surprisingly	   also	   the	   blood	   flow	   and	  biomechanical	   forces	   are	   shown	   to	   be	   crucial	   for	   EHT.	  When	  Ncx1	   gene	   is	   inactive,	   it	  results	   in	   embryonic	   lethal	   phenotype	   with	   no	   heartbeat	   although	   a	   fully	   formed	  vasculature	  and	  normal	  endothelial	  cells	  (Koushik	  et	  al.,	  2001).	  	  
Ncx-­‐1	  mutant	  mouse	   is	   shown	   to	  have	  normal	  yolk	   sac	  hematopoiesis	  but	  embryo	  proper	  doesn’t	  have	  hematopoietic	  progenitors(Lux	  et	  al.,	  2008).	  This	  may	  mean	  either	  the	  role	  of	  migration	  of	  yolk	  sac	  derived	  hematopoietic	  cell	   to	   initiate	   intra-­‐embryonic	  hematopoiesis	  or	  the	  role	  of	  normal	  biomechanical	  forces	  in	  circulation	  with	  functional	  heart	  to	  initiate	  EHT.	  Additional	  studies	  shed	  light	  on	  the	  later	  option.	  	  
Sheer	  stress	  generated	  with	  blood	  flow	  can	  be	  sensed	  by	  the	  endothelial	  cells	  of	  the	  vessels	   through	   mechanoreceptors	   and	   triggers	   a	   signaling	   pathway.	   Two	   groups	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showed	  that	  sheer	  stress	  triggers	  nitric	  oxide	  signaling	  even	  in	  vitro	  cultured	  cells	  and	  absence	   of	   this	   biomechanical	   force	   leads	   to	   decreased	   HSC	   emergence(Adamo	   et	   al.,	  2009;	  T.	  E.	  North	  et	  al.,	  2009)	  .	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Chapter2:	  Materials	  and	  Methods	  
1. Mouse	  embryonic	  stem	  cell	  culture	  and	  in	  vitro	  differentiation	  
1.1. General	  conditions	  of	  in	  vitro	  cell	  culture	  All	   in	   vitro	   cell	   culture	   experiments	   done	   under	   the	   laminar	   hood	   (Heraeus	  Hera	  Safe	  HS12,	  ThermoScientific),	  authorized	   to	  be	  used	  by	  only	  Lancrin	   lab	  members	  and	  for	  only	  cell	  lines	  derived	  from	  mouse.	  Before	  each	  use,	  the	  laminar	  hood	  was	  turned	  on	  for	  at	  least	  15	  minutes.	  Only	  sterile	  pipette	  tips	  and	  plastic	  pipettes	  are	  used.	  Every	  item	  put	   inside	   the	   hood	   is	   cleaned	   first	  with	   surface	   disinfectant	   1:100	   Chemgene	  HLD4L	  solution	  (MediMark	  Scientific	  Ref#:	  15126686).	  The	  regular	  cleaning	  is	  done	  with	  1:100	  Chemgene	   solution	   in	   every	   use	   of	   equipment,	   and	   weekly	   change	   of	   water	   in	   the	  waterbath,	  cleaning	  inside	  of	  the	  laminar	  hoods,	  cleaning	  of	  the	  aspirating	  pumps.	  	  The	  cell	  incubators	  are	  with	  steady	  state	  at	  37°C	  and	  5%	  carbon	  dioxide	  (Heraeus	  HeraCell	  and	  Thermo	  Scientific	  Series	  II	  Water	  Jacket).	  
1.2. mES	  cell	  maintenance	  culture	  
1.2.1. Medium	  preparation	  To	  decrease	  the	  risk	  of	  contamination,	  some	  measures	  are	  taken	  in	  advance.	  All	  the	  mediums	  are	  prepared	  under	  the	  laminar	  hood.	  Most	  of	  the	  reagents	  are	  aliquoted	  and	  each	  person	  uses	  a	  separate	  aliquot	  or	  a	  complete	  bottle.	   If	   the	  medium	  is	  going	   to	  be	  used	   for	  cells	   to	  be	  plated,	   they	  are	  sterile	   filtered	  with	  0.22µm	  porous	  syringe	  driven	  filters	  (Millipore	  Millex,	  Ref#:	  SLGP033RS)	  or	  vacuum	  driven	  filters	  (Millipore	  SteriCup,	  Ref#:	   SCGPU01RE).	   Prepared	   mediums	   are	   stored	   at	   4°C	   fridge	   to	   be	   used	   within	  maximum1	  month.	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1.2.2. Gelatinization	  of	  culture	  plates	  and	  dishes	  Culture	  treated	  dishes	  and	  plates	  are	  used	  to	  culture	  adherent	  cells,	  with	  exception	  of	   embryoid	   body	   culture	   in	   suspension.	   To	   increase	   adhesion	   and	   survival	   of	   the	  seeded	   cells,	   coating	   the	   dishes	   and	   plates	   with	   0.1%	   gelatin	   is	   needed.	   First	   sterile	  filtered	   1xPBS	   (Oxoid	   tablets,	   Cat:	   BR00146)	   solution	   is	   prepared	   in	   distilled	   water	  (GIBCO,	  Cat:	  15230-­‐147)	  for	  cell	  culture	  use	  only.	  Sterile	  filtered	  0.1%	  gelatin	  (BDH,	  Cat:	  440454B)	  solution	  in	  1xPBS	  is	  prepared.	  Before	  seeding	  the	  cells,	  gelatin	  solution	  is	  put	  into	  dishes	  to	  cover	  the	  bottom	  and	  kept	  at	  room	  temperature	  at	  least	  20	  minutes	  under	  the	  laminar	  hood.	  
1.2.3. Mouse	  embryonic	  fibroblast	  (MEF)	  coating	  as	  feeder	  cells	  Embryonic	  fibroblast	  cells	  are	  isolated	  from	  13	  days	  post	  coitus	  stage	  embryos	  from	  mouse	  line	  with	  Neomycin	  resistance	  transgene.	  Primary	  cell	  line	  is	  generated	  from	  the	  freshly	  isolated	  embryonic	  fibroblasts	  and	  then	  frozen	  in	  40%	  Fetal	  Bovine	  Serum	  (FBS)	  (PAA	  Clone,	  Cat:	  A15-­‐102)	  at	  -­‐80°C	  freezer,	  transferred	  to	  liquid	  nitrogen	  tank.	  To	  make	  a	  stock	  of	  MEFs,	   the	  primary	  cell	  containing	  vial	   is	   thawed	   in	  one	  15cm	  dish.	  Cells	  are	  passaged	  for	  two	  times	  in	  15	  cm	  dishes	  and	  grown	  for	  5	  days.	  After	  5	  days,	  the	  MEFs	  are	  in	  15	  x	  15cm	  dishes	  with	  70-­‐90%	  confluence.	  The	  old	  medium	  is	  removed	  and	  the	  cells	  are	   incubated	   in	   a	   medium	   containing	   Mitomycin	   C	   at	   10µg/ml	   final	   concentration	  (Sigma,	  Ref#:	  M4287-­‐2mg	  dissolved	  in	  1xPBS	  and	  mixed	  with	  MEF	  medium)	  solution	  for	  3	   hours	   in	   the	   incubator.	   After	   2	   washings	   with	   1xPBS,	   all	   MEFs	   are	   harvested	   and	  counted.	  The	  mitomycin	  treated,	  neomycin	  resistant	  MEFs	  are	  frozen	  as	  approximately	  2x106	  cell	  per	  vial	  in	  a	  freezing	  medium	  containing	  DMEM	  (GIBCO,	  Ref:	  41965-­‐039)	  with	  40%	  FBS	  (PAA	  Clone,	  Cat:	  A15-­‐102)	  and	  10%	  DMSO	  (Sigma,	  Ref:	  D2438).	  All	   cells	  are	  suspended	   in	   freezing	   medium	   and	   frozen	   at	   -­‐80°C	   first	   then	   transferred	   into	   liquid	  nitrogen	  tank	  for	  long-­‐term	  storage.	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At	  least	  one	  day	  before	  starting	  the	  ES	  cell	  culture,	  the	  culture	  plate	  has	  to	  be	  coated	  with	  Mitomycin	   treated	   Neomycin	   resistant	  MEF.	   One	   vial	   of	   stock	  MEF	   consisting	   of	  2x106	  cells,	  is	  thawed	  in	  10	  gelatinized	  wells	  of	  6-­‐well-­‐plate.	  The	  medium	  to	  be	  used	  for	  MEF	  thawing	  is	  the	  same	  medium	  of	  ES	  cell	  growing,	  because	  afterwards	  ES	  cells	  will	  be	  introduced	  on	  top	  of	  this	  MEFs.	  
1.2.4. Mouse	  embryonic	  stem	  (mES)	  cell	  expansion	  culture	  The	  mES	  cell	  lines	  I	  used	  in	  my	  experiments	  are	  feeder	  dependent,	  so	  coating	  of	  the	  culture	   dishes	   with	   MEFs	   beforehand	   is	   necessary,	   as	   it	   is	   described	   in	   the	   previous	  section.	  Minimum	  after	   12	   hours	   of	   coating	  with	  MEFs,	   one	   vial	   of	  mES	   cell	   line	   (0.6-­‐1.2x10^6	   cells/vial)	   is	   thawed	   on	   1	   well	   of	   MEF	   coated	   6-­‐well-­‐plate	   in	   the	   medium	  containing	   DMEM-­‐KO	   (GIBCO,	   Ref:	   10829-­‐018)	   with	   15%	   FBS	   (PAA	   Clone,	   Cat:	   A15-­‐102),	   0.024µg/ml	   LIF	   (produced	   in	   EMBL	   HD	   protein	   expression	   facility,	   stock	  concentration	   1mg/ml),	   0.12mM	   β-­‐Mercapto-­‐ethanol	   (GIBCO,	   Ref:	   31350-­‐010),	   1%	  Penicillin/Streptomycin	  (GIBCO,	  Ref:	  15140-­‐122),	  1%	  L-­‐Glutamine	  (GIBCO,	  Ref:	  25030-­‐024),	  	  1%	  non-­‐essential	  amino	  acids	  (GIBCO,	  Ref:	  11140-­‐035).	  	  	  
The	  same	  medium	  is	  used	  for	  splitting	  the	  mES	  cells.	  The	  next	  day	  after	  thawing	  mES	  cells,	   the	   cells	   are	   harvested.	   First	   of	   all,	   the	   medium	   is	   aspirated	   and	   1ml	   of	   warm	  TrypLE-­‐Express	  (GIBCO,	  Ref:12605-­‐010)	   is	  kept	  on	  cells	   for	  3	  minutes.	  The	  reaction	  is	  stopped	  by	  adding	  1ml	  of	  medium	  and	  the	  detached	  cells	  are	  collected	  in	  a	  tube.	  Then	  the	  cells	  are	  counted	  by	  using	  hemocytometer.	  For	  splitting	  into	  MEF	  coated	  wells	  of	  6-­‐well-­‐plate,	   cell	   density	   of	   0.3*10^6	   cell/well	   is	   needed.	   The	   volume	   is	   calculated	   and	  mixed	  with	  necessary	  amount	  of	  fresh	  medium.	  The	  old	  medium	  inside	  the	  MEF	  coated	  wells	   is	   aspirated.	   The	   homogenized	   cell	   mix	   is	   added	   on	   top	   of	   wells.	   The	   cells	   are	  passaged	  on	  MEFS	  exactly	  2	  times	  after	  thawing.	  	  
For	   making	   a	   stock	   of	   mES	   cells,	   at	   the	   second	   passage	   after	   the	   thawing,	   the	  harvested	  cells	  can	  be	  frozen.	  There	  should	  be	  at	  least	  0.6*10^6	  cells/vial.	  The	  freezing	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medium	   is	   the	   DMEM-­‐KO	   with	   1%	   Penicillin/Streptomycin	   (GIBCO,	   Ref:	   15140-­‐122),	  1%	  L-­‐Glutamine	   (GIBCO,	   Ref:	   25030-­‐024),	   1%	  non-­‐essential	   amino	   acids	   (GIBCO,	   Ref:	  11140-­‐035),	   40%FBS	   (PAA	   Clone,	   Cat:	   A15-­‐102)	   and	   10%DMSO(Sigma,	   Ref:	   D2438).	  Freezing	   is	   done	   first	   at	   -­‐80°C	   and	   then	   the	   vials	   are	   transferred	   into	   liquid	   nitrogen	  tank.	  
After	   2	   passages	   on	   MEFs,	   feeder	   cells	   should	   be	   eliminated	   before	   starting	   the	  differentiation	   of	   mES	   cells.	   For	   that,	   2	   more	   passages	   are	   needed	   on	   gelatin	   coated	  wells.	   The	   splitting	   process	   is	   exactly	   the	   same	   from	   cells	   on	   MEF,	   except	   that	   the	  TrypLE	   reaction	   takes	   place	   only	   for	   2	   minutes	   to	   detach	   less	   MEFs.	   Although	   some	  MEFs	  can	  still	  be	  carried	  over	  to	  the	  new	  wells,	  since	  MEFs	  cannot	  proliferate,	  there	  will	  be	  less	  MEFs	  after	  2	  passages.	  Before	  starting	  the	  differentiation	  of	  mES	  cells,	  in	  the	  last	  passage	   on	   gelatin,	   the	   medium	   base	   DMEM-­‐KO	   is	   replaced	   by	   IMDM	   for	   better	  adaptation	  into	  the	  differentiation	  medium	  later.	  The	  IMDM	  based	  stock	  medium;	  IMDM	  (Lonza,	  Ref:	  BE12-­‐726F),	   1%	  Penicillin/Streptomycin	   (GIBCO,	  Ref:	   15140-­‐122),	   1%	  L-­‐Glutamine	  (GIBCO,	  Ref:	  25030-­‐024),	  	  is	  preraed	  and	  named	  as	  IMDM*	  in	  the	  rest	  of	  the	  protocol.	  
1.2.5. Embryoid	  body	  (EB)	  culture	  EB	   mix	   is	   prepared	   with	   IMDM	   (Lonza,	   Ref:	   BE12-­‐726F),	   1%	  Penicillin/Streptomycin	  (GIBCO,	  Ref:	  15140-­‐122),	  1%	  L-­‐Glutamine	  (GIBCO,	  Ref:	  25030-­‐024),	   0.6%	   Transferrin	   (Roche,	   Ref:	   10652),	   0.03%	   MTG	   (Sigma,	   Ref:	   M6145-­‐25ml),	  50mg/ul	  Ascorbic	  Acid	  (Sigma,	  Ref:	  A-­‐4544)	  and	  sterile	  filtered	  through	  0.22µm	  vacuum	  driven	   filtration	  unit	   (Millipore	  SteriCup,	  Cat:	   SCGPU	  01RE).	  mES	   cells	   on	  gelatin	  with	  IMDM-­‐ES	  medium	  are	  harvested	  after	  2	  minutes	  of	   treatment	  of	  TrypLE	  and	   total	   cell	  number	   is	   counted.	  The	  cell	  density	   should	  be	  0.25*10^6	  cell/10	  cm	  dish	   in	  10mL	  EB	  mix.	   The	   necessary	   amount	   of	   cells	   are	   mixed	   with	   calculated	   volume	   of	   warm	   EB	  medium	  and	  then	  distributed	  into	  10cm	  dishes	  (Sterilin)	  very	  slowly	  through	  the	  walls	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of	   the	  dishes.	   The	  dishes	   are	  non-­‐culture	   treated,	   for	   non-­‐adherent	   cultures.	   The	   cells	  are	  kept	  in	  the	  incubator	  for	  3	  days	  and	  monitored	  daily	  monitoring.	  Usually	  the	  EBs	  are	  forming	   from	   the	  day	  1	   and	   some	  of	   them	  attached	   to	   the	  bottom,	  which	   is	   inhibiting	  their	   proper	   differentiation.	   At	   the	   second	   day,	   to	   eliminate	   those	   sticky	   EBs,	   the	  medium	  with	  floating	  EBs	  is	  slowly	  transferred	  into	  a	  fresh	  dish.	  At	  day	  3	  of	  EB	  culture,	  the	  diameter	  of	  the	  EBs	  can	  reach	  to	  200µm.	  
1.2.6. Isolation	  of	  blast	  colony	  forming	  cells	  from	  EBs	  Inside	   the	   EBs,	   there	   are	   several	   types	   of	   cells	   differentiating,	   including	   the	   blast	  colony	   forming	  cells	   (BL-­‐CFCs),	  which	  can	  give	   rise	   to	  hematopoietic	   cells,	   endothelial	  cells	   and	   smooth	   muscle	   cells.	   BL-­‐CFCs	   inside	   the	   EBs	   are	   present	   in	   the	   Flk-­‐1+	  population	  between	  day	  3	  and	  day	  3.5	  and	  can	  be	  isolated	  with	  this	  cell	  surface	  marker.	  The	  maximum	  amount	  of	  Flk-­‐1+	  cells	  can	  be	  isolated	  at	  day3.25.	  In	  order	  to	  isolate	  the	  BL-­‐CFCs	   at	   day3.25	   EB	   culture,	   I	   used	   magnetic-­‐activated	   cell	   separation	   (MACS)	  technique	  to	  elute	  cell	  population	  enriched	  for	  Flk-­‐1	  expressing	  cells.	  All	  EBs	  are	  pooled	  down	  together	  in	  the	  same	  tube,	  centrifuged	  to	  pellet	  them	  and	  remove	  the	  media.	  Then	  2ml	   TrypLE/tube	   is	   applied	   for	   2	   minutes	   in	   the	   37°C	   waterbath	   while	   shaking	   the	  tubes.	   The	   reaction	   is	   stopped	   by	   adding	   5ml	   of	   IMDM+20%FBS.	   The	   single	   cell	  suspension	   is	   filtered	   through	   0.22µm	   pores.	   The	   dead	   cells	   are	   removed	   in	   cell	  suspension	   with	   a	   separate	   phase	   of	   lymphocyte	   separation	   medium	   1077	   (GE	  Healthcare,	  Ref:	   J11-­‐004)	  by	   centrifuging	   at	  800g	   for	  20	  minutes	  without	   acceleration	  and	   brake.	   After	   centrifuging	   the	   middle	   phase	   includes	   alive	   cells.	   They	   are	  resuspended	  and	  counted	  with	  a	  hemocytometer.	  The	   first	  staining	  of	  cells	   is	   in	  MACS	  buffer	   (1xPBS,	   0.5%	   FBS,	   0.5mM	   EDTA	   sterile	   filtered)	   with	   cell	   density	   of	   1*10ˆ8	  cell/ml	   and	   1/33	   diluted	   Flk-­‐1-­‐APC	   antibody	   (eBioscience,	   Ref:	   17-­‐5821-­‐81)	   for	   5	  minutes	  at	  4°C	  fridge,	  light-­‐protected.	  Afterwards	  the	  cells	  are	  washed	  with	  10ml	  MACS	  buffer	  and	  spun	  down	  with	  1200rpm	  for	  5minutes.	  The	  second	  staining	  is	  done	  with	  cell	  density	   of	   1*10ˆ8	   cell/ml	   in	   MACS	   buffer	   and	   1/5	   diluted	   anti-­‐APC	   magnetic	   beads	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(Miltenyi	  Biotech,	  Ref:	  130-­‐090-­‐855)	  for	  15	  minutes	  at	  4°C	  fridge,	  light-­‐protected.	  Again	  the	  cells	  are	  washed	  and	  resuspended	  in	  500ul	  of	  MACS	  buffer.	  For	  magnetic	  sorting,	  the	  cell	  suspension	  is	  put	  through	  LS	  columns	  (Miltenyi	  Biotec,	  Ref:	  130-­‐042-­‐401)	  attached	  to	  medium	   size	  magnet.	   After	   3	  washings	  with	  MACS	   buffer,	   the	   column	   is	   separated	  from	  the	  magnet	  and	  the	  plunger	  made	  the	  Flk-­‐1+	  cell	  population	  is	  eluted	  in	  the	  tube.	  With	  that	  method,	  approximately	  90%	  purity	  can	  be	  reached	  in	  the	  Flk-­‐1+	  fraction.	  
1.2.7. Blast	  culture	  The	  Flk-­‐1+	  cells	  are	  resuspended	  and	  counted	  in	  IMDM*+20%	  FBS	  (PAA	  Clone,	  Cat:	  A15-­‐102)	   medium.	   The	   cell	   density	   should	   be	   0.10*10ˆ6	   cells/cm2,	   which	   makes	  0.55*10ˆ6	  cells	  per	  10cm	  dish	  or	  0.10*10ˆ6	  cells	  per	  1	  well	  of	  6	  well	  plate.	  The	  needed	  wells	   or	  dishes	   are	   gelatinized	  beforehand.	  The	  Blast	  medium	   is	   prepared	   as	   IMDM*+	  15%FBS	   (PAA	   Clone,	   Cat:	   A15-­‐102),	   0.03%	   MTG	   (Sigma,	   Ref:	   M6145-­‐25ml),	  0.025mg/ml	  Ascorbic	   acid	   (Sigma,	  Ref:	  A-­‐4544),	   1%	  L-­‐Glutamine	   (GIBCO,	  Ref:	   25030-­‐024),	   0.6%	   Transferrin	   (Roche,	   Ref:10652-­‐202-­‐001),	   0.005µg/ml	   VEGF	   (RandD,	   Ref:	  293-­‐VE-­‐010),	   0.01µg/ml	   IL-­‐6	   (RandD,	   Ref:	   406-­‐ML),	   D4T	   supernatant	   and	   sterile	  filtered.	   	   D4T	   supernatant	   is	   prepared	   as	   the	   medium	   (30mg	   Endothelial	   Cell	  growth	  supplement	   (Lot	   81879)	   added	   into	   500	   ml	   of	   IMDM	   10%	   FBS)	   of	   D4T	  endothelial	  cells	  collected	  after	  culture	  for	  4-­‐10	  days.	  The	  cells	  are	  mixed	  with	  necessary	  amount	  of	  blat	  mix	  and	  put	  on	  the	  gelatinized	  wells	  and	  dishes.	  
1.2.8. Hemogenic	  endothelium	  culture	  In	   order	   to	   facilitate	   endothelial	   to	   hematopoietic	   transition,	   we	   used	   another	  culture	  medium	  consisting	  of	   IMDM*	  (IMDM	  with	  1%	  L-­‐Glutamine	  and	  1%	  L-­‐Ascorbic	  Acid),	   10%	  FBS	   (PAA	   Clone,	   Cat:	   A15-­‐102)	   +	   1%	   L-­‐Glutamine	   (GIBCO,	   Ref:	   25030-­‐024),	  	  0.6%	   Transferrin	   (Roche,	   Ref:10652-­‐202-­‐001),	  0.03%	  MTG	  (Sigma,	   Ref:	   M6145-­‐25ml),	  	  
0.05mg/ml	  Ascorbic	  acid	  (Sigma,	  Ref:	  A-­‐4544),	   	  0.024µg/ml	  LIF	   (produced	   in	  EMBL	  HD	  protein	  expression	  facility,	  stock	  concentration	  1mg/ml),	  0.05µg/ml	  SCF	  (Peprotech,	  Cat:	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250-­‐03),	  0.025µg/ml	  IL-­‐3	  (RandD,	  Cat:	  403-­‐ML),	  0.005µg/ml	  IL-­‐11	  (RandD,	  Cat:	  418-­‐ML),	  
0.01µg/ml	   IL-­‐6	   (RandD,	   Cat:	   406-­‐ML),	   0.01	   µg/ml	   OncostatinM	   (RandD,	   Cat:	   495-­‐MO),	  	  
0.001µg/ml	   bFGF	   (recombinant	   human	   bFGF,	   RandD,	   Ref:233-­‐FB).	   The	   sterile	   filtered	  
medium	  prepared	  and	  the	  cells	  are	  plated	  in	  the	  density	  of	  0.20*10ˆ6	  cells/cm2.	   It	   can	  be	  kept	  in	  the	  incubator	  for	  maximum	  3	  days	  without	  changing	  the	  medium.	  
1.2.9. Hematopoietic	  progenitor	  culture	  Later	  to	  test	  the	  potential	  of	  cells	  to	  give	  rise	  to	  myeloid	  and	  erythroid	  cells,	  we	  used	  hematopoietic	   progenitor	   culture,	   which	   contains	   growth	   factors	   to	   facilitate	  hematopoietic	  commitment.	  It	  is	  a	  semi-­‐liquid	  medium	  with	  55%	  methylcellulose	  (VWR,	  	  Ref:	  9004-­‐67-­‐5	  500g	  dissolved	  in	  1L	  IMDM	  solution).	  The	  medium	  is	  first	  prepared	  with	  liquid	   ingredients,	   which	   are	   IMDM*	   (Lonza,	   Ref:	   BE12-­‐726F),	   15%	   PDS	   serum	  replacement	   (Antech),	   1%	  L-­‐Glutamine	   (GIBCO,	  Ref:	   25030-­‐024),	   0.05mg/ml	  Ascorbic	  acid	   (Sigma,	   Ref:	   A-­‐4544),	   0.6%	  Transferrin	   (Roche,	   Ref:10652-­‐202-­‐001),	   0.03%	  MTG	  (Sigma,	   Ref:	   M6145-­‐25ml),	   10%	   PFMH-­‐II	   (GIBCO,	   Ref:12040-­‐077),	   0.05µg/ml	  murine	  SCF	  (Peprotech,	  Cat:	  250-­‐03),	  0,025µg/ml	  IL-­‐3	  (RandD,	  Cat:	  403-­‐ML),	  Epo	  (RandD,	  Cat:	  959-­‐ME),	   GM-­‐CSF	   (RandD,	   Cat:	   425-­‐ML),	   M-­‐CSF	   (RandD,	   Cat:	   416-­‐ML),	   Oncostatin	   M	  (RandD,	  Cat:	  495-­‐MO),	  0.01µg/ml	  IL-­‐6	  (RandD,	  Cat:	  406-­‐ML),	  0.005µg/ml	  IL-­‐11	  (RandD,	  Cat:	  418-­‐ML),	  0.024ug/ml	  LIF	  (produced	  in	  EMBL	  HD	  protein	  expression	  facility,	  stock	  concentration	  1mg/ml),	  0.001mg/ml	  bFGF	  (recombinant	  human	  bFGF,	  RandD,	  Ref:233-­‐FB).	   	  The	  sterile	   filtered	  medium	  is	  prepared	  and	  then	  the	  0.09*10ˆ6cells	  are	  mixed	   in	  1.7ml	  of	  the	  filtered	  medium,	  and	  they	  are	  mixed	  with	  1.8ml	  of	  warm	  methyl-­‐cellulose.	  To	  make	   a	   homogenous	  mix,	   the	   tube	   is	   vortexed	   for	   a	  minute.	   By	   using	   syringe,	   the	  viscous	  liquid	  is	  distributed	  into	  3	  dishes	  (50mm,	  Sterilin,	  item	  code	  122).	  Then	  3	  dishes	  are	   incubated	   for	   8	   days.	   The	   number	   of	   colonies	  with	   their	   phenotype	   is	   counted	   at	  day5	   and	   at	   day8	   of	   the	   culture.	   The	   classification	   of	   colonies	   is	   done	   according	   to	  literature.	  The	  average	  of	  the	  counts	  from	  3	  dishes	  is	  taken	  for	  each	  condition.	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2. Defining	  cell	  type	  and	  population	  identity	  
2.1. Flow	  cytometry	  and	  Fluorescent-­‐activated	  cell	  sorting	  All	  stainings	  are	  done	  with	  single	  cell	  suspensions	  with	  known	  cell	  count.	  Staining	  is	  performed	   in	   1xPBS+5%FBS	   (PAA	  Clone,	   Cat:	   A15-­‐102)	   	   if	   the	   cells	   are	   used	   only	   for	  flow	  cytometry	  analysis.	  Otherwise,	  when	   the	   cells	   are	  going	   to	  be	   seeded	  afterwards,	  the	   staining	   is	   done	   in	   IMDM*+10%FBS	   and	   sorted	   cells	   are	   collected	   in	  IMDM*+20%FBS.	   Fluorophore	   conjugated	   antibodies	   are	   used	   for	   single	   staining	  otherwise	  a	  primary	  antibody	  with	  secondary	  and/or	  tertiary	  antibodies	  are	  used,	  as	  it	  is	  explained	  in	  the	  table.	  The	  equipment	  and	  technical	  support	  is	  provided	  by	  the	  EMBL	  Monterotondo	   flow	   cytometry	   facility.	   Flow	   cytometry	   analysis	   is	   performed	   on	   FACS	  Canto	  and	  FACS	  Aria	  (both	  from	  BD	  Biosciences),	  cell	  sorting	  is	  performed	  only	  with	  the	  FACS	  Aria.	  All	  of	  the	  raw	  data	  is	  analyzed	  by	  using	  the	  FlowJo	  software	  (Tree	  Star).	  The	  graphs	  shown	  in	  the	  figures	  are	  after	  gating	  of	  live	  cell	  population	  without	  doublets.	  For	  dead	   cell	   staining,	   either	   100X	   7AAD	   (Sigma,	   Cat:A9400-­‐1MG,	   dissolved	   in	  1xPBS+Mg+Ca,	   final	   concentration	   1mg/ml)	   or	   100X	   Sytox	   Blue	   (Invitrogen,	   Cat:	  S34857,	   dissolved	   in	   DMSO,	   final	   concentration	   is	   0.1mM)	   is	   used,	   depending	   on	   the	  combination	  with	  other	  flurophores.	  	  
Anti-­‐	   Alternative	  
name	  
Clone	   Conjugated	   Catalog	  n.	  
(eBiosciences)	  
Diluti
on	  CD309	   Flk-­‐1	   Avas12a1	   APC	   17-­‐5821-­‐81	   1/33	  hCD4	   T4,	  L3T4	   S3.5	   PE	   MHCD04044	  (invitrogen	  life	  tech.)	   1/300	  CD41	   Integrin	  alpha2b	   eBioMWReg30	   Bio	   13-­‐0411-­‐81	   1/200	  CD41	   Integrin	  alpha2b	   eBioMWReg30	   PE	   12-­‐0411-­‐82	   1/400	  CD144	   VE-­‐Cadherin,	  Cdh-­‐5	   eBioBV13	   Fluor®	  660	  (replacement	  of	  Alexa647)	   50-­‐1441-­‐82	   1/200	  Streptavidin	   SA,	  SAV	   	   PE-­‐Cy7	   25-­‐4317-­‐82	   1/300	  
Table	  2.1	  Antibodies	  used	  for	  flow	  cytometry	  analysis	  and	  sorting	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2.2. Bright	  field	  and	  time-­‐lapse	  imaging	  Cell	   morphology	   and	   growth	   is	   regularly	   monitored	   by	   using	   Leica	   bright	   field	  microscopy.	   The	   phase-­‐contrast,	   time	   lapse	   images	   were	   taken	  with	   the	   IncuCyte	   HD	  (Essen	  Biosciences)	  inside	  the	  incubator,	  every	  15	  minutes,	  9	  spots	  in	  a	  well.	  The	  time-­‐lapse	   video	   is	   generated	   as	   10	   frames	   per	   second	   by	   using	   Fiji	   software.	   For	  quantification	  of	   the	  number	  of	   round	  cells	   in	  each	   frame,	   the	   image	  stacks	   from	  each	  spot	  is	  analyzed	  by	  CellProfiler	  software	  with	  a	  customized	  pipeline	  written	  by	  Christian	  Tischer	  from	  EMBL	  Heidelberg	  Advanced	  Light	  Microscopy	  Facility.	  For	  each	  time	  point,	  the	  average	  and	   standard	  deviation	  of	   counts	   from	  each	  9	   spots	   is	   calculated	   to	  make	  graph	  on	  Microsoft	  Office	  Excel	  software.	  
2.3. Total	  RNA	  extraction	  from	  frozen	  cell	  pellets	  The	   in	  vitro	   cultured	  cells	   are	   collected	   in	  a	   tube	  and	  centrifuged	   for	  5	  minutes	  at	  2000rpm.	  Then	  the	  supernatant	  is	  aspirated,	  leaving	  only	  the	  cell	  pellet	  at	  the	  bottom	  of	  the	  tube,	  which	  is	  snap-­‐frozen	  on	  dry-­‐ice.	  The	  cell	  pellet	  is	  kept	  at	  -­‐80°C	  for	  maximum	  1	  month	  storage.	  For	  RNA	  extraction	  the	  supplier’s	  (Qiagen)	  protocol	  is	  followed.	  The	  cells	  are	  lysed	  into	  RLT	  buffer	  with	  1%	  β-­‐Mercapto	  ethanol	  and	  homogenized	  by	  centrifuging	  on	  QIAshredder	  columns.	   If	   the	  number	  of	  cells	  are	  within	  the	  range	  of	  3*10^6cells	   to	  0.5*10^6	  cells,	  RNA	  extraction	  is	  done	  by	  using	  Qiagen	  RNeasy	  Plus	  Mini	  kit.	  If	  the	  cell	  number	   is	   lower	   than	   0.5*10^6cells,	   the	   Qiagen	   RNeasy	   Micro	   kit	   is	   used	   for	   RNA	  extraction.	   After	   the	   elution	   of	   total	   RNA	  with	   RNase	   free	  water,	   the	   concentration	   is	  measured	   with	   Nanodrop	   and	   the	   samples	   are	   stored	   at	   -­‐80°C	   freezer	   for	   long	   term	  storage.	  
2.4. Reverse	  transcription	  For	   synthesizing	   cDNA,	   total	   RNA	   samples	   are	   thawed	   on	   ice.	   Depending	   on	   the	  measured	  concentration,	  necessary	  amount	  of	  RNA	  sample	  is	  put	  into	  the	  tubes.	  Reverse	  transcription	   reaction	   is	   done	   according	   to	   the	   RevertAid	  H	  Minus	   First	   Strand	   cDNA	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Synthesis	  kit	  (Thermo	  Scientific,	  K#1631).	  Random	  hexamer	  primers	  are	  used	  from	  the	  kit.	  Denaturation	  step	  is	  applied	  at	  65°C	  for	  5	  minutes.	  Then	  after	  addition	  of	  dNTP	  mix,	  RNase	  inhibitor,	  reaction	  buffer	  and	  reverse	  transcriptase	  enzyme,	  the	  tube	  is	  incubated	  at	  25°C	  for	  5	  minutes	  and	  at	  42°C	  for	  60	  minutes.	  For	  0.2ng	  template	  RNA,	  I	  diluted	  the	  final	  volume	  up	  to	  100µl.	  That	  concentration	  I	  kept	  for	  further	  qPCR	  reaction.	  
2.5. Quantitative	  real	  time	  polymerase	  chain	  reaction	  Primer	   design	   is	   done	   by	   using	   primer3	   based	   online	   tool	   from	   Roche	   universal	  probe	   center	   (http://lifescience.roche.com/shop/en/be/overviews/brand/universal-­‐probe-­‐library).	  We	   selected	   specifically	   intron	   spanning	   primers,	  which	  will	   recognize	  all	   transcript	   variants	   of	   a	   gene.	   We	   excluded	   primers	   with	   high	   probability	   of	  hybridization	  with	  itself	  or	  with	  its	  pair.	  Lastly	  the	  primers	  were	  checked	  for	  recognition	  of	   wanted	   transcripts	   but	   not	   other	   genes,	   by	   using	   nucleotide	   BLAST	   website	  (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi?PROGRAM=blastn&PAGE_TYPE=BlastSearch&LINK_LOC=blasthome).	   The	   designed	   primers	  were	   synthesized	   by	   Sigma	  Aldrich	  and	   resuspended	   at	   100mM	   in	   distilled	   water.	   The	   stock	   primers	   are	   kept	   at	   -­‐20°C	  freezer.	  (See	  Table	  2.2	  for	  the	  complete	  list	  of	  primers)	  
For	   qRT-­‐PCR	   reaction,	   LightCycler	   480	   SYBR	   Green	   I	   Master	   kit	   (Roche,	  04707516001)	   is	   used	   with	   Roche	   LightCycler	   480	   RT-­‐PCR	   instrument.	   For	   each	  reaction,	   2ul	   of	   PCR-­‐grade	  water	   (provided	   in	   the	   kit),	   0.5ul	   of	   10uM	   of	   forward	   and	  reverse	  primer	  mix,	  5ul	  of	  2x	  master	  mix	  (provided	  in	  the	  kit)	  and	  finally	  2.5ul	  of	  cDNA	  template	   is	   added	   into	   one	   well	   in	   a	   96	   well	   plate.	   The	   reaction	   program	   has	   initial	  denaturation	  at	  95°C	  for	  5	  minutes,	  then	  45	  amplification	  cycles	  of	  95°C,	  60°C,	  72°C	  for	  10seconds	  in	  each	  temperature.	  At	  the	  end	  of	  amplification	  cycles,	  melting	  curve	  step	  is	  added	  as	  95°C	  for	  5	  seconds,	  65°C	  for	  1	  minute	  and	  continuously	  increasing	  up	  to	  97°C.	  At	  last	  as	  a	  cooling	  step,	  the	  temperature	  is	  dropped	  to	  40°C	  for	  30	  seconds.	  For	  the	  ct	  value	   quantification	   and	   amplification	   curves,	   “Absolute	   Quantification/2nd	   Derivative	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Max”	   analysis	   is	  done	   through	   the	  Light	  Cycler	   software.	   For	  quantification	  of	  melting	  peaks	   and	   melting	   curves,	   “TM	   Calling”	   analysis	   is	   done	   through	   the	   software.	   The	  primers	  forming	  amplicons	  with	  different	  length	  (with	  different	  melting	  peaks),	  strong	  amplicons	   in	   no	   template	   control	   samples	   (strong	   primer	   dimers),	   secondary	  melting	  peaks	   (uneven	   denaturation)	   were	   eliminated.	   For	   those,	   the	   primer	   design	   and	   test	  steps	  are	  repeated.	  
Gene	  Name	   Forward	  primer	  sequence	   Reverse	  primer	  sequence	  
H2afz	   Acagcgcagccatcctggagta ttcccgatcagcgatttgtgga 
Hprt1	   gcttgctggtgaaaaggacctctcgaag ccctgaagtactcattatagtcaagggcat 
Ppia	   cgcgtctccttcgagctgtttg tgtaaagtcaccaccctggcacat 
Adcy4	   ggccaggatttcgagtagc	   tggccatagtgaataccagga	  
Cacna2d1	   caatggacaaatgtgtatttgga	   gacgttgaagactggtagagttcc	  
Cdh5	   Tcatcaaacccacgaagtcc	   ggtctgtggcctcaatgtaga	  
Col4a2	   Gcgcacaaccaggaccta	   tacaggaaaggcatggtgct	  
Col4a5	   Ccctggagagagaggtagtcc	   Catacccatttcgcctttga	  
Dpysl3	   Agaaggccacgttctgagc	   Tgatggcacggaacacag	  
Enpp1	   Cggacgctatgattccttaga	   agcacaatgaagaagtgagtcg	  
Eps8	   Cactgggagatagttgggtga	   ggacgtaaggtgggatgaac	  
Esam	   Tgctcagtaccagtgggaga	   ctttaaagatccacgaacagca	  
Fam122b	   Cgagtcctgttctcaatccaa	   accaagaacactgggcctaa	  
Flrt2	   Ggagacaaggctgccaga	   caggcaggcaaatcttcttt	  
Fmo1	   Tggcctccatcaagtgct	   Gactggctctcccttcttca	  
Gpr126	   Aatgcaccttcaaattttagcat	   Ctgtccgttcccgaagt	  
Lad1	   Ctagggactgcctccctttc	   ttggcaaaataacccagctt	  
Lgr5	   Cttcactcggtgcagtgct	   cagccagctaccaaataggtg	  
Meis2_set1	   Ccagtcaaatcgagcaggtt	   gggctgaccctctggactat	  
Meis2_set2	   Catcatcattccctgtcagc	   caggtgaagctacgctgttg	  
Meis2_set3	   Tgacctcgtgattgatgagag	   Aggatgaagggttgtggtc	  
Met	   Caccaccaagtcagatgtgtg	   Aggggctcctctcgtcat	  
Myb	   Tgtcaacagagaacgagctga	   Gctgcaagtgtggttctgtg	  
Npr1	   Tggagacacagtcaacacagc	   cgaagacaagtggatcctgag	  
Pcdh12	   Cctgttggaccctaatacaggt	   gtgaggggcaatgacaatct	  
Pdzd2_set1	   Gccgacaccctaatccaaa	   Gtgctgcgtgctatcacttc	  
Pdzd2_set2	   Ggaagctgtggctattctgc	   Ctcttctgacccgagcatct	  
Plcd1	   Tacagtcccgtggagatgtg	   ggggtttggaagttcagagc	  
Ppp1r16b	   Ccatggatgagatgccaata	   ccaacagcaggaccttgaat	  
Samd4_set1	   Ttagacaagtgtcttgttcatgagg	   gagggaaagaccgaaagagc	  
Samd4_set2	   Caagcgcgtaagccagac	   ttgccattggttaatgattcc	  
	  	   Gtacccaagcccgctttc	   gcaggtggatatcattgcag	  
Sash1	   Agaaatgaaaaagcccagca	   ttcatcttggactggggaat	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Serca3	   Agcagttcatccgctacctc	   gaattgctgtgaggaagatgc	  
Sla	   Gaggccgttatccagcagt	   aggagatgggtagtcagtcagc	  
Upp1	   Accgctacgccatgtataaag	   Atgccgatggaaggaatg	  
Gdpd5	   Cttctcagagatcagtgatgg	   ttagcataggtgtcgtaactg	  
Gria4	   Gacgaaactaatggatcgct	   gcagaagtgtactttggagg	  
Palld	   Tgctgatggatacccagtg	   Tcctggtgcatgcttactc	  
Dcaf12l1_set1	   Caatgcgctctacactcac	   cagttccactctgagaagga	  
Dcaf12l1_set2	   Cactcactgctacaactgg	   Cagttccaccttagctcca	  
Ptprm	   Gaattggtagttaaagagccac	   ctgtatccacagataggttgc	  
She	   Ggacacgcaggagaagaatgg gggtcagcgtagtcctctaaaa 
Myom1	   Cacctattcttgtgatgtgacag	   Agcagacgtttcatttcctc	  
Notch1	   Tcaatgttcgaggaccagatg tcactgttgcctgtctcaag 
Lat	   Gtccctgttgtctcctctg	   atcttcacacgactccacag	  
Fbn1	   Cagatccatccaacactgc	   Taccctttctggcacagac	  
Ptprb	   Atggctctacagtaccatctc	   cacgagaccaggaaattagga	  
Kdr	   Tctttgcgctaggtatcca	   agagtaaagcctatctcgctg	  
Tek	   Cttagtgacattctccctcc	   tgtccaagaaaccatagctg	  
Cldn5	   Ttcccggtcaagtactctg	   Tcttcttgtcgtaatcgcc	  
Eng	   Gttgcaacttagctctgcg	   Aaggcctttaccagacagg	  
Akt1	   Agctcttcttccacctgtc	   Gaggttctccagcttcagg	  
Akt2	   Cgacccaacacctttgtca	   Gatagcccgcatccactct	  
Akt3	   tggaccactgttatagagagaacattt	   Tggatagcttccgtccactc	  
Cdh2	   Gccatcatcgctatccttct	   ccgtttcatccataccacaaa	  
Tgfb1	   Accaaggagacggaatacag	   Cgttgatttccacgtggag	  
Tgfb2	   Ggcttcaccacaaagacag	   aattattagacggcacgaagg	  
Snai1	   Gaagatgcacatccgaagc	   Gaatggcttctcaccagtg	  
Snai2	   Gacacattagaactcacactgg	   Aaagccctattgcagtgag	  
Csfr1	   Cagcaatgatgttggcaca	   ggtcaagtttaagtaggcactctcc	  
Mpo	   Tacatgtggccctagacct	   Gcaggtgtcaacacatctg	  
Lmo2	   Gacggaaattgtgcaggag	   Gatgcacagagaccatcct	  
Lef1	   Ccgtcagatgtcaactccaa	   gggtagaaggtggggatttc	  
Sfrp4	   Acctgagcaaaaactacagctatg	   ctaccacagttgtgacctcattg	  
Wnt7b	   Tcatgaaccttcacaacaatga	   Tggtccagcaagttttggt	  
Axin2	   Ctgctggtcaggcaggag	   Tgccagtttctttggctctt	  
Porcn	   Tgcttcttaccatctgcttcg	   Tgcttgcatgcttcaggtaa	  
Nxn	   Ttgccaagtacaaagccaaa	   ggtgtaatctctcagggagtcagt	  
Tle3	   Agaaagacagcctcagcag	   Ttgctgggtcctcattagag	  
Htra3	   Ctgcagaagggtgcctgt	   Gaacttgtaccgcggactg	  
Bmp2	   Cttccatcacgaagaagcc	   Tgagaaactcgtcactggg	  
Ltbp1	   Ctcaagccaaagccatcaa	   ctgggaagataagggtgcaa	  
Ltbp1_1	   Cagaggtgcaccaaacagg	   Gctggacagcgcaggtat	  
Ltbp1_2	   Gggcccacattgtgagaa	   cattccaccaggacagatttc	  
Ltbp1_3	   Cccacattgtgagaaatgtcc	   Gttcccacgaggaggtca	  
Tgfb3	   Cgagtggctgttgaggaga	   gctgaaaggtgtgacatgga	  
Gpr97	   Aacttcgctgagcactgatg	   Ctcttccgtggtctcctcat	  
	   	   	  60	  
Gpr141	   Gaacaaggagggtggatgtg	   tcgagagtcagtcattaccacct	  
Gpr39	   Ctccagctgaggaagtcag	   caccacaatcagtctcagga	  
Gnao1	   Ggagtgcttcaaccgatctc	   gatccaggctgtccaggtag	  
Gpr77	   Gaatgagaggcagagaacag	   gtggtgtggttcatcattctg	  
Gpsm3	   Gcaccatccttagtcaccagt	   ctccaccctgaactctcagc	  
Acvrl1	   Acacccaccatccctaacc	   tggggtaccagcactctctc	  
Acvr1	   Attgaagggctcatcaccac	   Aagaccggagccacttcc	  
Bmpr1a	   Tggctgtctgtatagttgctatgat	   tgcttgagatactcttacaataatgct	  
Acvr1b	   Agagggtggggaccaaac	   Tgcttcatgttgattgtctcg	  
Tgfbr1	   Aaattgctcgacgctgttct	   ggtacaagatcataataaggcaactg	  
Bmpr1b	   Tcgatggagcagtgatgagt	   Cgcccagcactctgtcata	  
Acvr1c	   Tgggaaatagctcgaaggtg	   gtaaggcaactggtactcctcaa	  
Table	  2.2.	  List	  of	  primers	  used	  for	  conventional	  qRT-­‐PCR	  
2.6. mRNA	  microarray	  The	  total	  RNA	  extracted	  as	  it	  is	  explained	  above	  was	  sent	  to	  EMBL	  Heidelberg	  Gene	  Core	   facility.	   Jelena	  Pistolic	  performed	   the	  quality	   control	   analysis	   of	  RNA	   samples	  by	  BioAnalyzer,	   concentration	   measurement	   by	   Qubit.	   Then	   she	   runs	   samples	   by	   using	  Affymetrix	  GeneChip	  Mouse	  Gene	  2.0	  ST	  Array.	  She	  made	  the	  initial	  analysis	  of	  the	  raw	  data	  with	   Gene	   Script	   software	   then	   by	   using	   the	   customized	   code	   in	   R.	   Each	   pair	   of	  samples	  were	   compared	   to	   calculate	   the	   log2	   fold	   change	  values	   and	   corresponding	  p	  values.	   Those	   values	   are	   used	   to	   draw	   fold	   change	   graphs	   and	   to	   assess	   the	   gene	  ontology	   (GO)	   terms.	   For	   GO	   analysis	   the	   web	   based	   Gene	  Ontology	   enRIchment	  anaLysis	   and	   visuaLizAtion	   tool	   (Gorilla	   http://cbl-­‐gorilla.cs.technion.ac.il/)	   is	   used;	  only	  the	  GO	  biological	  process	  terms	  are	  shown.	  
3. Sample	  isolation	  from	  mouse	  embryos	  and	  population	  identity	  For	   in	   vivo	   analysis	   C57B6/N	  wild	   type	  mouse	   line	   is	   used.	   Violetta	   Paribeni	   and	  Maria	  Kamber	   from	   the	  EMBL	  Monterotondo	  Mouse	  Facility	   took	   care	   about	   the	  mice	  maintenance	   and	   breeding.	   All	   mice	   related	   procedures	   are	   in	   accordance	   with	  European	   and	   Italian	   ethics	   regulations.	   For	   time	   control	  mating,	   2-­‐6	  months	   old	   one	  male	  and	  two	  female	  mice	  are	  put	  together	  in	  a	  cage	  at	  around	  3pm.	  The	  next	  morning	  the	  males	  and	  females	  are	  put	  in	  separate	  cages.	  If	  there	  is	  any	  vaginal	  plug	  seen	  in	  the	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females,	  it	  is	  accepted	  as	  E0.5	  time	  point	  of	  embryo	  development.	  The	  pregnant	  mouse	  is	  then	  sacrificed	  to	  isolate	  the	  embryos	  from	  the	  womb.	  During	  the	  embryo	  dissection,	  embryos	  are	  kept	   in	  1xDPBS	  (GIBCO,	  Ref:14190-­‐136)+10%	  FBS	  (PAA	  Clone,	  Cat:	  A15-­‐102)	   on	   ice.	   First	   the	   tissues	   belonging	   to	   the	   mother,	   such	   as	   womb	   and	   fat,	   are	  removed.	  Then	  the	  placenta	  and	  covering	  vasculature	  is	  removed.	  Lastly	  the	  yolk	  sac	  is	  torn	  gently	  and	  separated	  from	  embryo	  proper	  by	  tearing	  off	  the	  umbilical	  and	  vitelline	  vessels.	   At	   that	   stage,	   the	   somite	   pairs	   of	   the	   mouse	   are	   counted	   to	   determine	   the	  developmental	  stage	  of	  the	  embryo.	  Further	  dissection	  is	  done	  to	  remove	  head,	  tail,	  limb	  buds,	   ventral	   organs	   and	   somites	   to	   ultimately	   isolate	   the	   aorta-­‐gonad	   mesonephros	  (AGM)	  region	  (if	  it	  is	  earlier	  then	  E9.5	  the	  region	  is	  named	  para-­‐aortic	  splanchnopleura).	  Yolk	   sac	   and	   AGM	   samples	   from	   the	   same	   embryonic	   development	   stage	   within	  corresponding	  somite	  pair	  stages	  are	  pulled	  down	  in	  the	  same	  tube.	  
In	   order	   to	   use	   the	   isolated	   AGM	   and	   yolk	   sac	   samples	   for	   FC	   analysis	   and	   FACS	  sorting,	  single	  cell	  suspension	  is	  made	  by	  collagenase	  treatment	  for	  30	  min.	  at	  37°C	  in	  1	  ml	   of	   1xDPBS+10%FBS	   solution.	   To	   stop	   the	   reaction,	   9ml	   cold	   1xDPBS+10%FBS	   is	  added.	  If	  the	  cells	  are	  going	  to	  be	  used	  only	  for	  FC	  analysis,	  the	  same	  1xDPBS+10%FBS	  solution	   is	   used	   for	   the	   rest	   of	   the	   procedures.	   If	   the	   cells	   are	   going	   to	   be	   sorted	   and	  plated	   in	   culture	   IMDM+10%FBS	   solution	   is	   used	   for	   later	   steps.	   The	   single	   cell	  suspension	   of	   AGM	   and	   yolk	   sac	   is	   counted	   by	   using	   a	   hemocytometer.	   Cells	   are	  resuspended	   at	   a	   density	   of	   5*10ˆ6	   cells/ml	   and	   stained	  with	   appropriate	   antibodies:	  1/200	   VE-­‐Cadherin-­‐	   eFluor®	   660,	   1/400	   CD41-­‐PE,	   1/200	   CD41-­‐Biotin	   are	   used	   for	  staining	  for	  15	  minutes	  at	  room	  temperature,	  light-­‐protected,	  on	  shaker.	  Then	  the	  tubes	  are	  washed	  and	  centrifuged.	  If	  any	  primary	  antibody	  with	  biotin	  is	  used	  as	  the	  primary	  staining,	  1/300	  Streptavidin-­‐Pecy7	   is	  used	  as	  a	  secondary	  staining.	  Lastly	   the	  cells	  are	  suspended	   and	   filtered	   through	   FACS	   strainer	   tubes.	   For	   dead	   cell	   staining,	   7AAD	   or	  Sytox	   Blue	   is	   added	   to	   the	   cell	   suspension.	   The	   samples	   are	   always	   put	   on	   ice.	   The	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samples	   are	   run	   through	   FACS	   Aria	   for	   single	   cell	   sorting	   provided	   by	   the	   EMBL	  Monterotondo	  FACS	  facility.	  
4. Single	  cell	  gene	  expression	  analysis	  
4.1. Primer	  design	  In	  total	  I	  needed	  to	  have	  primers	  for	  96	  genes	  to	  use	  in	  96*96	  chip	  assays.	  A	  nested	  primer	   strategy	   was	   followed;	   basically	   to	   have	   2	   pairs	   of	   primers	   for	   reverse	  transcription	  and	  pre-­‐amplification	  reactions	  and	  2	  pairs	  of	  primers	  for	  qPCR	  reaction.	  The	   first	  48	  primers	  were	  designed	  by	  DeltaGene	  company	  while	   the	  second	  set	  of	  48	  primers	  were	  designed	  by	  me,	  by	  using	  the	  same	  parameters	  of	  DeltaGene.	  Primer3	  web	  based	  tool	  (http://primer3.ut.ee/)	  was	  used	  to	  design	  intron	  spanning	  outer	  and	  inner	  primers	   for	   each	   gene.	   Specifically	   primers	   were	   chosen	   to	   recognize	   two	   exons	  common	  for	  all	  transcript	  variants.	  The	  melting	  temperature	  (TM),	  G-­‐C	  content	  (GC%),	  primer	  size,	  amplicon	  size	  parameters	  are	  deciphered	  based	  on	  the	  statistics	  of	  first	  48	  primer	  design	  by	  DeltaGene.	   (See	  Table	   2.3	   and	  2.4	   for	   the	  parameters)	   Primers	  with	  high	   probability	   of	   self-­‐complementary	   or	   secondary	   structure	   formation	   were	  eliminated.	  (See	  Table	  2.5	  for	  the	  complete	  list	  of	  primers	  for	  single	  cell	  qRT-­‐PCR)	  
	   Min.	   Opt.	   Max.	  TM	  (°C)	   60.5	   65.5	   70.2	  G-­‐C%	   40	   50	   61.2	  Primer	  Size	  (bp)	   18	   20	   25	  Amplicon	  length	  (bp)	   95	   	   130	  
Table	  2.3	  Outer	  primer	  parameters	  for	  RT	  and	  pre-­‐amp.	  
	   Min.	   Opt.	   Max.	  TM	  (°C)	   58.6	   65.5	   78.9	  G-­‐C%	   36.7	   52.4	   68.8	  Primer	  Size	  (bp)	   16	   20	   30	  Amplicon	  length	  (bp)	   40	   	   Size	  of	  the	  cDNA	  
Table	  2.4	  Inner	  primer	  parameters	  for	  qPCR	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Gene	  name	   Outer	  forward	   Outer	  reverse	   Inner	  forward	   Inner	  reverse	  Acvr1	   cgaGTGCTAATGATGATGGCTTTCCC	   cgtTTCACAGTGGTCCTCGTTCC	   cgaTTCCCCGAGTGTGGAAGATGA	   cgaTTCCCCGAGTGTGGAAGATGA	  Acvrl1	   cgaATTGCCCATCGTGACCTCAA	   cgtGGTTGTTGCCGATATCCAGGTA	   cgaAGTCGCAATGTGCTGGTCAA	   cgaAGTCGCAATGTGCTGGTCAA	  Adcy4	   cgaTGGTGGCATCTTGTTCCCTA	   cgtTCAGCTTGGGTTCCTTCAGTA	   cgaCATTCCCACGCCTGGCTGTC	   cgaCATTCCCACGCCTGGCTGTC	  Atp2a3	   cgaCCATTGTGGCTGCAGTAGAA	   cgtCCCAGAATTGCTGTGAGGAA	   cgaGAGGGCAGGGCCATCTACA	   cgaGAGGGCAGGGCCATCTACA	  Bmpr1a	   acgTTCACCGAAAGCCCAGCTA	   tcgCGGATGCTGCCATCAAAGAA	   acgCGCAGGACAATAGAATGTTG	   acgCGCAGGACAATAGAATGTTG	  Cacna2d1	   acgCCAATGGTTTTAGCTGGTGACA	   cgtGATTGGCCAGTGACGTTGAA	   acgAGCAAGTTCAATGGACAAATGTG	   acgAGCAAGTTCAATGGACAAATGTG	  Cdh5	   cgaCACCATCGCCAAAAGAGAGAC	   cgtCTTAGCATTCTGGCGGTTCAC	   cgaGGATTTGGAATCAAATGCACATCG	   cgaGGATTTGGAATCAAATGCACATCG	  Col4a2	   cgaCCCTGGAAGCCCTGGATTTA	   cgtTGTCTTCCCTTAAGTCCCAACA	   cgaTGGCAGGGATGCCTGGT	   cgaTGGCAGGGATGCCTGGT	  Col4a5	   cgaGGACTCTCTGTGGATTGGCTA	   cgtATGAAGGGAGCGGAACGAA	   cgaTTCATGATGCATACAAGTGCAGGA	   cgaTTCATGATGCATACAAGTGCAGGA	  Dcaf12l1	   cgaAGGCCTCCATGGCAACTAC	   cgtGGTGGGGAGACCCAGAAAA	   cgaGCAGGCCTCTGGAGCTA	   cgaGCAGGCCTCTGGAGCTA	  Dpysl3	   cgaCCATTGGGAAGGACAACTTCAC	   cgtCGGCCACAAACTGGTTTTCA	   cgaCCATCCCTGAAGGCACCAAT	   cgaCCATCCCTGAAGGCACCAAT	  Enpp1	   cgaCCATGAAAGGAACGGCATCA	   cgtAATTTCCTGGCTTCGGATGAC	   cgaTCAGCGGTCCCGTGTTT	   cgaTCAGCGGTCCCGTGTTT	  Eps8	   cgaAGGCTGCCATGCCTTTCAA	   tcgTGCTGTTCCTCGCCACAAA	   acgCTCCTAATCACCAAGTAGATAGGAATTATG	   acgCTCCTAATCACCAAGTAGATAGGAATTATG	  Esam	   cgaAGTCTATGTCTGCAAGGCTCAA	   cgtCCCAACAAAAGTGCCCACAA	   cgaCAGAGTGGGCTTTGCCAAGT	   cgaCAGAGTGGGCTTTGCCAAGT	  Fam122b	   cgaAGTTTCTCCAGCTCCTTCCC	   cgtAAATGTCTTGGATTGAGAACAGGAC	   cgaCAACCAGAGGATTTGGAAAGCAATG	   cgaCAACCAGAGGATTTGGAAAGCAATG	  Fbn1	   acgTGGCGGGGAATGTACAAACA	   cgtCAGAGCTGTGTAGCAGTAACCA	   cgaCTGTCAGCAGCTACTTCTGCAAAT	   cgaCTGTCAGCAGCTACTTCTGCAAAT	  Flrt2	   cgaTGCCGCTCTAGCTTCTTCC	   cgtAGTGGAGAGCAGCCTAGGAA	   cgaCCGGACCCGGTTGGATT	   cgaCCGGACCCGGTTGGATT	  Fmo1	   cgaAACCACGTGAATTACGGTGTA	   tcgCCTTGATGCTGGGCTTGATA	   cgaGCTCCAGAAGACAGGACTCA	   cgaGCTCCAGAAGACAGGACTCA	  Gdpd5	   cgaACTTCCGACA cgtTGCCGATGAT cgaTTTCTCGGG cgaTTTCTCGG
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ACTCCCATACC	   GAGGCTGAA	   TGCCTTCTCCA	   GTGCCTTCTCCA	  Gfi1	   cgaGAGATGTGCGGCAAGACC	   cgtAGCGTGGATGACCTCTTGAA	   cgaGTGAGCCTGGAGCAACACAA	   cgaGTGAGCCTGGAGCAACACAA	  Gfi1b	   cgaTGGACACTTACCACTGTGTCA	   cgtAGGTTTTGCCACAGACATCAC	   cgaAGTGCAACAAGGTGTTCTCC	   cgaAGTGCAACAAGGTGTTCTCC	  Gpr126	   cgaCTGTGCAGCCACTTCACTCA	   cgtGGCAGATATTCCGCACCCAATA	   cgaTGGAGTTCTGATGGATCTTCC	   cgaTGGAGTTCTGATGGATCTTCC	  Gria4	   cgaCGCCCATGGTGACGAAACTA	   cgtGCCATTACCAAGACACCATCGTA	   acgATGGATCGCTGGAAGAAACTAGA	   acgATGGATCGCTGGAAGAAACTAGA	  Lad1	   cgaCCTCTTTGAGAAGGAGCTGTCA	   cgtCCTGGGTCTTGCTGATCCA	   cgaGGCCAGAACCGCACAGAAC	   cgaGGCCAGAACCGCACAGAAC	  Lat	   cgaTGCTGCCTGACAGTAGTCC	   cgtTCACTCTCAGGAACATTCACGTA	   cgaCTGCCGTCCCTGTTGTCT	   cgaCTGCCGTCCCTGTTGTCT	  Lgr5	   cgaGCAACAACATCAGGTCAATACC	   cgtCAGGCAAATGCTGAAAAGCA	   cgaGGAGCGAGCGTTCGTAGG	   cgaGGAGCGAGCGTTCGTAGG	  Meis2	   cgaCCCGTACCCTTCAGAAGAACAGAA	   cgtTGGTCAATCATGGGCTGCACTA	   cgaGAAACAGTTAGCGCAAGACAC	   cgaGAAACAGTTAGCGCAAGACAC	  Met	   cgaGATCATTGGTGCGGTCTCAA	   tcgACTCTTGCGTCATAGCGAAC	   cgaGTAGTTTTGTTATTATCCGGGCTCTT	   cgaGTAGTTTTGTTATTATCCGGGCTCTT	  Myb	   cgaGTGGCAGAAAGTGCTGAACC	   cgtTGCTTGGCAATAACAGACCAAC	   cgaCATCAAAGGTCCCTGGACCAAA	   cgaCATCAAAGGTCCCTGGACCAAA	  Myom1	   cgaTTCCGTGTACGTGCTGTCAA	   cgtTCCGTCATCATCCACACTCAC	   acgCCAGGCAGGCGTTGGAAAG	   acgCCAGGCAGGCGTTGGAAAG	  Notch1	   cgaCCAACCCTGTCAACGGCAAA	   cgtATTTGCCTGCGTGCTCACAA	   cgaTGCCCCTCGGGGTACA	   cgaTGCCCCTCGGGGTACA	  Npr1	   cgaCAGATTTGTGGGAGCTTGTACC	   cgtCGAAACATCCAGTCCAGGGTA	   cgaGACCCTCCCAACATCTGTATC	   cgaGACCCTCCCAACATCTGTATC	  Palld	   cgaGCTTCGCTTCAAGGAGGAC	   cgtTCTGGCTCCTGGATGTTGAA	   cgaCTTCTGAACAATGGCCAACC	   cgaCTTCTGAACAATGGCCAACC	  Pcdh12	   cgaTGGCTGCTTTTGCGGAAC	   tcgTGGTTTGGTTTGGGCTGGAA	   cgaGGAACCCGGTGGAGGA	   cgaGGAACCCGGTGGAGGA	  Pdzd2	   cgaCAACTTGGAAAGCCCCAAAC	   cgtGTCCCCATTTCGTACCATCA	   cgaAGGGCAACAGTAAAATGAAACTCAAG	   cgaAGGGCAACAGTAAAATGAAACTCAAG	  Plcd1	   cgaTGGCTTCTCCAGTCCTAGCA	   cgtCCCACGTTATGGCGGACAA	   cgaTCTGGGCAGGCATTCTATGAGATGG	   cgaTCTGGGCAGGCATTCTATGAGATGG	  Ppia	   cgaCCGACTGTGGACAGCTCTAA	   cgtAGTGAGAGCAGAGATTACAGGAC	   cgaTTTCTTTTGACTTGCGGGCATT	   cgaTTTCTTTTGACTTGCGGGCATT	  Ppp1r16b	   cgaGCGTGTGGA cgtGATGTCCTGG cgaATGGCTGGG cgaATGGCTGG
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TGTGAAGGAC	   CACTGAGACTA	   AGCCTCT	   GAGCCTCT	  Ptprb	   acgCCAAGAGCGGCAATTATGCA	   cgtTGCACCCAGGACACCTTTAA	   cgaCCACTCCTTCACCGAGGAA	   cgaCCACTCCTTCACCGAGGAA	  Ptprm	   cgaCAGACCTCCTCCAACACATCA	   tcgTCTCGTCTTTCTTAGCAGAGTCC	   cgaTCAGATGAAGTGCGCTGAG	   cgaTCAGATGAAGTGCGCTGAG	  Runx1	   cgaACTACTCGGCAGAACTGAGAA	   cgtACGGTGATGGTCAGAGTGAA	   cgaATGCTACCGCGGCCATG	   cgaATGCTACCGCGGCCATG	  Samd4	   cgaACAGCTCCGTCCAGAAGAC	   cgtACTCCAGCCTATTGTTGATGTCA	   acgTCGCTGCCCGTGCATA	   acgTCGCTGCCCGTGCATA	  Sash1	   cgaTTGATCTCACTGAGGAGCCCTA	   tcgCCATGTTGGTGGCAACATCC	   cgaCTGATAAGCATGGCCGTTGT	   cgaCTGATAAGCATGGCCGTTGT	  She	   cgaACATGGAACCGTACGATGCA	   tcgTCACAGTCTCCCCTGGTTCA	   acgTAACAGAAATCAGACGCCGTGGTT	   acgTAACAGAAATCAGACGCCGTGGTT	  Sla	   cgaCGAATCTTCCGTCTTCCCAAC	   tcgGGTGAGCACACAGCATAGAC	   cgaACTGGTACTACATCTCACCAAGG	   cgaACTGGTACTACATCTCACCAAGG	  Snai1	   cgaTCTGCACGACCTGTGGAAA	   cgtGAGCGGTCAGCAAAAGCA	   cgaCTCTAGGCCCTGGCTGCTT	   cgaCTCTAGGCCCTGGCTGCTT	  Snai2	   cgaGCACATTCGAACCCACACA	   cgtTGCAGTGAGGGCAAGAGAAA	   cgaTTGCCTTGTGTCTGCAAGA	   cgaTTGCCTTGTGTCTGCAAGA	  Upp1	   cgaGAAGGAAGACGTGCTCTACCA	   cgtATGAAGGTGTTCATCCGGGAA	   cgaTTCAACCTCAGCACTAGCACAC	   cgaTTCAACCTCAGCACTAGCACAC	  Acta2	   AGGCACCACTGAACCCTAAG	   CACAGCCTGAATAGCCACAT	   CCAACCGGGAGAAAATGAC	   ATGGCGGGGACATTGAAG	  Acvr1b	   ATGCTGCGCCATGAAAACATC	   TCGTGATAGTCAGAGACAAGCCACA	   TTGGCTTTATTGCTGCTGACA	   TGGGTCCAGGTGCCATTATC	  Acvr2a	   GCTGGCAAGTCTGCAGGTGA	   TCAGAAATGCGTCCCTTTGGA	   ACCCATGGGCAGGTTGGTA	   TTTATAGCACCCTCCAACACCTCTG	  Acvr2b	   GAAGGGCTGCTGGCTAGATGA	   AGTTGCCTTCGCAGCAGCA	   TCAATTGCTACGACAGGCAGGA	   AAGTACACCTGGGGGTTCTCCTC	  Bmp4	   CAGCCGAGCCAACACTGTGA	   TGGGATGCTGCTGAGGTTGA	   AGTTTCCATCACGAAGAACATCTGG	   GAGGAAACGAAAAGCAGAGC	  Bmpr2	   CAGACGGCCGCATGGAGTAT	   ATGAGCCAGACGGCAAGAGC	   TGCTTGTGATGGAGTATTATCCCAATG	   TACCCAATCACTTGTGTGGAGACTCA	  Cdh2	   ATCAACAATGAGACTGGGGACATCA	   CTTCCATGTCTGTGGCTTGAA	   CACTGTGGCAGCTGGTCTGG	   ATTAACGTATACTGTTGCACTTTCTCTCG	  Cldn5	   TGGCAGGTGACTGCCTTCCT	   TGCATGTGCCCGGTACTCTG	   ACCACAACATCGTGACGGCGCAGA	   ACCACGCACGACATCCACAG	  Ctnnb1	   AACTCCTGCACCCACCATCCCA	   GTTCCCGCAAAGGCGCATGA	   TGGCCTCTGATAAAGGCAACTG	   TGCTGGGCAAAGGGCAAG	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Eng	   GCCTGACTTTCTGGGACTCCAGC	   TGCTGACCACATGGGCTGTCAC	   GCCAGGCTGAAGACACTGACG	   TCATGCCGCAGCTGGAGTAG	  Epo	   GGTTGTGCAGAAGGTCCCAGA	   GGGACAGGCCTTGCCAAACT	   CTGAGTGAAAATATTACAGTCCCAGA	   TATGGCCTGTTCTTCCACCTCCA	  Epor	   TGAAGTGGACGTGTCGGCAG	   ACAGCGAAGGTGTAGCGCGT	   CAACCGGGCAGGAGGGACA	   CCGCCCCGCAGGTTGCTCAGAA	  Erg	   TCCCGAAGCTACGCAAAGAA	   TTTGGACTGAGGGGTGAGGTG	   TACAACTAGGCCAGATTTACCTTATGA	   TGTGGCCGGTCCAGGCTGAT	  Fli1	   TGCTGTTGTCGCACCTCAGTT	   TTCCTTGACATTCAGTCGTGAGGA	   CTCAGGGAAAGTTCACTGCTGGCCTA	   TGGTCTGTATGGGAGGTTGTG	  Gata1	   CCTGTGCAATGCCTGTGGCT	   TGCCTGCCCGTTTGCTGACAA	   GTATCACAAGATGAATGGTCAGAACC	   CATTCGCTTCTTGGGCCGGATG	  Gata2	   AAGCAAGGCTCGCTCCTG	   CACAGGCATTGCACAGGTAGT	   CAGAAGGCCGGGAGTGTGTC	   GCCCGTGCCATCTCGT	  Hbb-­‐b1	   GCCGATGAAGTTGGTGGTGA	   CCCATGATAGCAGAGGCAGAGG	   GCCCTGGGCAGGCTGCTGGTTGTCT	   TAGGTCTCCAAAGCTATCAAAGTACCG	  Hbb-­‐bh1	   GAGCTGCACTGTGACAAGCTTCA	   GGGGTGAATTCCTTGGCAAAA	   TGGATCCTGAGAACTTCAAGC	   GAGTAGAAAGGACAATCACCAACA	  Itga2b	   TTCCAACCAGCGCTTCACCT	   TGCTCGGATCCCCATCAAAC	   CGACAACAGCAACCCAGTGTTT	   GCCCACGGCTACCGAATATC	  Itgam	   AGCAGGGGTCATTCGCTACG	   CAGCTGGCTTAGATGCGATGG	   ATTGGGGTGGGAAATGCCTTC	   GTCGAGCTCTCTGCGGGACT	  Itgb3	   TCCTCCAGCTCATTGTTGATGC	   AGGCAGGTGGCATTGAAGGA	   ACGGGAAAATCCGCTCTAAA	   AGTGACAGTTCTTCCGGCAGGT	  Kdr	   TGTGGGGCTTGATTTCACCTG	   TCGCCACAGTCCCAGGAAAG	   CACTCTCCACCTTCAAAGTCTCATCA	   TTTCACATCCCGGTTTACAATCTTC	  Kit	   CTGGCTCTGGACCTGGATGA	   CCTGGCTGCCAAATCTCTGTG	   TGCTGAGCTTCTCCTACCAGGTG	   ATACAATTCTTGGAGGCGAGGAA	  Lmo2	   TCGGCCATCGAAAGGAAGAG	   GCGGTCCCCTATGTTCTGCT	   CTGGACCCGTCTGAGGAACC	   GCAGCCACCACATGTCAGCA	  Lyl1	   GCTGAAGCGCAGACCAAGCCAT	   GCTCACGGCTGTTGGTGAACACT	   GTGAGCTGGACTTGGCTGACG	   CCGAGCCACCTTCTGGGGTTG	  Mpo	   TGGCCCTAGACCTGCTGAAGAG	   TTGACACGGACAACAGATTCAGC	   AAGCTGCAGCCCCTGTGG	   GAGCAGGTGTCAACACATCTGTAA	  Pecam1	   TGCGGTGGTTGTCATTGGAG	   CTGGACATCTCCACGGGTTT	   GTCATCGCCACCTTAATAGTTGCAG	   TGTTTGGCCTTGGCTTTCCTC	  Ptprc	   GGCTTCAAGGAACCCAGGAAATA	   TGACAATAACTGTGGCCTTTTGCTC	   ATTGCTGCACAAGGGCCCCGGGATG	   CAGATCATCCTCCAGAAGTCATCAA	  Ramp2	   TCCCACTGAGGACAGCCTTG	   TCCTTGACAGAGTCCATGCAA	   TCAAAAGGGAAGATGGAAGACTACGA	   TCTTGTACTCATACCAGCAAGGTAGGACA	  Serpine1	   AAAACCCGGCGG CTTGTTCCACGG GATGCTATGGG CCTTGGAGAGC
	   	   	  67	  
CAGATCCA	   CCCCATGA	   ATTCAAAGTCAA	   TGGCGGAGGGCATGA	  Sfpi1	   GTGGGCAGCGATGGAGAAAG	   TGCAGCTCTGTGAAGTGGTTCTC	   ATAGCGATCACTACTGGGATTTCTCC	   GGGAAGTTCTCAAACTCGTTGTTG	  Smad1	   TCTCAGCCCATGGACACGAA	   CACCAGTGTTTTGGTTCCTCGT	   ATGATGGCGCCTCCACTGC	   GCAACTGCCTGAACATCTCCTC	  Smad2	   TGCTCTCCAACGTTAACCGAAA	   TCAGCAAACACTTCCCCACCT	   GCCACTGTAGAAATGACAAGAAGACA	   TGTAATACAAGCGCACTCCCCTTC	  Smad3	   CCAATGTCAACCGGAATGCAG	   TGAGGCACTCCGCAAAGACC	   CGTGGAACTTACAAGGCGACA	   CCCCTCCGATGTAGTAGAGC	  Smad4	   TTGCCTCACCACCAAAACG	   TGGAATGCAAGCTCATTGTGA	   CCATCTTCAGCACCACCCGCCTA	   TGGCCAGTAATGTCCAGGATG	  Smad5	   AACCATGGATTCGAGGCTGTG	   TGACGTCCTGTCGGTGGTACTC	   TGAGCTCACCAAGATGTGTACC	   GCTCCCCAGCCCTTGACAAA	  Smad6	   TTCTCGGCTGTCTCCTCCTGAC	   TTCACCCGGAGCAGTGATGA	   GTACAAGCCACTGGATCTGTCCGATT	   GGAGTTGGTGGCCTCGGTTT	  Smad7	   GGAAGATCAACCCCGAGCTG	   TGAGAAAATCCATTGGGTATCTGGA	   TGTGCTGCAACCCCCATCAC	   AAGGAGGAGGGGGAGACTCTA	  Smad9	   GCACGATTCGGATGAGCTTTG	   TGCAGCGGTCCATGAAGATG	   GAAGGGCTGGGGAGCAGAGT	   TCTCGATCCAGCAGGGGGTGCT	  Sox7	   AGAACCCGGACCTGCACAAC	   CCGCTCTGCCTCATCCACAT	   CGGAGCTCAGCAAGATGC	   GGTCTCTTCTGGGACAGTGTCAGC	  Tal1	   ACCGGATGCCTTCCCCATGTT	   GCGCCGCACTACTTTGGTGT	   CCAACAACAACCGGGTGAAGA	   AGGACCATCAGAAATCTCCATCTCA	  Tek	   TCCAAAGGAGAATGGCTCAGG	   TCCGGATTGTTTTTGGCCTTC	   TTCCAGAACGTGAGAGAAGAACCA	   TGTTAAGGGCCAGAGTTCCTGA	  Tgfb1	   ACCCCCACTGATACGCCTGA	   GCAGTGAGCGCTGAATCGAA	   TGGCTGTCTTTTGACGTCACTG	   GCCCTGTATTCCGTCTCCTTGG	  Tgfb2	   GGCATGCCCATATCTATGGAGTTC	   CAGATCCTGGGACACACAGCA	   GACACTCAACACACCAAAGTCCTCA	   GGGAAGCGGAAGCTTCGGGATTTA	  Tgfb3	   CATGTCACACCTTTCAGCCCAAT	   CTCCACGGCCATGGTCATCT	   GAGACATACTGGAAAATGTTCATGAGGTG	   CATTGTCCACTCCTTTGAATTTGA	  Tgfbr1	   GCAGACTTGGGACTTGCTGTGA	   CATCTAGAACTTCAGGGGCCATGT	   CATGATTCTGCCACAGATACAA	   CCTTTTAGTGCCTACTCTGTGGTTTGG	  Tgfbr2	   TGGCCGCTGCATATCGTCCT	   GCATCTTTCTGGGCTTCCATTTCCA	   TGGACGCGCATCGCCAGCA	   ATCCGACTTGGGAACGTG	  Thpo	   CCGACGTCGACCCTTTGTCT	   TGCCCCTAGAATGTCCTGTGC	   TCCCTGTTCTGCTGCCTGCT	   TGCTCTGTTCCGTCTGGGTTTT	  
Table	  2.5	  Primer	  list	  used	  for	  the	  single	  cell	  qRT-­‐PCR	  analysis.	  The	  green	  shaded	  cells	  indicate	  the	  
primers	  designed	  by	  the	  DeltaGene,	  and	  the	  blue	  shaded	  cells	  indicate	  the	  primers	  designed	  by	  me.	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4.2. Primer	  test	  The	  designed	  primers	  are	  tested	  in	  silico	  to	  make	  sure	  it	  recognizes	  only	  the	  target	  transcripts	  within	   the	   right	   sequences,	  which	   are	   aimed.	   The	   primers	   are	   ordered	   for	  synthesis	  through	  Sigma	  Aldrich.	  The	  primer	  stock	  is	  prepared	  to	  be	  100mM	  for	  storage.	  The	   96	   outer	   primers	   are	   pooled	   to	   have	   500nM	   as	   final	   concentration	   for	   all	   assays,	  which	  makes	  10x	  STA	  primer	  stock.	  The	  forward	  and	  reverse	  inner	  primers	  are	  kept	  in	  100mM	   stock	   concentration,	   which	   will	   be	   5µM	   in	   each	   inlet,	   and	   500nM	   in	   each	  reaction	  chamber.	  Afterwards	  the	  synthesized	  outer	  primer	  pool	  of	  96	  genes	  was	  tested	  with	   sample	   mouse	   cDNA	   first	   in	   STA	   reaction	   then	   for	   each	   96	   inner	   primers	   in	  conventional	  qPCR	  reaction.	  Later	   the	  primers	  are	   tested	  with	  our	  own	  cells	  sorted	  as	  500	  cell/well	  followed	  by	  RT	  and	  pre-­‐amplification	  with	  outer	  primers	  and	  conventional	  qPCR	  with	  inner	  primers.	  At	  last,	  the	  real	  single	  cell	  experiment	  is	  tested	  with	  our	  cells	  sorted	  as	  1cell/well,	  RT	  and	  pre-­‐amplification	  reactions	   for	  20	  cycles;	  diluted	  cDNA	   in	  varying	  ratios	  (1/5,	  1/10,	  1/20)	  and	  loaded	  for	  BioMark	  microfluidics	  chip	  run	  of	  qPCR.	  Primer	   dimer	   formation,	   transcriptome	   size	   within	   samples	   and	   the	   compatibility	   of	  results	  with	   the	   biological	   expectation	  was	   evaluated.	   The	   20	   pre-­‐amplification	   cycles	  and	  1/5	  dilution	  of	  cDNA	  was	  determined	  to	  have	  a	  good	  ct	  values	  between	  6-­‐20	  for	  all	  96	  genes	  within	  our	  cells.	  
4.3. Single	  cell	  sort	  For	  the	  RT-­‐STA	  reactions,	   the	  reagents	  are	   from	  the	  CellsDirect	  One-­‐Step	  qRT-­‐PCR	  kit	   (Invitrogen	   cat.	   No.	   11753).	   	   The	   complete	   protocol	   for	   sorting,	   following	   RT-­‐STA	  reactions	   and	   chip	   run	   in	   BioMark	   is	   followed	   as	   it	   is	   written	   in	   Fluidigm	   Advanced	  Development	   Protocol,	   section	   41.	   Each	  well	   of	   the	   96	  well	   plate	   (Bio-­‐Rad	  Hard-­‐Shell	  PCR	  plates	  cat.	  No.	  HSP9611)	  is	  filled	  with	  5	  µl	  of	  2x	  reaction	  mix,	  which	  serves	  as	  a	  lysis	  solution.	   The	   plate	   with	   reaction	  mix	   is	   kept	   on	   ice	   before	   sorting.	  When	   the	   sorting	  gates	   are	   determined	   in	   FACS	   Aria,	   the	   plate	   with	   reaction	   mix	   is	   put	   on	   the	   cold	  platform	  for	  96	  well	  plates.	  The	  sorting	  precision	  is	  set	  for	  single	  cells	  and	  sorting	  on	  96	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well	  plate	  is	  calibrated	  before	  sorting.	  Depending	  on	  the	  population	  frequency,	  complete	  sorting	  may	  take	  time	  between	  a	  few	  seconds	  to	  5	  minutes.	  When	  the	  sorting	  is	  finished,	  the	  plate	  is	  snap-­‐frozen	  on	  a	  pre-­‐cooled	  metal	  block	  in	  a	  closed	  box	  full	  of	  dry-­‐ice,	  then	  the	  plate	  is	  stored	  at	  -­‐80°C	  freezer	  for	  not	  longer	  then	  2	  weeks.	  
4.4. Reverse	  transcription	  and	  pre-­‐amplification	  reactions	  A	  master	  mix	  for	  each	  well	  is	  prepared	  on	  ice.	  For	  one	  well	  2.8µl	  of	  DNA	  suspension	  mix,	  1µl	  of	  outer	  primer	  mix	  (STA	  pool),	  0.2µl	  of	  SuperScript	  III	  enzyme	  is	  needed.	  When	  the	  master	  mix	  ready	  on	  ice,	  4µl	  of	  it	  is	  added	  on	  top	  of	  the	  frozen	  reaction	  mix	  with	  cell.	  After	  a	  short	  spin	  down,	  the	  plate	  is	  put	  into	  the	  thermal	  cycler	  and	  the	  RT-­‐STA	  program	  is	  immediately	  initiated.	  RT	  reaction	  takes	  place	  in	  first	  15	  minutes	  at	  50°C,	  followed	  by	  inactivation	   of	   RT	   at	   95°C	   for	   2	   minutes.	   Then	   20	   cycles	   of	   pre-­‐amplification	   (STA)	  reaction	   at	   95°C	   for	   15	   seconds	   and	   60°C	   for	   4	   minutes	   are	   performed.	   When	   the	  program	  is	  finished,	  the	  temperature	  is	  set	  at	  4°C.	  The	  plates	  are	  shortly	  spun	  down	  and	  stored	   at	   -­‐20°C	   before	   sending	   them	   to	   EMBL	   Heidelberg	   Gene	   Core	   facility.	   The	  shipment	  is	  done	  on	  dry	  ice.	  
4.5. BioMark	  microfluidics	  chip	  run	  for	  qPCR	  reaction	  Bianca	   Baying	   and	   Paul	   Collier	   in	   EMBL	  Heidelberg	   Gene	   Core	   Facility	   performed	  this	  part.	  The	  cDNA	  within	  each	  well	  of	  the	  shipped	  96	  well	  plate	  is	  diluted	  as	  1/5	  and	  sample	  mix	   is	  prepared	  with	   loading	  reagent	  (Fluidigm)	  and	  EvaGreen	  SuperMix	  (Bio-­‐Rad).	   In	   parallel	   96	   individual	   assay	  mixes	   are	   prepared	   as	   5µM	  primer	   inner	   primer	  mix,	  with	  DNA	  suspension	  buffer	  and	  assay	  loading	  reagent.	  After	  the	  priming	  of	  96.96	  dynamic	   array	   IFC,	   the	   sample	   mix	   and	   assay	   mixes	   are	   put	   together	   in	   the	  corresponding	  inlets	  and	  loaded	  into	  the	  chip.	  Finally	  the	  chip	  is	  run	  in	  BioMark	  by	  using	  	  the	  BioMark	  Data	  Collection	  Software	  and	  the	  GE	  96x96	  PCR+Melt	  v2.pcl	  program.	  After	  the	  run,	  the	  chip	  is	  discarded.	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4.6. Analysis	  of	  the	  data	  Raw	   data	   can	   be	   opened	   and	   analyzed	   by	   the	   Fluidigm	   Real	   Time	   PCR	   Analysis	  software.	  For	  each	  primer	  dynamics,	  Ct	  values	  and	  melting	  curves	  can	  be	  visualized.	  For	  detailed	  bioinformatics	  analysis,	   the	  raw	  data	   is	   imported	   in	  analysis	  view,	  AutoGlobal	  Ct	   threshold	  method,	   quality	   threshold	   0.65	   and	   linear	   derivative	   baseline	   correction	  method.	   The	   imported	   Ct	   values	   are	   analyzed	   by	   using	   Fluidigm	   SingularToolSet3.0	  package	  scripts	  and	  R	  software.	  The	  outliers	  are	  removed	  which	  has	  all	  (or	  the	  majority	  of)	  genes	  not	  working	  according	  to	  global	  gene	  expression	  with	  the	  limit	  of	  detection	  24	  Ct.	   By	   using	   the	   build	   functions	   of	   Singular	   ToolSet3.0,	   I	   have	   generated	   hierarchical	  clustering	  heatmap	  for	  samples	  and	  genes,	  principal	  component	  analysis,	  violin	  or	  box	  plot	  for	  sample	  cluster’s	  gene	  expression.	  
5. In	  vitro	  treatment	  with	  TGFB	  inhibitor	  and	  activator	  To	  observe	  the	  results	  of	   inhibiting	  the	  TGFβ	  pathway,	  SB-­‐431542	  (Tocris,	  Cat.	  No.	  1614,	   re-­‐suspended	   in	   DMSO)	   small	   molecule	   inhibitor	   is	   added	   into	   the	   culture	  ng/medium	  in	  10nM	  concentration.	  In	  contrast,	  to	  see	  the	  results	  of	  activation	  of	  TGFβ	  pathway,	  recombinant	  mouse	  TGFβ-­‐2	  (R&D	  systems,	  Cat.	  No.	  7346-­‐B2,	  re-­‐suspended	  in	  4mM	   HCl	   +0.1%	   BSA	   in	   1xPBS)	   is	   added	   into	   the	   culture	   medium	   in	   5ng/ml	  concentration.	  For	  vehicle	  control	  of	  SB-­‐431542,	  the	  same	  volume	  of	  DMSO,	  for	  vehicle	  control	  of	  TGFβ-­‐2,	  the	  same	  volume	  of	  4mM	  HCl	  +0.1%	  BSA	  in	  1xPBS	  solution	  is	  added	  in	   the	   culture.	  When	   both	   inhibitor	   and	   activator	   is	   needed	   to	   be	   used,	   only	  DMSO	   is	  added	  as	  vehicle	  control.	  Depending	  on	  the	  experiment,	  it	  is	  either	  added	  into	  the	  blast	  medium	   or	   the	   hemogenic	   endothelium	   medium.	   Depending	   on	   the	   experiment,	   the	  medium	  is	  kept	  for	  maximum	  3	  days	  before	  harvesting	  the	  cells.	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Chapter3:	  Exploring	  the	  cellular	  heterogeneity	  during	  EHT	  
1. Introduction	  In	  order	  to	  understand	  the	  underlying	  mechanism	  of	  EHT,	  one	  needs	  to	  identify	  the	  changes	   in	   cell	   characteristic	   throughout	   the	   transition.	   According	   to	   our	   current	  knowledge	  on	  hematopoietic	  and	  endothelial	  markers,	  we	  define	  the	  EHT	  as	  hemogenic	  endothelial	   (HE)	   cells	   transiting	   through	   pre-­‐hematopoietic	   progenitor	   (Pre-­‐HP)	   state	  towards	   to	   become	   hematopoietic	   stem/progenitor	   cells	   (HSPC)(Eilken,	   Nishikawa,	   &	  Schroeder,	  2009;	  Lancrin	  et	  al.,	  2009).	  However,	   the	  cell	  populations	   isolated	  by	  using	  endothelial	   and	   hematopoietic	   markers	   are	   a	   lot	   more	   in	   number	   than	   the	   actual	  functional	   HE	   or	   pre-­‐HP	   cells	   (Boisset	   et	   al.,	   2014;	   Lancrin	   et	   al.,	   2009b)	   which	   is	  possibly	  due	  to	  cellular	  heterogeneity.	  In	  this	  project,	  I	  aim	  to	  define	  the	  HE	  and	  pre-­‐HP	  populations	   by	   comprehensive	   gene	   expression	   profiling	   ultimately	   to	   find	   exclusive	  markers	  of	  each	  populations.	  	  
1.1. Current	  markers	  to	  identify	  populations:	  Specifying	  genes	  for	  the	  endothelial	  cells	  to	  have	  hematopoietic	  capacity	  have	  been	  the	   focusing	   point	   for	   a	   long	   time.	   In	   theory,	   hemogenic	   endothelial	   cells	   have	   cell	  surface	   endothelial	   markers	   VE-­‐Cadherin,	   Flk-­‐1,	   Tie2/Tek	   and	   also	   the	   early	  hematopoietic	  lineage	  markers	  CD41,	  C-­‐Kit,	  CD45	  (Eilken	  et	  al.,	  2009b;	  Ferkowicz,	  2003;	  Lancrin	  et	   al.,	   2009a;	  W.	  Li	   et	   al.,	   2005;	  Mikkola,	  Fujiwara,	   Schlaeger,	  Traver,	  &	  Orkin,	  2003;	   Zovein	   et	   al.,	   2008).	   Combination	   of	   those	   markers	   let	   us	   enrich	   hemogenic	  endothelial	   cells	   among	   all	   endothelial	   cells.	   However	   finding	   a	   putative	   marker	   of	  hemogenic	  endothelium	  is	  still	  an	  unachieved	  goal.	  
Runx1	   has	   been	   the	   mostly	   studied	   gene	   for	   regulation	   of	   EHT.	   Although	   its	  expression	  is	  vital	  for	  the	  successful	  EHT,	  not	  all	  Runx1	  expressing	  endothelial	  cells	  are	  going	  through	  the	  transition.	  Additionally,	  Runx1	  is	  expressed	  in	  non-­‐hemogenic	  tissues	  such	  as	  olfactory	  epithelium,	  spinal	  ganglia,	  maxillary	  processes	  (T.	  North	  et	  al.,	  1999)	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and	   various	   stages	   of	   murine	   life,	   not	   only	   during	   embryonic	   development.	   Several	  studies	   done	   for	   the	   Runx1	   function	   in	   hematopoiesis,	   identified	   two	   promoters	   are	  activated	  during	  developmental	  hematopoiesis(Enid	  Yi	  Ni	  Lam	  et	  al.,	  2009;	  Nottingham	  et	  al.,	  2007)	   indicating	  very	  specific	   regulation	  of	  Runx1	  activity	   in	  HE	  or	  Pre-­‐HP	  cells	  (Bee	   et	   al.,	   2010;	   Sroczynska,	   Lancrin,	  Kouskoff,	   et	   al.,	   2009b).	  Regarding	   that	   specific	  function,	  reporter	  cell	  and	  mouse	   lines	  are	  generated	  to	  trace	  the	  Runx1	  proximal	  and	  distal	   promoter	   activity	   to	  mark	   cells	   initiated	   EHT	   (Sroczynska,	   Lancrin,	   Kouskoff,	   &	  Lacaud,	  2009a).	   	  The	  staining	  of	  Runx1	  proximal	  promoter	  with	  endothelial	  markers	  is	  so	  far	  the	  only	  specific	  marker	  for	  the	  hemogenic	  endothelium	  population.	  
In	   early	   studies,	   Sca1/Ly6a	   has	   been	   used	   as	   an	   isolating	  marker	   for	   HSCs	   in	   the	  bone	   marrow	   (Spangrude,	   Heimfeld,	   &	   Weissman,	   1988)	   and	   fetal	   liver	   (Huang	   &	  Auerbach,	   1993).	   Sca1/Ly6a	   expression	   in	   endothelial	   cells	   is	   recently	   claimed	   to	   be	  marking	  hemogenic	  endothelial,	  which	  will	  give	  rise	  to	  only	  HSC	  (M.	  F.	  T.	   .	  de	  Bruijn	  et	  al.,	   2002).	   Recent	   study	   with	   CBFB	   deficient	   mice	   with	   induced	   rescue	   under	   the	  promoters	   of	   Tie2	   or	   Sca1	   genes	   show	   that	   hemogenic	   endothelial	   cells	   with	  erythroid/myeloid	  progenitors	  (EMP)	  or	  HSC	   forming	  potential	  can	  be	  separated.	  This	  study	   brings	   an	   important	   argument	   as	   EMP	   forming	   hemogenic	   endothelium	   can	   be	  labeled	  with	  Tie2	  promoter,	  at	  the	  same	  time	  HSC	  forming	  hemogenic	  endothelium	  can	  be	   labeled	  with	   Sca1/Ly6a	  promoter,	  which	   indicates	   separate	   hemogenic	   endothelial	  cells	  related	  with	  particular	  progenitor	  function	  (Chen	  et	  al.,	  2011).	  However	  the	  neither	  Ly6a	  nor	  Tie2	   is	   putatively	   labeling	   these	   specific	   hemogenic	   endothelial	   cells	   (Figure	  3.1.A).	  
SRY-­‐related	  HMG	  box	  (SOX)	  family,	  F	  sub	  group	  of	  transcription	  factors	  were	  one	  of	  the	   claimed	   hemogenic	   endothelium	   markers.	   Sox7,	   Sox17,	   and	   Sox18	   are	   the	   3	  transcription	   factors	   belong	   to	   that	   subgroup.	   Sox7	   has	   role	   in	   primitive	   parietal	  endoderm	  differentiation	   (Futaki,	  Hayashi,	   Emoto,	  Weber,	  &	   Sekiguchi,	   2004).	   Sox7	   is	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found	   to	   be	   expressed	   transiently	   in	   Flk-­‐1+	  mesoderm,	   then	   Sox7	   expression	   is	   down	  regulated	   towards	   hematopoiesis.	  When	   Sox7	   is	   over-­‐expressed	   in	   HP	   cells,	   it	   blocks	  their	   maturation.	   When	   Sox7	   is	   knocked	   down,	   number	   of	   hematopoietic	   and	  endothelial	   precursors	   are	   decreased	   (Gandillet	   et	   al.,	   2009).	   Sox7	   and	   Sox18	   were	  shown	   to	   be	   redundant	   especially	   in	   regulation	   of	   angiogenesis	   and	   vasculogenesis	  (Sakamoto	   et	   al.,	   2007).	  	   Sox18	   is	   transiently	   expressed	   during	   hematopoiesis,	   unlike	  Sox7,	   its	   expression	   is	   high	   on	   CD41+	   HP	   cells.	  When	   Sox18	   is	   over-­‐expressed	   in	   HP	  cells,	  it	  blocks	  maturation	  and	  induce	  proliferation	  (Serrano,	  Gandillet,	  Pearson,	  Lacaud,	  &	  Kouskoff,	  2010).	  Studies	  on	  zebrafish	  show	  also	  knock	  down	  of	  Sox7	  and	  Sox18	  show	  defective	   vasculogenesis	   and	   angiogenesis,	   although	   hematopoiesis	   is	   claimed	   not	   be	  affected	  (Chung,	  Ma,	  Fung,	  &	  Leung,	  2011).	  Lastly,	  Sox7	  is	  expressed	  in	  endothelial	  cells	  including	   hemogenic	   endothelium	   and	   plays	   role	   in	   sustaining	   endothelial	   gene	  expression	   such	   as	  VE-­‐cadherin	   (Costa	   et	   al.,	   2012).	   Consequently	   its	   expression	  does	  not	  discriminate	  between	  hemogenic	  and	  non	  hemogenic	  endothelial	  cells.	  
Sox17	  is	  important	  for	  definitive	  endoderm	  specification(Kanai-­‐Azuma	  et	  al.,	  2002).	  Its	   expression	   is	   found	   weak	   during	   hematopoietic	   specification	   and	   HSCs.	   But	   over-­‐expression	  of	  Sox17	  in	  HPs	  increases	  apoptosis	  rate	  (Serrano	  et	  al.,	  2010).	  The	  studies	  in	  zebrafish	  show	  also	  expression	  of	  Sox17	   in	   the	   intermediate	  cell	  mass.	  Knock	  down	  of	  Sox17	   results	   in	   reduced	   primitive	   erythrocytes	   but	   not	   affected	   definitive	  hematopoietic	  cells	  (Chung	  et	  al.,	  2011).	  It	  is	  shown	  to	  be	  important	  for	  maintenance	  in	  fetal	  HSCs(Kim,	  Saunders,	  &	  Morrison,	  2007).	  Also	  it	  is	  expressed	  in	  intra-­‐aortic	  clusters	  and	  ectopic	  expression	  of	  Sox17	   increases	   self-­‐renewal	  of	   clusters	   in	  vivo	  and	   in	  vitro	  (Nobuhisa	  et	  al.,	  2014).	  In	  parallel	  with	  its	  role	  in	  HSC	  maintenance,	  Sox17	  is	  claimed	  to	  be	  marking	  hemogenic	  endothelial	  cells	  too	  (Clarke	  et	  al.,	  2013).	  	  
Sox7,	  Sox17	  and	  Sox18	  are	  all	  suggested	  to	  have	  important	  role	  for	  balancing	  the	  cell	  fate	   decision	   between	   proliferation	   and	   differentiation,	   but	   cumulative	   analysis	   of	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studies	  during	  hematopoiesis	   indicates	  cell	   type	  specific	  expression	  of	  each(Serrano	  et	  al.,	  2010)	   (Figure3.1.B).	  Although	  Sox7	  and	  Sox18	  have	  overlapping	  expression	  during	  mesoderm	  specification	   to	  hemogenic	  endothelium,	  Sox7	   is	  highly	  expressed	   in	  Flk-­‐1+	  hemangioblast	  cells	  (Gandillet	  et	  al.,	  2009)	  while	  Sox18	  is	  expressed	  more	  abundantly	  in	  CD41+	   HP	   cells	   (Serrano	   et	   al.,	   2010).	   On	   the	   other	   hand,	   Sox17	   is	   shown	   to	   be	  expressed	  highly	  in	  intra-­‐aortic	  clusters	  (Nobuhisa	  et	  al.,	  2014)	  and	  HSCs	  (Clarke	  et	  al.,	  2013)	  	  (Figure	  3.1.C).	  	  
Lastly	   retinoic	  acid	   signaling	   is	   suggested	   to	  be	   regulating	  HSC	   formation	   from	  HE	  cells.	   Retinal	   aldehyde	   expressing	   endothelial	   cells	   are	   claimed	   to	   be	   hemogenic	  endothelium,	   which	   will	   give	   rise	   to	   HSCs	   (Chanda,	   Ditadi,	   Iscove,	   &	   Keller,	   2013).	  Although	  the	  sorting	  of	  aldehyde	  receptor	  expressing	  cells	  together	  with	  VE-­‐Cadherin+	  and	   Runx1+	   gates,	   isolate	   the	   cells	   with	   HSC	   potential;	   single	   staining	   of	   aldehyde	  receptor	  expression	  does	  not	  specify	  the	  hemogenic	  endothelium	  (Figure	  3.1.D).	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Figure	  3.0.1	  Markers	  reported	  to	  be	  labeling	  hemogenic	  endothelium	  in	  previous	  studies.	  A.	  E10.5	  
whole	  mount	  immunofluorescence	  staining	  of	  transgenic	  mouse	  lines.	  (Adapted	  from	  figure	  6	  of	  Chen	  
et	  al.,	  2011,	  Cell	  Stem	  Cell)	  B.	  E10.5	  AGM	  in	  situ	  hybridization	  staining	  of	  Sox17,	  Sox7	  and	  Sox18.	  
(Adapted	  from	  figure	  4	  of	  Nobuhisa	  et.	  al.	  2014,	  Mol.	  And	  Cell.	  Bio.)	  C.	  E10.5	  intra-­‐aortic	  hematopoietic	  
cluster	  of	  Sox17	  GFP/+	  mouse	  staining	  with	  C-­‐kit	  and	  CD31.	  (Adapted	  from	  figure	  2.b	  of	  Clarke	  et.	  al.	  
2013,	  Nature	  Cell	  Biology)	  D.	  E11.5	  AGM	  of	  retinoic	  acid	  receptors	  staining	  (Adapted	  from	  figure	  1	  of	  
Chanda	  et.	  al.	  2013,	  Cell)	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1.2. Functional	  heterogeneity	  within	  marked	  populations:	  Independent	   studies	   claim	   to	   identify	   hemogenic	   endothelial	   cells	   depending	   on	  their	   combination	  of	   cell	   surface	  markers	  and	   transgenic	   reporter	  genes.	  However	   the	  marked	   cells	   out-­‐number	   the	   actually	   functional	   hemogenic	   endothelium	   or	   pre-­‐HP	  populations,	  which	   is	   only	   possible	   to	   be	   confirmed	   in	   functional	   assays.	   Due	   to	   non-­‐consensual	  definitions	  of	  cell	  types	  and	  lack	  of	  combinatorial	  study	  for	  all	  markers,	  it	  is	  difficult	   to	   draw	   a	   definitive	   conclusion	   about	   cell	   type	   specific	   expression	   of	   these	  markers.	  
Not	   all	  marked	  hemogenic	  endothelial	   cells	   are	  going	   through	   the	  EHT	  and	  not	   all	  marked	  pre-­‐HP	  cells	  have	  the	  same	  hematopoietic	  potential.	  The	  in	  vitro	  studies	  showed	  that	  only	  1	  in	  79	  endothelial	  cells	  could	  give	  rise	  to	  differentiated	  HP	  cells	  (Lancrin	  et	  al.,	  2009).	  The	  hematopoietic	  cells	  composing	  the	  intra-­‐aortic	  clusters	  (IAHCs)	  are	  showing	  differential	   expression	   of	   some	   markers,	   which	   initially	   thought	   to	   be	   related	   with	  hematopoietic	  maturity.	  Among	  500-­‐600	  IAH	  cells	   in	  E10.5	  AGM	  (Figure	  3.2.A),	  only	  1	  HSC	  is	  found	  which	  is	  confirmed	  to	  give	  rise	  to	  all	  types	  of	  hematopoietic	  cells	  upon	  in	  vivo	   transplantation	   (Boisset	   2014).	   At	   E11.5	   the	   intra-­‐aortic	   cluster	   forming	   cells	  decrease	  (Figure	  3.2.B)	  but	  cells	  with	  HSC	  capacity	  may	  increase	  up	  to	  11	  cells.	  The	  rest	  of	  the	  cells	  are	  showing	  limited	  hematopoietic	  lineage	  potency.	  
Figure	  3.0.2	  Mapping	  of	  C-­‐Kit+	  intra-­‐arterial	  hematopoietic	  clusters	  in	  A.	  E10.5	  and	  B.	  E11.5	  embryos.	  
(Adapted	  from	  figure	  2	  of	  Yokomizo	  et.	  al.	  2010	  Development)	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Previous	   studies	   on	   marked	   HE	   and	   Pre-­‐HP	   populations	   suggested	   the	   presence	  functional	  heterogeneity	  (Boisset	  et	  al.,	  2014;	  Lancrin	  et	  al.,	  2009).	  Partially	  it	  might	  be	  related	   with	   the	   lack	   of	   exclusive	   marker	   of	   those	   populations.	   It	   may	   also	   be	   the	  reflection	  of	  population	  with	  basic	  potential,	  which	  can	  only	  become	  functional	  upon	  an	  extrinsic	   signal	   to	   trigger	   differentiation.	   If	   we	   can	   identify	   highly	   homogeneous	  population	  and	  visualize	  its	  frequency	  in	  AGM	  and	  YS	  hematopoiesis	  in	  time	  course,	  we	  can	  enlighten	  the	  heterogeneous	  EHT.	  
1.3. Our	  approach	  and	  hypothesis	  Cell	   identity	   can	   be	   defined	   by	   gene	   expression	   profile	   and	   functional	   protein	  repertoire.	  Up	  until	  recently,	  material	  needed	  for	  gene	  expression	  analysis	  wouldn’t	  be	  enough	   from	   one	   cell.	   The	   microfluidics	   technology	   developed	   in	   the	   last	   few	   years	  made	  it	  possible	  to	  do	  single	  cell	  qRT-­‐PCR	  and	  single	  cell	  total	  mRNA	  sequencing.	  
2. Results:	  
2.1. The	  establishment	  of	  the	  single	  cell	  qRT-­‐PCR	  technique	  The	  single	  cell	  qRT-­‐PCR	  for	  96	  genes	  is	  a	  technique	  established	  in	  the	  last	  few	  years	  (Sthalberg	  2010).	  Comparing	  with	  the	  conventional	  qRT-­‐PCR,	  it	  requires	  extra	  steps	  and	  precautions	  due	  to	  the	  low	  amount	  of	  RNA	  material	  to	  begin	  with.	  The	  optimization	  of	  the	  technique	  and	  later	  the	  verification	  of	  the	  results	  with	  expectation	  is	  the	  vital	  part	  of	  this	  project.	  	  	  
The	   establishment	   of	   the	   technique	  was	   based	   on	   two	   aspects;	   the	   variety	   of	   cell	  types	   and	   the	   panel	   of	   genes.	   	   In	   vitro	   differentiation	   of	   mES	   cells	   allows	   us	   to	   sort	  population	   of	   cells	   within	   its	   controlled	   timing	   during	   EHT.	   Our	   knowledge	   of	   gene	  expression	   change	   can	   be	   classified	   for	   endothelial	   and	   hematopoietic	   genes.	   All	  together,	   expected	   gene	   expression	  pattern	  of	   relatively	   known	   cell	   types	  became	  our	  guide	  to	  test	  the	  technique.	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2.2. Selection	  of	  first	  samples	  to	  test:	  Sorted	  cell	  populations	  derived	  from	  in	  
vitro	  differentiation	  system	  For	   the	   selection	   of	   cell	   types,	   I	   used	   the	  mES	   cell	   differentiation	   protocol	   on	   the	  Runx1	  +/hCD4	  cell	  line	  generated	  previously	  (Sroczynska	  2009).	  In	  this	  cell	  line	  human	  CD4	  gene	   is	  knocked-­‐in	   in	   the	  proximal	  promoter	  of	   the	  Runx1	  to	   trace	  hematopoietic	  specific	  expression	  of	  Runx1	  via	  hCD4	  specific	  antibody	  (Figure	  3.3.A).	  It	  makes	  an	  ideal	  reporter	   cell	   line	   to	   isolate	   hemogenic	   endothelial	   (HE)	   population,	   which	   is	   not	  distinguishable	  from	  the	  non-­‐hemogenic	  endothelial	  (NonHE)	  phenotype	  by	  expression	  of	   endothelial	  markers	   (such	   as	   VE-­‐Cadherin),	   yet	   not	   transcribing	   the	   hematopoietic	  markers.	   Further	   in	   EHT,	   HE	   cells	   start	   to	   express	   early	   hematopoietic	   markers	   like	  CD41,	  giving	  rise	  to	  pre-­‐hematopoietic	  progenitor	  (pre-­‐HP)	  cells.	  	  Those	  cells	  lose	  their	  endothelial	   markers	   and	   gain	   round	   morphology	   and	   finally	   become	   hematopoietic	  progenitor	  (HP)	  (Figure3.3.B).	   In	  order	  to	  isolate	  all	  of	  the	  populations,	  day1.5	  of	  blast	  culture	  was	  chosen	  to	  be	  the	  best	  time	  point	  because	  populations	  from	  all	  stages	  of	  EHT	  are	   found	   approximately	   in	   equal	   proportions.	   VE-­‐Cadherin	   is	   used	   as	   endothelial	  marker,	   CD41	   is	   used	   as	   early	   hematopoietic	  marker	   and	   the	   hCD4	   is	   used	   as	   Runx1	  expression	  reporter	  to	  isolate	  NonHE,	  HE,	  Pre-­‐HP,	  and	  HP	  populations	  (Figure3.3.C).	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Figure	  3.0.3	  The	  strategy	  to	  isolate	  cell	  populations	  by	  using	  Runx1	  hCD4/+	  cell	  line.	  A.	  The	  cell	  line	  has	  
one	  WT	  and	  one	  hCD4	  knock-­‐in	  Runx1	  alleles.	  (adapted	  from	  Sroczynska	  2009)	  B.	  The	  markers	  and	  
corresponding	  populations	  are	  depicted	  as	  they	  are	  expected	  to	  appear	  during	  EHT.	  C.	  The	  sample	  
sorting	  strategy	  for	  isolation	  of	  the	  4	  populations.	  
2.3. Choice	  of	  96	  genes	  to	  check	  expression	  in	  single	  cells	  The	  selection	  of	  genes	  has	  to	  be	  distinctive	  enough	  to	  spot	  the	  separate	  populations	  and	   also	   has	   to	   be	   extensive	   enough	   to	   conclude	   about	   the	   nature	   of	   the	   populations.	  The	   largest	   microfluidics	   chip	   allows	   us	   to	   run	   qPCR	   for	   96	   genes	   in	   96	   single	   cells.	  Considering	  the	  loss	  of	  endothelial	  phenotype	  and	  gain	  of	  hematopoietic	  features	  during	  EHT,	   we	   decided	   to	   choose	   two	   large	   sets	   of	   endothelial	   and	   hematopoietic	   marker	  genes.	   We	   included	   also	   a	   list	   of	   transcription	   factors	   having	   role	   in	   developmental	  hematopoiesis.	   The	   addition	   of	   epithelial	   to	   mesenchymal	   transition	   (EMT)	   and	  TGFβ/BMP	   pathway	   related	   genes	   is	   more	   regarding	   the	   other	   project	   in	   my	   thesis.	  Lastly,	  one	  reference	  gene	   (Ppia)(Handschumacher,	  Harding,	  Rice,	  Drugge,	  &	  Speicher,	  1984)	  was	  selected	  to	  see	  equal	  mRNA	  material	  among	  different	  single	  cells	  (Table	  3.1).	  I	  have	  tested	  Hprt1,	  H2afz	  and	  Ppia	  primers	  for	  qPCR	  study	  with	  cells	  isolated	  form	  ES	  cell	  culture,	  which	  claimed	  to	  have	  stable	  gene	  expression	  for	  ES	  cells	  (Mamo,	  Gal,	  Bodo,	  &	  Dinnyes,	  2007).	  Only	  the	  Ppia	  primers	  gave	  the	  most	  consistent	  Ct	  values	  for	  different	  samples,	  therefore	  we	  added	  Ppia	  into	  the	  primer	  panel	  for	  the	  single	  cell	  study.	  
Marker NonHE HE Pre-HP HP 
VE-
Cadherin 
+ + + - 
hCD4 
(Runx1) 
- + + + 
CD41 - - + + 
were only detected from day 4 of differentiation with increasing
level at later stages.
To follow distal and proximal Runx1 ranscription at the single-ce l
level, we established ES-cell lines containing reporter genes for both
distal and proximal Runx1 expression. The GFP gene was first inserted
by homologous recombination under the control of Runx1 distal
promoter, downstream of the distal 5!UTR at the level of the first coding
ATG of Runx1c (Figure 1C; supplemental Figure 1A, available on the
Blood website; see the Supplemental Materials link at the top of the
online article). The neomycin selection cassette was then excised from
correctly targeted clones by Cre-mediated recombination. Subsequently,
a truncated human CD4 cDNA (hCD4) was introduced by homologous
recombination downstream of the proximal 5! UTR at the level of the
first coding ATG of Runx1b (Figure 1C; supplemental Figure 1B). The
neomycin selection cassette was then excised by Cre-mediated deletion
in clones selected for the introduction of hCD4 on the same allele as the
distal-GFP targeting.The correct genetic modifications in the distal-GFP/
proximal-hCD4 double KI ES-cell line were confirmed by southern
blots (supplemental Figure 1C-G).
To confirm that the transcription of the KI reporter genes
correlates with those of the endogenous Runx1 isoforms, we
monitored the levels of GFP and hCD4 mRNA during the course of
a 7-day differentiation (supplemental Figure 2A) and compared
these expression patterns to those observed for distal Runx1 and
proximal Runx1 mRNA (Figure 1B). The transcription of hCD4
followed closely the transcription of proximal Runx1, increasing
from day 2 to 3.5 and then gradually decreasing. Likewise, GFP
transcripts were detected at the same time as the distal Runx1
transcription around day 4 of EB differentiation, and the levels of
both transcripts increased similarly subsequently (supplemental
Figure 2A). We next analyzed the expression of both proximal-
hCD4 and distal-GFP at the protein level by flow cytometry during
the course of EB differentiation (supplemental Figure 2B). The
hCD4 protein was first detected by day 2 of EB differentiation, and
the frequency of hCD4" cells peaked around day 4 and decreased
at later days. The first emerging distal-GFP" cells were detected by
day 4 of differentiation, and their frequency increased subse-
quently. Finally, to validate that detection of hCD4 and GFP
proteins reflects, respectively, proximal and distal Runx1 transcrip-
tion, we sorted GFP", hCD4"GFP#, and hCD4#GFP# cell popula-
tions from day 5 EBs and analyzed for proximal and distal Runx1
transcription. As shown in supplemental Figure 2C, distal Runx1
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Figure 1. Expression of proximal and distal Runx1 during ES/EB differentiation. (A) Schematic representation of differences in the N-terminal amino acid sequences
between distal and proximal Runx1 isoforms. The N-terminally located Runt domain binds DNA and core binding factor-$ subunit. (B) Semiquantitative reverse-transcription
PCR analysis of expression of distal and proximal Runx1 during ES/EB differentiation. (C) Schematic representation of Runx1 WT allele and double KI allele. Gray and white
boxes indicate positions of Runx1 coding and noncoding parts, respectively. Arrows mark positions of PCR primers used for specific detection of both isoforms.
(D) Fluorescence-activated cell-sorting (FACS) analysis of Flk-1 and proximal-hCD4 expression during EB differentiation between days 2 and 3.5. (E) FACS analysis of CD41
and proximal-hCD4 expression during EB differentiation between days 3 and 6. (F) FACS analysis of CD41 and distal-GFP expression during EB differentiation between
days 4 and 6. (G left) FACS analysis of proximal-hCD4 and distal-GFP expression in presort (P1) and sorted populations (P2-P4) from day 6 EBs. (Middle) Numbers of
hematopoietic colo ies generated in methylcellulose by populations P1 to P4 from day 6 EBs. Error bars indicate SD of the mean (n % 3). (Right) FACS analysis of CD45 and
distal-GFP expression 7 days after replating in methylcellulose media. Numbers represent percentages of respective populations.
RUNX1 TRANSCRIPTION IN HEMATOPOIETIC DEVELOPMENT 5281BLOOD, 17 DECEMBER 2009 ! VOLUME 114, NUMBER 26
were only detected from day 4 of differentiation with increasing
level at later stages.
To follow distal and proximal Runx1 transcription at the single-cell
level, we established ES-cell lines containing reporter genes for both
distal and proximal Runx1 expression. The GFP gene was first inserted
by homologous recombination under the control of Runx1 distal
promoter, downstream of the distal 5!UTR at the level of the first coding
ATG of Runx1c (Figure 1C; supplemental Figure 1A, available on the
Blood website; see the Supplemental Materials link at the top of the
online article). The neomycin selection cassette was then excised from
correctly targeted clones by Cre-mediated recombination. Subsequently,
a truncated human CD4 cDNA (hCD4) was introduced by hom logous
recombination downstream of the proximal 5! UTR at the l vel of the
first coding ATG of Runx1b (Figure 1C; supplemental Figure 1B). The
neomycin s lection cass tte was then excised by Cre-mediate d letion
in clones s lected for the introduction of hCD4 on the same all le as the
distal-GFP targeting.The correct g netic modifications in the distal-GFP/
proximal-hCD4 double KI ES-cell line w re confirmed by southern
blot (supplemental Figure 1C-G).
To confirm that the transcription of the KI reporter genes
correlates with those of the endogenous Runx1 is forms, we
monitored the levels of GFP and hCD4 mRNA during the course of
a 7-day differentiation (supplemental Figure 2A) and compared
these expression patterns to those observed for distal Runx1 and
proximal Runx1 mRNA (Figure 1B). The transcription of hCD4
followed closely the transcription of proximal Runx1, increasing
from day 2 to 3.5 and then gradually decreasing. Likewise, GFP
transcripts were detected at the same time as the distal Runx1
transcription around day 4 of EB differentiation, and the levels of
both transcripts increased similarly subsequently (supplemental
Figure 2A). We next analyzed the expression of both proximal-
hCD4 and distal-GFP at the protein level by flow cytometry during
the course of EB differentiation (supplemental Figure 2B). The
hCD4 protein was first d tected by day 2 of EB diff rentiation, and
the frequency of hCD4" cells peaked aroun day 4 an decreased
at later days. The first emerging distal-GFP" cells w re d tected by
day 4 of diff rentiation, and their frequency increased subse-
quently. Finally, to validate that d tection of hCD4 and GFP
proteins reflects, respectively, proximal an distal Runx1 transcrip-
tion, we sorted GFP", hCD4"GFP#, and hCD4#GFP# cell popula-
tions from day 5 EBs and analyzed for proximal an distal Runx1
transcription. As shown in supplemental Figure 2C, distal Runx1
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Figure 1. Expression of proximal and distal Runx1 during ES/EB differentiation. (A) Schematic represent ti n of differences in the N-terminal amino acid equences
between distal and proximal Runx1 isoforms. The N-terminally locate Runt domain binds DNA and core binding factor-$ subunit. (B) Semiq antitative r verse-transcription
PCR analysis of expression of distal and proximal Runx1 during ES/EB differentiation. (C) Schematic representation of Runx1 WT allele and double KI allele. Gray and white
boxes indicate positions of Runx1 coding and noncoding parts, respectively. Arrows mark positions of PCR primers used for specific detection of both isoforms.
(D) Fluorescence-activated cell-sorting (FACS) analysis of Flk-1 and proximal-hCD4 expression during EB differentiation between days 2 and 3.5. (E) FACS analysis of CD41
and proximal-hC 4 expression during EB differentiation between days 3 and 6. (F) FACS analysis of CD41 and distal-GFP expression during EB differentiation between
days 4 and 6. (G left) FACS analysis of proximal-hCD4 and distal-GFP expression in presort (P1) and sorted populations (P2-P4) from day 6 EBs. (Middle) Numbers of
hematopoietic colonies generated in methylcellulose by populations P1 to P4 from day 6 EBs. Error bars indicate SD of the mean (n % 3). (Right) FACS analysis of CD45 and
distal-GFP expression 7 days after replating in methylcellulose media. Numbers represent percentages of respective populations.
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were only detected from day 4 of differentiation with increasing
level at later stages.
To follow distal and proximal Runx1 transcription at the single-cell
level, we established ES-cell lines containing reporte genes for both
distal and proximal Runx1 expression. The GFP gene was first inserted
by homologous recombination under the control of Runx1 distal
promoter, dow stream of th distal 5!UTR at the level of the first coding
ATG of Runx1c (Figure 1C; supplemental Figure 1A, available on the
Blood website; see the Supplemental Materials link at the top of the
online article). The neomycin selection cassette was then excised from
correctly targeted clones by Cre-mediated recombination. Subsequently,
a truncated human CD4 cDNA (hCD4) was introduced by hom logous
recombination downstream of the proximal 5! UTR at the level of the
first coding ATG of Runx1b (Figure 1C; supplemental Figure 1B). The
neomycin selection cassette was then excised by Cre-mediated deletion
in clones selected for the introduction of hCD4 on the same allele as the
distal-GFP targeting.The correct genetic modifications in the distal-GFP/
proximal-hCD4 double KI ES-cell line were confirmed by southern
blots (supplemental Figure 1C-G).
To confirm that the transcription of the KI reporter genes
correlates with those of the endogenous Runx1 isoforms, we
monitored the levels of GFP and hCD4 mRNA during the course of
a 7-day differentiation (supplemental Figure 2A) and compared
these expression patterns to those observed for distal Runx1 and
proximal Runx1 mRNA (Figure 1B). The transcription of hCD4
followed closely the transcription of proximal Runx1, increasing
from day 2 to 3.5 and then gradually decreasing. Likewise, GFP
transcripts were detected at the same time as the distal Runx1
transcription around day 4 of EB differentiation, and the levels of
both transcripts increased similarly subsequently (supplemental
Figure 2A). We next analyzed the expression of both proximal-
hCD4 and distal-GFP at the protein level by flow cytometry during
the course of EB differentiation (supplemental Figure 2B). The
hCD4 protein was first detected by day 2 of EB differentiation, and
the frequency of hCD4" cells peaked around day 4 and decreased
at later days. The first merging distal-GFP" cells wer det cted by
day 4 of differentiation, and their frequency increased subse-
quently. Finally, to validate that detection of hCD4 and GFP
proteins reflects, respectively, proximal and distal Runx1 transcrip-
tion, we sorted GFP", hCD4"GFP#, and hCD4#GFP# cell popula-
tions from day 5 EBs and analyzed for proximal and distal Runx1
transcription. As shown in supplemental Figure 2C, distal Runx1
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Figure 1. Expression of proximal and distal Runx1 during ES/EB differentiation. (A) Schematic representati n of differences in the N-terminal amino acid sequ nces
b tween distal and proximal Runx1 isoforms. The N-terminal y l cated Runt do ain binds DNA and core binding factor-$ subu it. (B) Semiquantitative reverse-transcription
PCR analysis of expression of distal and proxi al Runx1 during ES/EB differentiation. (C) Sch m tic representa on of Runx1 WT allele and double KI allele. Gray and white
boxes indicate positions of Runx1 coding and noncoding parts, respectively. Arrows mark positions of PCR primers used for specific detection of both isoforms.
(D) Fluorescence-activated cell-sorting (FACS) analysis of Flk-1 and proximal-hCD4 expression during EB differentiation between days 2 and 3.5. (E) FACS analysis of CD41
and proximal-hCD4 expression during EB differentiation between days 3 and 6. (F) FACS analysis of CD41 and distal-GFP expression during EB differentiation between
days 4 and 6. (G left) FACS analysis of proximal-hCD4 and distal-GFP expression in presort (P1) and sorted p pulations (P2-P4) from day 6 EBs. (Middle) Nu bers of
hematopoietic colonies generated in methylcellulose by populations P1 to P4 from day 6 EBs. Error bars indicate SD of the mean (n % 3). (Right) FACS analysis of CD45 and
distal-GFP expression 7 d ys after replating in methylcellulose media. Numbers represent percentages of respective populations.
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Among	  96	  genes,	   there	   are	  39	  genes	   as	   the	   transcriptional	   effectors	  of	  Runx1	  and	  Gfi1,	  which	  we	  thought	  important	  for	  EHT	  regulation.	  Recently,	  we	  have	  shown	  that	  Gfi1	  and	   Gfi1b	   are	   down-­‐stream	   targets	   of	   Runx1,	   which	   decreases	   the	   endothelial	   gene	  expression	   in	   hemogenic	   endothelial	   cells	   during	   the	   transition	   (Lancrin	   2012).	   The	  Runx1	   KO	   cells	   fail	   in	   forming	   functional	   hematopoietic	   progenitors	   through	   EHT.	  However	   induced	   Gfi1	   or	   Gfi1b	   expression,	   in	   the	   absence	   of	   Runx1	   can	   rescue	   the	  emergence	   of	   round	   hematopoietic	   progenitors.	   In	   parallel,	   the	   double	   Gfi1	   and	  Gfi1b	  KO	   mouse	   has	   hematopoietic	   progenitors,	   which	   cannot	   detach	   from	   the	   endothelial	  layer	  during	  EHT	  in	  yolk	  sac.	  This	  indicates	  the	  crucial	  role	  of	  Gfi1	  and	  Gfi1b	  function	  in	  repression	  of	  endothelial	  gene	  expression	  and	  morphology.	  
Since	  Gfi1	  is	  a	  direct	  binding	  target	  of	  Runx1	  and	  plays	  an	  important	  role	  in	  the	  loss	  of	   endothelial	   characteristics,	   the	   genes	  whose	   expression	   is	   regulated	  by	  both	  Runx1	  and	  Gfi1	  took	  our	  attention	  as	  a	  potential	  marker	  for	  hemogenic	  endothelium.	  To	  reveal	  the	   transcriptional	   change	   when	   Runx1	   or	   Gfi1	   is	   expressed	   in	   Runx1	   KO	   cells,	  previously	   Christophe	   Lancrin	   performed	   two	   sets	   of	   mRNA	  microarray	   experiments	  (unpublished	   data).	   Surprisingly	   there	   were	   7	   up-­‐regulated	   and	   32	   down-­‐regulated	  genes	  by	  both	  Runx1	  and	  Gfi1	  activity.	  Confirmation	  of	  the	  expression	  pattern	  change	  of	  39	   genes	   upon	   Runx1	   and	   Gfi1	   activity	   was	   done	   by	   conventional	   qRT-­‐PCR.	  	  We	   found	   that	   the	   majority	   of	   the	   fold	   changes	   gathered	   from	   Runx1	   and	   Gfi1	  microarray	   experiments	   have	   consistent	   pattern	   in	   the	   conventional	   qRT-­‐PCR	  experiments	  (Figure	  3.4	  for	  Runx1	  experiments,	  Figure	  3.5	  for	  Gfi1	  experiments).	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Table	  63.1	  The	  list	  of	  96	  genes	  selected	  for	  single	  cell	  qRT-­‐PCR,	  and	  their	  classification	  related	  
with	  their	  reason	  of	  choice.	  
Gene	  classification	   Gene	  names	  
Housekeeping	  gene	  (1)	   PPIA	  
Genes	  regulated	  by	  Runx1	  and	  Gfi1	  (39)	   ADCY4,	  ATP2A3,	  CACNA2D1,	  CDH5,	  COL4A2,	  COL4A5,	  DCAF12L1,	  DPYSL3,	  ENPP1,	  EPS8,	  ESAM,	  FAM122B,	  FBN1,	  FLRT2,	  FMO1,	  GDPD5,	  GPR126,	  GRIA4,	  LAD1,	  LAT,	  LGR5,	  MEIS2,	  MET,	  MYB,	  MYOM1,	  NOTCH1,	  NPR1,	  PALLD,	  PCDH12,	  PDZD2,	  PLCD1,	  PPP1R16B,	  PTPRB,	  PTPRM,	  SAMD4,	  SASH1,	  SHE,	  SLA,	  UPP1	  TGFB-­‐BMP	  pathway	  related	  genes	  (22)	   ACVR1,	  ACVR1B,	  ACVR2A,	  ACVR2B,	  ACVRL1,	  BMP4,	  BMPR1A,	  BMPR2,	  ENG,	  SMAD1,	  SMAD2,	  SMAD3,	  SMAD4,	  SMAD5,	  SMAD6,	  SMAD7,	  SMAD9,	  TGFB1,	  TGFB2,	  TGFB3,	  TGFBR1,	  TGFBR2	  EMT	  related	  genes	  (11)	   ACTA2,	  CDH2,	  SERPINE1,	  SNAI1,	  SNAI2,	  TGFB1,	  TGFB2,	  TGFB3,	  TGFBR1,	  TGFBR2,	  CTNNB1	  
Endothelial	  genes	  (17)	   CDH5,	  CLDN5,	  ENG,	  ERG,	  ESAM,	  FBN1,	  GPR126,	  KDR,	  MEIS2,	  NOTCH1,	  NPR1,	  PCDH12,	  PTPRB,	  PTPRM,	  RAMP2,	  SOX7,	  TEK	  Hematopoietic	  genes	  (22)	   EPO,	  EPOR,	  GATA1,	  GATA2,	  GFI1,	  GFI1B,	  HBB-­‐B1,	  HBB-­‐BH1,	  ITGA2B,	  ITGAM,	  ITGB3,	  KIT,	  LMO2,	  LYL1,	  MPO,	  MYB,	  PTPRC,	  RUNX1,	  SFPI1,	  SLA,	  TAL1,	  THPO	  Transcription	  factors	  (16)	   ERG,	  FLI1,	  GATA1,	  GATA2,	  GFI1,	  GFI1B,	  LMO2,	  LYL1,	  MEIS2,	  MYB,	  RUNX1,	  SFPI1,	  SNAI1,	  SNAI2,	  SOX7,	  TAL1	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Figure	  3.0.4	  The	  fold	  changes	  of	  the	  39	  genes	  in	  induced	  Runx1	  expressed	  cells	  versus	  Runx1	  
knock-­‐out	  cells.	  The	  red	  bars	  represent	  the	  mRNA	  microarray	  and	  the	  blue	  bars	  represent	  the	  qRT-­‐PCR	  
fold	  change	  values.	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Figure	  3.0.5	  The	  fold	  changes	  of	  the	  39	  genes	  in	  induced	  Gfi1	  expressed	  cells	  versus	  Runx1	  knock-­‐
out	  cells.	  The	  red	  bars	  represent	  the	  mRNA	  microarray	  and	  the	  blue	  bars	  represent	  the	  qRT-­‐PCR	  fold	  
change	  values.	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2.4. The	  first	  single	  cell	  qRT-­‐PCR	  results	  of	  blast	  culture	  isolated	  cells	  	  The	   first	   two	   experiments	   of	   single	   cell	   qRT-­‐PCR	   were	   done	   with	   sorted	   4	  populations	  (Figure3.6.B)	  from	  blast	  day	  1.5	  culture	  of	  Runx1	  hCD4/+	  cell	  line.	  	  NonHE,	  HE,	   Pre-­‐HP	   and	   HP	   cell	   populations	   are	   defined	   according	   to	   their	   VE-­‐cadherin,	  hCD4/Runx1,	  CD41	  expression	  as	  it	  is	  explained	  before	  (Figure3.3).	  After	  removal	  of	  the	  samples	  with	  no	  expression	  of	  the	  96	  genes,	  called	  outliers,	  135	  single	  cell	  samples	  were	  left.	  The	  global	  Z	  score	  expression	  value	  of	  96	  genes	  for	  each	  single	  cell	  is	  represented	  in	  hierarchical	  clustering	  of	  samples	  (on	  the	  horizontal	  axis)	  and	  the	  genes	  (on	  the	  vertical	  axis)	   (Figure	   3.6.A).	   The	   sample	   clustering	   done	   by	   the	   algorithm	   in	   general	   does	   not	  fully	   overlap	  with	   the	   sorted	  population	   identity,	   although	  HP	   cells	   are	   clearly	  distant	  from	  HE	   and	  NonHE	   cells.	   The	   principal	   component	   analysis	   of	   the	   results	   shows	   the	  similarity	  of	  cells	  belong	  to	  4	  populations	  within	  2	  principal	  components	  (Figure	  3.6.C).	  In	   contrast	   the	   expected	   EHT	   course	   of	   action	   among	   populations	   is	   represented	   as	  distribution	  of	  cells	  in	  the	  PCA	  score	  plot.	  The	  NonHE	  cells	  are	  overlapping	  with	  the	  HE	  cells;	  HE	  cells	  are	  overlapping	  with	  Pre-­‐HP	  cells	  and	  Pre-­‐HP	  cells	  are	  overlapping	  with	  HP	   cells,	   while	   the	   distance	   between	   endothelial	   and	   hematopoietic	   cloud	   is	   evident	  (Figure	  3.6.C).	  
To	   identify	   gene	   expression	   pattern	   in	   detail,	   each	   gene	   expression	   value	   was	  investigated	  among	  4	  populations	  by	  violin	  plots.	  The	  expression	  profile	  of	  single	  cells	  within	  a	  population	  can	  be	  visualized	  as	  a	  distribution	  of	  Log2	  expression	  values	  in	  the	  violin	   plots.	   The	   common	   effectors	   of	   Gfi1	   and	   Runx1,	   39	   genes	   (Figure	   3.7),	   were	  checked	  as	  comparison	  with	  the	  microarray	  and	  qPCR	  data	  (Figure	  3.4	  and	  Figure	  3.5).	  Among	   the	   7	   up-­‐regulated	   genes,	   5	   of	   them	   (Atp2a3,	  Myom1,	  Myb,	   Sla,	   Enpp1)	   show	  higher	  expression	  in	  HP	  population	  than	  in	  NonHE,	  HE	  and	  Pre-­‐HP	  populations.	  Among	  32	   down-­‐regulated	   genes,	   26	   genes	   (Adcy4,	   Cdh5,	   Col4a2,	   Col4a5,	   Dcaf12l1,	   Dpysl3,	  Eps8,	   Esam,	   Fbn1,	   Fmo1,	   Gdpd5,	   Gpr126,	   Met,	   Meis2,	   Notch1,	   Npr1,	   Palld,	   Pcdh12,	  Pdzd2,	  Plcd1,	  Ptprb,	  Ptprm,	  Ppp1r16b,	  Samd4,	  She,	  Upp1)	  show	  lower	  expression	  in	  HP	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population	  than	  in	  the	  others.	  It	  is	  also	  interesting	  to	  see	  some	  genes	  have	  a	  fashion	  of	  gradual	  decrease	  or	  increase	  in	  the	  expected	  fashion	  of	  EHT:	  NonHE,	  HE,	  Pre-­‐HP	  and	  HP.	  
The	  violin	  plot	  of	  endothelial	  genes	  show	  the	  expected	  pattern	  of	  gradual	  or	  sudden	  expression	   decrease	   in	   the	   order	   of	   EHT	   from	   NonHE	   to	   HP.	   Among	   18	   endothelial	  genes,	  all	  but	  2	  (Pecam1,	  Cldn5)	  show	  the	  lower	  expression	  towards	  EHT	  (Figure	  3.8.A).	  On	  the	  contrary,	  among	  22	  hematopoietic	  genes,	  only	  11	  genes	  (Epor,	  Gata1,	  Gfi1b,	  Hbb-­‐b1,	  Hbb-­‐bh1,	  Itgb3,	  Mpo,	  Myb,	  Runx1,	  Sla,	  Sfpi1)	  show	  expression	  increase	  towards	  EHT	  (Figure	   3.8.B).	   The	   other	   hematopoietic	   genes	   either	   don’t	   vary	   significantly	   among	  populations,	  or	  don’t	  follow	  the	  expected	  increase	  during	  the	  EHT	  course.	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Figure	  3.0.6	  Single	  cell	  qRT-­‐PCR	  analysis	  of	  sorted	  4	  populations	  from	  blast	  day1.5	  culture	  of	  Runx1	  
hCD4/+	  cell	  line.	  A.	  Hierarchical	  clustering	  of	  cells	  sorted	  as	  4	  populations	  with	  their	  expression	  level	  of	  
96	  genes.	  The	  expression	  level	  is	  represented	  as	  global	  Z	  score,	  (blue)	  low	  to	  (red)	  high.	  B.	  The	  sorted	  
population	  according	  to	  3	  markers	  expression,	  VE-­‐Cadherin	  as	  endothelial,	  hCD4/Runx1	  as	  EHT	  
initiation,	  CD41	  as	  early	  hematopoietic	  markers.	  C.	  Principal	  component	  analysis	  score	  plot	  of	  cells	  
with	  their	  sorted	  population	  identity.	  
	  
Marker NonHE HE Pre-HP HP 
VE-
Cadherin 
+ + + - 
hCD4 
(Runx1) 
- + + + 
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Figure	  3.0.7	  Violin	  Plots	  of	  4	  populations	  and	  the	  expression	  of	  39	  genes	  regulated	  by	  Runx1	  and	  Gfi1.	  
Among	  the	  gene	  expression	  values	  within	  populations,	  the	  genes	  with	  ANOVA	  p	  value	  is	  lower	  than	  0.05	  
are	  indicated	  with	  *	  next	  to	  the	  gene	  name.	  The	  first	  7	  (Atp2a3,	  Myom1,	  Lat,	  Myb,	  Sla,	  Enpp1,	  Lgr5)	  are	  
the	  common	  up-­‐regulated	  genes	  by	  Runx1	  and	  Gfi1;	  the	  rest	  32	  genes	  are	  the	  common	  down-­‐regulated	  
ones.	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Figure	  3.0.8	  Violin	  Plots	  of	  4	  populations	  with	  the	  expression	  of	  A.	  endothelial	  genes	  and	  B.	  
hematopoietic	  genes.	  Among	  the	  gene	  expression	  values	  within	  populations,	  the	  genes	  with	  ANOVA	  p	  
value	  is	  lower	  than	  0.05	  are	  indicated	  with	  *	  next	  to	  the	  gene	  name.	  The	  genes	  are	  listed	  in	  
alphabetical	  order.	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2.5. Investigation	  of	  in	  vivo	  endothelial	  to	  hematopoietic	  transition	  by	  single	  
cell	  qRT-­‐PCR	  technique	  In	   order	   to	   explore	   the	   in	   vivo	   EHT	   at	   the	   single	   cell	   level,	   we	   decided	   to	   isolate	  hemogenic	  endothelial	  cells	  and	  pre-­‐hematopoietic	  progenitors	  from	  two	  hematopoietic	  tissues:	   yolk	   sac	   (YS)	   and	   aorta-­‐gonad	   mesonephros	   (AGM)	   (Figure	   3.9.A).	   YS	   is	   the	  region	  where	  first	  hematopoietic	  progenitors	  emerge	  and	  AGM	  is	  the	  first	  tissue	  where	  the	  HSCs	  appear.	  Therefore	  the	  comparison	  of	  cells	  isolated	  from	  these	  two	  tissues	  will	  be	   valuable	   to	  understand	   the	  differences	  of	  hematopoietic	  programs.	  Also	   to	   address	  the	  timing	  of	  EHT	  in	  these	  two	  tissues,	  we	  decided	  to	  isolate	  cells	  from	  E9.0,	  E10.5	  and	  E11.0	  mouse	   embryos.	   Since	  we	   do	   not	   have	   a	   Runx1	   hCD4	   reporter	  mouse	   line,	   we	  used	   only	   VE-­‐Cadherin	   and	   CD41	   markers	   to	   sort.	   We	   aim	   to	   sort	   all	   VE-­‐Cadherin	  positive	   cells,	  with	  CD41	   expression	   level:	   negative,	  medium	  or	   high.	   I	   sorted	  32	   cells	  per	  population	  per	  time	  point	  and	  tissue	  (except	  for	  E9.0	  AGM,	  I	  managed	  only	  to	  get	  9	  cells	  due	   to	   its	  very	   low	   frequency)	   (Figure	  3.9.B).	  We	  have	  run	  6	  micro-­‐fluidics	  chips	  (96	  single	  cells	  *96	  genes)	  with	  the	  AGM	  and	  YS	  derived	  cells.	  	  
2.5.1. The	  identification	  of	  subpopulations	  from	  mouse	  embryo	  derived	  cells	  	  EHT	   can	   be	   analyzed	   at	   single	   cell	   level	   as	   a	   step-­‐wise	   transition	   of	   specific	   cell	  types.	   The	   cell	   types	   can	   be	   visualized	   in	   the	   single	   cell	   qRT-­‐PCR	   as	   subpopulations	  depending	  on	  the	  shared	  gene	  expression	  pattern.	  By	  combining	  the	  expression	  values	  of	  cells	  collected	  from	  YS	  and	  AGM	  within	  3	  time	  points,	  I	  aim	  at	  identifying	  all	  cell	  types	  during	  EHT	  with	  high	  resolution.	  
All	  6	  chip	  run	  results	  were	  combined	  in	  analysis	  and	  samples	  with	  no	  expression	  of	  the	  96	  genes,	  defined	  as	  outliers,	  were	   removed.	  After	   removal	  of	  outliers,	   there	  were	  510	   single	   cells	   in	   total	   for	   YS	   and	  AGM	  within	   3	   time	  points	   (Figure	   3.10.A).	   For	   the	  unbiased	  analysis	  of	  hematopoiesis	  within	  two	  tissues,	  we	  decided	  to	  combine	  the	  data	  from	  510	   cells	   to	   check	   its	   sample	   annotations	   afterwards.	  Because	   I	  will	   address	   the	  TGFB/BMP	  pathway	  in	  the	  chapter	  4,	  I	  removed	  the	  22	  genes	  (Table	  3.1)	  related	  with	  it	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from	   this	   analysis.	  The	  hierarchical	   clustering	  of	   the	  merged	  data	   from	  all	   tissues	   and	  time	  points	   is	   shown	   in	  Figure	  3.10.B.	   In	   the	  hierarchical	   clustering,	  6	   sample	  clusters	  were	  defined	  (Figure	  3.10.B).	  
The	  violin	  plots	  visualize	  the	  distribution	  of	  gene	  expression	  within	  a	  population.	  	  In	  figure	  3.11.A,	  the	  violin	  plots	  of	  endothelial	  genes	  for	  each	  sample	  cluster	  is	  shown.	  For	  SC_2	   (green),	   SC_4	   (orange)	   and	   SC_5	   (purple),	   all	   endothelial	   genes	   have	   high	  expression	   values.	   	   In	   comparison	  with	   them,	   SC_3	   (blue)	   has	   lower	   but	   still	   positive	  expression	   profile	   of	   endothelial	   genes.	   SC_6	   (pink)	   cells	   have	   lower	   endothelial	  expression	  and	   for	   some	  genes	   (Npr1,	  Ptprm,	  Ramp2,	   Sox7)	   there	   is	   a	  bi-­‐modal	   (both	  low	   and	   high)	   expression	   profile	   indicating	   heterogeneity	   within	   the	   population.	   In	  contrast	  to	  all,	  SC_1	  (red)	  cells	  have	  either	  no	  or	  lower	  expression	  of	  endothelial	  genes	  (Cdh5,	  Esam,	  Notch1,	  Eng,	  Pecam1)	  compared	  with	  the	  other	  sample	  clusters.	  Although	  all	  of	  the	  cells	  were	  sorted	  through	  VE-­‐Cadherin	  positive	  gate,	  SC_1	  cells	  show	  almost	  no	  VE-­‐Cadherin	  (also	  known	  as	  Cdh5)	  gene	  expression.	  It	  might	  be	  explained	  by	  SC_1	  cells	  bearing	  VE-­‐Cadherin	  protein	  on	  the	  cell	  surface	  but	  switched	  off	  its	  gene	  expression.	  In	  summary,	  SC_1	  has	  almost	  no;	  SC_3	  and	  SC_6	  have	  intermediate;	  SC_2,	  SC_4,	  SC_5	  have	  high	  endothelial	  gene	  expression	  profile	  (Figure	  3.11.A).	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Figure	  3.0.9	  Single	  cell	  sorting	  of	  isolated	  cells	  from	  AGM	  and	  YS	  tissues	  at	  stages	  of	  E9.0,	  E10.5	  and	  
E11.0	  mouse	  embryos.	  A.	  The	  representative	  scheme	  of	  E10.5	  mouse	  embryo,	  to	  show	  AGM	  and	  YS	  
localization.	  B.	  The	  FACS	  plots	  used	  for	  sorting	  of	  single	  cells	  from	  3	  time	  points	  and	  2	  tissues.	  VE-­‐
Cadherin	  and	  CD41	  staining	  was	  applied	  to	  sort	  3	  cell	  populations	  (VE-­‐Cadherin+,	  CD41	  negative	  
/intermediate	  /high)	  from	  each	  time	  point	  and	  tissue.	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The	  violin	  plots	  of	  hematopoeitic	  genes	  for	  all	  sample	  clusters	  are	  shown	  in	  Figure	  3.11.B.	  Unlike	  the	  endothelial	  genes	  in	  figure	  3.11.A,	  hematopoietic	  gene	  expressions	  are	  not	   following	  a	   common	  up/down	  regulation.	  This	  might	  be	  due	   to	   the	   fact	   that	   some	  hematopoietic	  genes	  up-­‐regulated	  in	  only	  specific	  population	  of	  cells	  depending	  on	  the	  progress	  of	  EHT.	  Population	  SC_1	  and	  SC_6	  show	  high	  expression	  of	  Itgam,	  Itgb3,	  Myb,	  Ptprc,	   Runx1,	   Sfpi1	   and	   Sla.	   Despite	   that	   similarity	   with	   SC_1,	   only	   SC_6	   show	   high	  expression	  of	  Gata2,	  Gfi1,	  Gfi1b,	  Kit,	  Mpo,	  Tal1;	  while	  SC_1	  does	  not	  present	  distinctive	  expression	  for	  other	  hematopoietic	  genes.	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Figure	  3.0.10	  Single	  cell	  analysis	  of	  merged	  cells	  isolated	  from	  YS	  and	  AGM	  from	  all	  time	  points.	  A.	  
The	  number	  of	  cells	  isolated	  from	  each	  tissue,	  each	  time	  point	  and	  each	  CD41	  sorting	  gate	  is	  indicated.	  
B.	  The	  hierarchical	  clustering	  of	  all	  isolated	  cells	  from	  mice	  with	  74	  genes	  expression	  values.	  The	  
sample	  clustering	  with	  a	  distance	  threshold	  of	  0.62	  identified	  6	  clusters.	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Figure	  3.0.11	  The	  violin	  plots	  of	  gene	  expression	  of	  A.	  endothelial	  genes	  and	  B.	  hematopoietic	  genes	  
within	  sample	  clusters.	  	  Among	  the	  gene	  expression	  values	  within	  populations,	  the	  genes	  with	  ANOVA	  p	  
value	  is	  lower	  than	  0.05	  are	  indicated	  with	  *	  next	  to	  the	  gene	  name.	  The	  genes	  are	  listed	  in	  
alphabetical	  order.	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SC_3,	  SC_4	  and	  SC_5	  present	  a	  highly	  similar	   low	  or	  none	  expression	  profile	   for	  all	  hematopoietic	   genes,	   however	   SC_5	   has	   slightly	   higher	   values	   for	   genes	   Gata2,	   Kit,	  Lmo2,	   Lyl1,	  Myb,	   Tal1	   and	   SC_4	  has	   a	   few	   cells	   expressing	  Hbb-­‐b1	   and	  Hbb-­‐bh1.	   It	   is	  important	  to	  emphasize	  the	  either	  no	  expression	  or	  bi-­‐modal	  expression	  pattern	  for	  the	  aforementioned	  genes	  within	  these	  populations.	  It	  may	  due	  to	  heterogeneity	  especially	  within	  SC_5	  population.	  
Lastly	   SC_2	   population	   seems	   to	   express	   some	   hematopoietic	   genes	   (Epor,	   Gata1,	  Gata2,	  Gfi1b,	  Hbb-­‐b1,	  Hbb-­‐bh1,	  Itga2b,	  Itgb3,	  Kit,	  Lmo2,	  Lyl1,	  Myb,	  Ptprc,	  Tal1,	  Thpo)	  at	  high	   levels.	   Interestingly	   Runx1,	   Sfpi1,	   Sla	   ,	   Itgam	   are	   not	   expressed	   but	   Epor,	   Gata1,	  Hbb-­‐b1,	  Hbb-­‐bh1;	  	  which	  are	  the	  genes	  related	  to	  the	  erythroid	  lineage	  are	  expressed	  at	  the	  highest	  level	  in	  the	  SC_2	  compared	  to	  other	  populations.	  
All	   together	   endothelial	   and	  hematopoietic	   gene	   expression	  profiles	   give	  us	   a	   clue	  about	   the	   identity	   of	   6	   sample	   clusters.	   According	   to	   Figure	   3.11.A	   and	   B,	   SC_3,	   SC_4,	  SC_5	   populations	   have	   dominant	   endothelial	   profile.	   SC_3	   can	   be	   separated	   by	   lower	  endothelial	   genes	  while	  SC_5	   is	  particular	  with	   co-­‐expressing	   some	  key	  hematopoietic	  genes.	   In	   that	   terms,	   SC_5	  might	   contain	   hemogenic	   endothelial	   cells,	   while	   SC_3	   and	  SC_4	  are	  closer	  to	  non-­‐hemogenic	  endothelial	  cells.	  
On	   the	   other	   hand,	   SC_1,	   SC_2	   and	   SC_6	   have	   gene	   expression	   profiles	   close	   to	  hematopoiesis	  with	   separate	   characteristics.	   SC_1	   is	   clearly	  not	  expressing	  endothelial	  genes	   and	   express	   some	   hematopoietic	   genes	   including	   Runx1.	   Since	   we	   sorted	   VE-­‐Cadherin	  presenting	  cells	  in	  their	  surface,	  cells	  composing	  SC_1	  should	  be	  the	  cells	  close	  to	   the	   the	   final	   step	   of	   the	  EHT.	   SC_6	   is	   interesting	  with	   both	   strong	   endothelial	   gene	  expression	  and	  some	  hematopoietic	  genes	  similar	  to	  SC_1.	  Regarding	  that,	  SC_6	  appears	  to	  be	  the	  cells	  with	  common	  gene	  expression	  profile	  of	  SC_5	  and	  SC_1.	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Above	  all,	  the	  most	  interesting	  population	  is	  SC_2	  with	  very	  high	  expression	  of	  both	  endothelial	   genes	   and	   some	   erythroid	   related	  marker	   genes	   (Hbb-­‐b1,	   Hbb-­‐bh1,	   Epor,	  Gata1,	   Thpo)	   without	   expressing	   Runx1,	   Sfpi1	   and	   Sla.	   Since	   such	   a	   population	   with	  erythroid-­‐endothelial	   profile	   has	   not	   been	   identified	   before,	   it	   requires	   further	  confirmation.	  	  
Previously	  we	  have	  seen	  that	  isolated	  cells	  from	  blast	  culture	  day	  1.5	  has	  a	  pattern	  of	  expression	  in	  parallel	  with	  the	  progression	  in	  EHT	  for	  39	  genes	  regulated	  by	  Runx1	  and	   Gfi1.	   Commonly	   up-­‐regulated	   7	   genes	   have	   higher	   expression	   and	   some	   down-­‐regulated	  genes	  have	  lower	  expression	  from	  HE	  towards	  HP	  population	  (Figure	  3.7).	  In	  order	   to	   check	   expression	   level	   of	   39	   genes	  within	   sample	   clusters	   of	  mouse	   embryo	  isolated	   cells,	   I	   analyzed	   the	   expression	   of	   39	   genes	   (Figure	   3.12).	   According	   to	   the	  previous	   analysis	  with	   endothelial	   and	   hematopoietic	   genes,	   in	   vivo	   EHT	   steps	  might	  follow	  the	  sequence	  SC_4è	   SC_5	  èSC_6	  è	   SC_1.	   In	   this	  sense,	  when	   I	  analyze	   the	  39	  genes’	   expression	   change	   from	   SC_4,	   SC_5,	   SC_6	   to	   SC_1,	   I	   saw	   the	   up-­‐regulation	   of	  Atp2a3,	  Myom1,	  Lat,	  Myb,	  Sla,	  Enpp1.	  Among	  the	  other	  32	  genes,	  most	  of	  them	  (Adcy4,	  Cdh5,	   Col4a2,	   Col4a5,	   Dcaf12l1,	   Dpysl3,	   Esam,	   Fam122b,	   Fbn1,	   Fmo1,	   Gdpd5,	   Meis2,	  Notch1,	  Npr1,	  Palld,	  Pcdh12l1,	  Pdzd2,	  Ptprb,	  Ptprm,	  Samd4,	  She,	  Upp1)	  showed	  down-­‐regulation	  in	  the	  hypothesized	  direction	  from	  SC_4,	  SC_5,	  SC_6	  to	  SC_1.	  The	  expression	  of	  the	  39	  genes	  in	  vivo	  correlates	  with	  what	  we’ve	  found	  in	  vitro.	  However	  we	  found	  some	  discrepancies	   such	   as	   Eps8,	   which	   increases	   when	   the	   cells	   become	   progressively	  hematopoietic.	   Another	   example	   is	   Atp2a3	   whose	   expression	   is	   reduced	   in	   the	   SC_1	  population	   compared	   to	   SC_6.	   In	   general	   these	   39	   genes	  may	  be	   useful	   to	   classify	   the	  cells	  during	  the	  EHT.	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  Figure	  3.0.12	  The	  violin	  plots	  of	  the	  39	  genes	  commonly	  regulated	  by	  Runx1	  and	  Gfi1	  within	  sample	  
clusters.	  Among	  the	  gene	  expression	  values	  within	  populations,	  the	  genes	  with	  ANOVA	  p	  value	  is	  lower	  
than	  0.05	  are	  indicated	  with	  *	  next	  to	  the	  gene	  name.	  The	  first	  7	  (Atp2a3,	  Myom1,	  Lat,	  Myb,	  Sla,	  Enpp1,	  
Lgr5)	  are	  the	  commonly	  up-­‐regulated	  genes	  by	  Runx1	  and	  Gfi1;	  the	  rest	  32	  genes	  are	  the	  commonly	  
down-­‐regulated	  ones.	  
	   The	   initial	   sorting	   idea	  with	   CD41	   negative,	   intermediate	   and	   high	   annotations	   is	  based	   on	   the	   expectation	   of	   gradual	   increase	   in	   CD41	   expressing	   cells	   during	   the	  transition	  from	  HE	  to	  Pre-­‐HP.	  Since	  CD41	  is	  an	  early	  hematopoietic	  marker,	  it	  would	  be	  expected	   to	   have	   correlation	   with	   the	   EHT	   progression.	   To	   see	   this	   correlation,	   I	  calculated	  the	  CD41	  composition	  of	  each	  sample	  clusters	   in	   terms	  of	   their	   initial	  CD41	  gate	   related	   names	   and	   presented	   with	   principal	   component	   analysis	   (Figure	   3.13).	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Principal	   component	   analysis	   is	   a	   method	   to	   project	   the	   96	   dimensional	   data	   into	   2	  strongest	  principal	  components,	  which	  is	  helpful	  to	  see	  the	  sample	  clustering	  relations.	  PCA	   Score	   Plot	   of	   all	   sample	   clusters	   show	   that	   SC_3,	   SC_4,	   SC_5	   and	   SC_2	   cells	   look	  closer	  while	  SC_1	  is	  far	  from	  them	  and	  SC_6	  is	  dispersed	  in	  between	  SC_1	  and	  SC_5.	  The	  sample	  clusters	  are	  represented	  in	  PCA	  score	  plot	  with	  corresponding	  CD41	  annotation	  composition.	   Surprisingly,	   SC_1,	   the	   sample	   cluster	   with	   the	   most	   hematopoietic	  signature,	  is	  composed	  of	  only	  42%	  of	  CD41hi	  and	  58%	  of	  CD41mid.	  SC_6,	  the	  transitory	  population	   on	   the	   other	   hand,	   is	   composed	   of	   93%	   of	   CD41hi,	   which	   is	   the	   highest	  proportion	   for	   CD41hi	   cells	   and	   7%	  CD41mid.	   Surprisingly	   endothelial	   clusters,	   SC_3,	  SC_4	   and	   SC_5	   have	   also	   contribution	   from	  CD41	   hi	   and	  mid	   cells.	   SC_3	   has	   57%	   and	  SC_5	   has	   58%	   contribution	   from	   CD41neg	   cells,	   which	   can	   be	   related	   with	   their	  endothelial	   phenotype.	   However,	   the	   other	   endothelial	   population	   SC_4	   show	   almost	  equal	   contribution	   from	  all	  CD41	  annotated	  cells,	  which	  was	  not	  expected	  and	  will	  be	  addressed	  later	  in	  the	  discussion.	  Lastly,	  SC_2	  has	  contribution	  from	  all	  CD41	  annotated	  cells	  as	  well	  and	  45%	  of	  it	  is	  from	  CD41hi	  cells,	  which	  is	  fitting	  its	  endothelial-­‐erythroid	  phenotype.	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Figure	  3.0.13	  The	  PCA	  plot	  and	  CD41	  annotation	  composition	  for	  each	  sample	  cluster	  	  
	  
2.5.2. Investigating	  the	  tissue	  origin	  of	  the	  sample	  clusters	  The	  identified	  sample	  clusters	  are	  defined	  in	  the	  merged	  data,	  but	  the	  abundance	  of	  each	   cell	   population	   might	   be	   different	   depending	   on	   the	   tissue	   origin.	   The	  hematopoiesis	   in	  YS	  and	  AGM	  has	  been	  compared	   in	  several	   studies	  and	  often	  AGM	   is	  referred	   as	   the	   first	   hematopoietic	   site	   to	   support	   de	   novo	   HSC	   emergence.	   One	  explanation	  would	   be	   the	   tissue	  microenvironment	   as	   YS	   and	  AGM	  have	   very	   distinct	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cellular	  environment,	  which	  may	  influence	  the	  hematopoietic	  capacity	  of	   the	  emerging	  progenitors.	  	  Another	  explanation	  would	  be	  the	  different	  nature	  of	  the	  endothelial	  cells	  forming	   the	   YS	   vasculature	   compared	   to	   the	   ones	   in	   the	   dorsal	   aorta.	   To	   answer	   this	  question,	  I	  checked	  the	  tissue	  origin	  for	  each	  sample	  cluster	  considering	  also	  the	  CD41	  annotations	  (Figure	  3.14).	  The	  CD41	  annotations	  are	  shown	  in	  bar	  plots	  and	  number	  of	  cells	  detected	  within	  that	  group,	  and	  the	  total	  percentage	  for	  AGM	  or	  YS	  origin	  is	  shown	  in	  the	  adjacent	  pie	  chart.	  The	  SC_1,	  SC_5,	  SC_6	  populations	  are	  highly	  composed	  of	  cell	  isolated	  from	  AGM,	  regardless	  of	  their	  CD41	  annotation.	  SC_3	  and	  SC_4	  populations,	  on	  the	  other	  hand,	  mostly	   composed	  of	   cells	   isolated	   from	  YS.	   SC_2	   is	   a	   small	   population	  composed	  of	  cells	  derived	  only	  from	  YS.	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Figure	  3.0.14	  The	  cluster	  composition	  according	  to	  the	  tissue	  of	  origin.	  The	  bar	  plots	  are	  representing	  
the	  number	  of	  cells	  detected	  from	  AGM	  (blue)	  and	  YS	  (red)	  with	  CD41	  annotations	  in	  the	  sample	  
cluster.	  The	  adjacent	  pie	  chart	  is	  representing	  the	  frequency	  of	  tissue	  origin	  contributing	  in	  
corresponding	  sample	  cluster.	  
2.5.3. Investigating	  at	  which	  embryonic	  stage	  the	  sample	  clusters	  can	  be	  found	  Another	  difference	  between	  AGM	  and	  YS	  hematopoiesis	  is	  the	  timing.	  The	  YS	  is	  the	  first	  site	  of	  hematopoiesis,	  which	  provides	  the	  first	  erythroid	  cells	  at	  around	  E7.5-­‐E8.0	  in	   the	  mouse	  embryo.	  Afterwards	   the	  YS	  can	  also	   form	  myeloid-­‐erythroid	  progenitors.	  On	  the	  other	  hand,	  hematopoiesis	  in	  the	  AGM	  starts	  much	  later,	  at	  around	  E9.	  The	  blood	  flow	   starts	   after	   the	   initiation	   of	   the	   heartbeat	   at	   E8.25.	   Since	  we	   sorted	   VE-­‐cadherin	  positive	  cells,	  we	  assume	  the	  circulating	  mature	  HPs	  have	  been	  excluded	  and	  only	  cells	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associated	  with	   the	  endothelial	   lining	  were	   included	   in	  our	  analysis.	  This	   is	   important	  not	   to	  have	   cells	  mixed	   from	  another	   tissue	  or	   time	  point.	   In	   order	   to	   see	   the	   time	  of	  origin	   for	   each	  population,	   I	   calculated	   the	   composition	  of	   time	  points	  with	   the	   tissue	  origin	  (Figure	  3.15)	  
Figure	  3.0.15	  The	  cluster	  composition	  according	  to	  the	  embryonic	  stage.	  The	  bar	  plots	  are	  
representing	  the	  number	  of	  cells	  detected	  at	  E9.0	  (blue),	  E10.5	  (red)	  and	  E11.0	  (green)	  embryonic	  
stage	  with	  tissue	  annotations	  in	  the	  sample	  cluster.	  The	  adjacent	  pie	  chart	  is	  representing	  the	  
frequency	  of	  time	  point	  origin	  contributing	  in	  the	  regarding	  sample	  cluster.	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SC_1	   population	   is	   mostly	   composed	   of	   cells	   found	   at	   E11.0	   and	   second	   most	   at	  E10.5,	   regardless	   of	   the	   tissue	   origin.	   Since	   SC_1	   is	   representing	   the	   cells	   with	   the	  clearest	   hematopoietic	   profile,	   the	   number	   of	   cells	   increasing	   over	   time	   is	   fitting	   the	  expectation.	  SC_3	  has	  similar	  pattern	  of	  having	  higher	  contribution	  at	  later	  time	  points.	  SC_5	  is	  just	  the	  reverse,	  as	  the	  highest	  percentage	  is	  from	  E9.0	  time	  point.	  It	  makes	  sense	  as	   it	   might	   be	   the	   population	   with	   HE	   potential,	   so	   its	   frequency	   may	   drop	   when	   it	  differentiates	   into	   hematopoietic	   cells.	   Interestingly	   SC_2	   population	   is	   composed	   of	  only	   E10.5	   YS	   origin	   cells.	   SC_4	   population	   is	   almost	   equally	   contributed	   from	   all	   3	  embryonic	  stages.	  Lastly,	  the	  SC_6	  population	  can	  be	  found	  at	  all	  time	  points	  in	  AGM	  and	  YS.	   For	   AGM	   derived	   SC_6	   cells,	   E10.5	   is	   the	   time	   point	   at	   which	   they	   are	   the	   most	  frequent.	  For	  YS,	  E9.0	  is	  the	  time	  point	  with	  the	  highest	  frequency,	  while	   its	   frequency	  decreases	  towards	  E11.0.	  That	  may	  be	  consistent	  with	  the	  early	  blood	  formation	  in	  the	  yolk	  sac.	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Figure	  3.0.16	  The	  dot	  plots	  of	  cell	  counts	  of	  annotated	  sample	  clusters	  within	  A.	  YS	  and	  B.	  AGM	  for	  all	  
time	  points.	  
	   To	  visualize	  the	  calculated	  cell	  counts	  for	  each	  tissue	  and	  time	  point,	  I	  made	  the	  bar	  point	  of	  cell	  counts	  for	  sample	  clusters	  from	  YS	  (Figure	  3.16.A)	  and	  AGM	  (Figure	  3.16.B).	  According	   to	   that,	   the	  numbers	  of	   cells	   for	  each	  sample	  clusters	  within	  YS	   time	  points	  show	   small	   variations	   compared	   with	   AGM.	   Among	   the	   endothelial	   clusters,	   SC_4	  population	   is	   the	   dominant	   of	   YS.	   The	   cell	   count	   for	   SC_1	   is	   increasing	   from	  E10.5	   to	  E11.0	  time	  points,	  while	  SC_5,	  SC_6	  and	  SC_4	  composing	  cell	  counts	  are	  lowering.	  This	  is	  fitting	   with	   the	   expected	   pattern	   of	   less	   endothelial	   cells	   and	   more	   hematopoietic	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progenitors	  when	  the	  time	  passes.	  Since	  SC_2	  population	  is	  only	  found	  in	  the	  E10.5	  YS,	  it	  may	  represent	  a	  very	  small	  population	  appearing	  in	  a	  very	  short	  time	  window.	  
For	  cells	  derived	   from	  AGM,	  all	   sample	  clusters	  exhibit	  change	   in	  cell	  count	  within	  time	  points,	  except	  SC_2	  which	  is	  not	  existing	  in	  AGM.	  In	  AGM,	  the	  dominant	  endothelial	  cell	   population	   is	   SC_5	   and	   its	   cell	   counts	  decrease	   from	  E9.0	   to	  E11.0	   time	  points.	   In	  parallel,	  the	  SC_1	  cells	  are	  increasing	  in	  number	  from	  E9.0	  to	  E11.0	  stages.	  The	  opposing	  trend	   of	   SC_5	   cell	   counts	   decrease	   and	   the	   SC_1	   cell	   counts	   increase	   is	   fitting	   the	  expected	   pattern	   of	   EHT	   as	   the	   hemogenic	   endothelial	   cells	   are	   giving	   rise	   to	  hematopoietic	  progenitors.	  As	  the	  intermediate	  population	  between	  SC_5	  and	  SC_1,	  SC_6	  is	   found	  highest	   at	  E10.5	  AGM	   tissue	   then	   it	   is	   decreased	  at	  11.0.	   Surprisingly	   SC_6	   is	  found	   dominantly	   at	   the	   E10.5	   AGM,	   which	   might	   again	   indicate	   tightly	   regulated	  transient	  population	  emerging	  for	  a	  very	  short	  time	  window.	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3. Discussion:	  Up	   to	   now,	   the	   studies	   on	   EHT	   made	   the	   general	   frame	   of	   the	   process	   and	   its	  importance	  in	  the	  emergence	  of	  blood	  progenitor	  cells.	  Combined	  usage	  of	  well	  known	  hematopoietic	   and	   endothelial	   markers	   allowed	   us	   to	   enrich	   cell	   populations	   going	  through	  EHT.	  Gene	   loss/gain	   of	   function	   studies	   explained	   the	   important	  mechanisms	  on	  EHT	  regulation.	  However	  the	  conventional	  techniques	  become	  limited	  to	  gain	  precise	  information	  about	  the	  cell	   identity	  change	  during	  EHT,	  because	  it	   is	  happening	  to	  very	  rare	   cells	   and	   in	   a	   short	   time	   window	   during	   vertebrate	   development.	   Besides	   the	  scarcity	  of	  the	  cells,	  functional	  heterogeneity	  is	  detected	  within	  the	  labeled	  populations.	  With	  the	  recent	  advances	  of	  the	  single	  cell	  transcriptional	  analysis,	  it	  is	  now	  possible	  to	  gain	  detailed	  gene	  expression	  profile	  of	  those	  cells.	  Additionally	  we	  can	  gain	  information	  about	  the	  regulatory	  genes	  functioning	  in	  specific	  cells.	  By	  utilizing	  the	  single	  cell	  gene	  expression	  technique,	   in	   this	  chapter	   I	  aimed	  to	  dissect	   the	  cell	   identity	  change	  during	  EHT	  in	  detail.	  	  
3.1. The	  establishment	  of	  single	  cell	  qRT-­‐PCR	  technique	  for	  our	  cells	  	  The	  initial	  run	  with	  sorted	  NonHE,	  HE,	  Pre-­‐HP,	  and	  HP	  populations	  from	  blast	  culture	  day1.5	  worked	  as	  we	  expected,	  which	  confirms	  that	  the	  technique	  is	  functioning	  well.	  The	  selection	  of	  96	  genes	  is	  differentially	  expressed	  to	  allow	  sufficiently	  the	  identification	  of	  subpopulations.	  Indeed,	  the	  sample	  clustering	  made	  by	  the	  algorithm	  (Figure	  3.6.A)	  is	  similar	  to	  sorting	  identity	  of	  the	  cells	  (Figure	  3.6.B)	  but	  not	  identical,	  which	  indicates	  cellular	  heterogeneity	  within	  sorted	  populations.	  In	  the	  PCA	  score	  plot	  (Figure	  3.6.C)	  it	  was	  clear	  that	  NonHE	  cells	  are	  projected	  close	  to	  HE	  and	  HE	  is	  close	  to	  Pre-­‐HP	  and	  Pre-­‐HP	  is	  close	  to	  HP,	  which	  is	  very	  similar	  expected	  pattern	  of	  appearance	  during	  EHT.	  This	  indicates	  our	  selection	  of	  genes	  can	  monitor	  the	  transition	  stages	  in	  detail.	  The	  cellular	  heterogeneity	  regardless	  of	  its	  marker	  verifies	  our	  starting	  point	  that	  combination	  of	  VE-­‐Cadherin,	  CD41,	  and	  Runx1	  proximal	  promoter	  marker	  is	  not	  enough	  to	  isolate	  pure	  populations.	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The	   commonly	   up/down	   regulated	   genes	   by	   Runx1	   and	   Gfi1	   might	   be	   good	  candidates	  to	  monitor	  the	  EHT	  stage.	  Previously,	  by	  mRNA	  microarray	  and	  conventional	  qRT-­‐PCR,	  we	  have	  identified	  39	  genes	  commonly	  regulated	  by	  both	  Runx1	  and	  its	  direct	  target	  Gfi1.	  Regarding	  the	  overlapping	  transcriptional	  regulation	  role	  of	  Runx1	  and	  Gfi1,	  the	  common	  targets	  of	  them	  might	  reveal	  the	  set	  of	  gene	  expression	  change	  during	  EHT.	  Therefore	  we	  checked	  the	  39	  genes'	  expression	  for	  the	  sorted	  populations	  at	  single	  cell	  level.	  The	  violin	  plots	  shows	  that	  5	  genes	  out	  of	  7	  up-­‐regulated	  and	  22	  out	  of	  32	  down-­‐regulated	  genes	  are	   fitting	   to	   the	  expected	  pattern,	   in	   the	  order	  of	  populations	  as	  EHT	  (Figure	  3.7).	  That	  suggests	  that	  Gfi1	  and	  Runx1	  at	  the	  single	  cell	  level	  could	  regulate	  the	  majority	  of	  the	  39	  genes.	  Some	  genes	  don't	  fit	  the	  expected	  fashion	  of	  regulation,	  which	  might	   be	   related	  with	   the	   cells	   harvested	   at	   day1.5	   blast	   culture	   for	   single	   cell	   work,	  which	   was	   different	   for	   the	   samples	   used	   for	   the	   microarray	   and	   conventional	   qPCR	  analyses.	  Since	  we	  found	  27	  genes	  fitting	  the	  expected	  gene	  expression	  change,	  we	  can	  use	  them	  as	  a	  reference	  point	  to	  detect	  the	  stage	  of	  cells	  during	  the	  transition.	  
In	  addition	  to	  the	  39	  genes,	  the	  list	  of	  endothelial	  and	  hematopoietic	  genes	  are	  also	  fitting	   the	   expected	   pattern	   of	   gene	   expression	   regulation.	   Since	   endothelial	   cells	   are	  gaining	   hematopoietic	   characteristics	   and	   losing	   endothelial	   ones	   during	   EHT,	   within	  the	  population	  order	  from	  NonHE	  to	  HE,	  then	  to	  Pre-­‐HP,	  and	  then	  to	  HP,	  it	  is	  expected	  to	  have	   lower	   endothelial	   markers	   and	   higher	   hematopoietic	   markers.	   When	   the	  populations	  in	  EHT	  order	  is	  checked,	  the	  violin	  plot	  of	  endothelial	  genes	  (Figure	  3.8.A)	  are	   showing	   down-­‐regulation	   pattern	   (except	   for	   Cldn5)	   and	   hematopoietic	   genes	  (Figure	   3.8.B)	   are	   showing	   up-­‐regulation	   pattern	   in	   general	   (except	   for	   Epo,	   Itgam,	  Thpo).	  In	  conclusion,	  the	  initial	  run	  with	  blast	  culture	  day	  1.5	  isolated	  cells	  showed	  that	  our	  list	  of	  genes	  are	  sufficient	  to	  identify	  sub-­‐populations	  fitting	  the	  EHT	  progression.	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3.2. Analysis	  of	  EHT	  in	  AGM	  and	  YS	  by	  using	  single	  cell	  qRT-­‐PCR	  technique	  The	   EHT	   is	   happening	   in	   AGM	   and	   YS,	   the	   two	   main	   hematopoietic	   sites	   during	  embryogenesis;	   but	   the	   emerging	   cells	   types	   and	   its	   timing	   is	   very	   different	   for	   each	  tissue.	  Therefore,	  investigating	  the	  gene	  expression	  profile	  of	  the	  cells	  isolated	  from	  YS	  and	  AGM	  within	   time	  points	  E9.0,	  E10.5	  and	  E11.0,	  would	  help	  us	   to	  understand	  EHT	  progression	  for	  these	  tissues.	  Regarding	  that	  aim,	  our	  approach	  was	  to	  sort	  VE-­‐Cadherin	  positive	   and	   CD41	   negative	   (CD41neg)	   or	   intermediate	   (CD41mid)	   or	   high	   (CD41hi)	  expressing	  cells	  for	  each	  tissue	  of	  3	  time	  points	  (Figure	  3.	  9).	  
3.2.1. Identification	  and	  characterization	  of	  sample	  clusters	  The	   data	   for	   all	   time	   points	   and	   tissue	   of	   origin	   was	   merged	   to	   identify	   sample	  clusters	   common	   for	   all	   (Figure	   3.	   10.A).	   The	   hierarchical	   clustering	   without	   the	  TGFβ/BMP	  related	  genes,	  form	  gene	  clusters	  and	  6	  sample	  clusters	  (Figure	  3.10.B).	  The	  endothelial	   (Figure	   3.11.A),	   hematopoietic	   (Figure	   3.11.B)	   and	   39	   genes	   commonly	  regulated	   by	   Runx1	   and	   Gfi1	   (Figure	   3.12)	   gene	   expression	   was	   visualized	   in	   violin	  plots.	   Depending	   on	   the	   high	   endothelial	   gene	   expression	   and	   lack	   of	   hematopoietic	  gene	   expression,	   SC_3	   (blue),	   SC_4	   (orange),	   SC_5	   (purple)	   would	   define	   populations	  with	  more	  prominent	  endothelial	  phenotype.	  SC_2	   (green)	   is	  a	  population	  with	  strong	  endothelial	   gene	   expression	   as	   well	   as	   mature	   erythroid	   marker	   expression.	   	   On	   the	  other	   hand	   SC_1	   (red)	   has	   very	   clear	   hematopoietic	   gene	   expression	   profile	   and	   no	  endothelial	  gene	  expression.	  Finally,	  SC_6	  (pink)	  is	  representing	  a	  cell	  profile	  in	  between	  SC_5	  and	  SC_1	  by	  expressing	  very	  similar	  endothelial	  markers	  with	  SC_5	  but	  also	  some	  hematopoietic	  markers.	  
A	   detailed	   analysis	   for	   each	   sample	   cluster	   is	   useful	   to	   identify	   them,	   as	   it	   is	  simplified	   in	   the	  Figure	  3.17.A.	   	  SC_3	  seems	  to	  have	  no	  hematopoietic	  gene	  expression	  and	  the	  endothelial	  gene	  expression	  is	  lower	  than	  SC_4	  and	  SC_5	  populations.	  Therefore	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SC_3	   would	   represent	   a	   population	   with	   weaker	   endothelial	   phenotype.	   Another	  endothelial	  population,	   the	  SC_5	   is	  distinguishable	   from	  SC_4	  with	   lower	  expression	  of	  some	  endothelial	  markers	  (Gdpd5,	  Sox7,	  Npr1,	  Fmo1,	  Meis2)	  and	  higher	  expression	  of	  some	  hematopoietic	  markers	  (Kit,	  Erg)	  (Figure	  3.17.A).	  Therefore	  SC_5	  may	  represent	  a	  population	  with	  hemogenic	  endothelium	  potential.	  
SC_6	   is	   the	   population	   having	   expressed	   endothelial	   genes	   together	   with	   key	  hematopoietic	  genes.	  The	  endothelial	  signature	   is	   lower	   than	  SC_5	   for	   the	  genes	  Cdh5,	  Col4a2,	   Tek,	   Ptprb,	   Kdr,	   Ramp2,	   Pecam1,	   Gdpd5,	   Sox7,	   Npr1,	   Fmo1,	   and	   Meis2.	  Additionally	   some	   hematopoietic	   genes	   (Kit,	   Erg,	   Atp2a3,	   Myb,	   Itgb3)	   are	   expressed	  higher	   than	   SC_5.	   Above	   all,	   the	   signature	   SC_6	   is	   more	   prominent	   with	   the	   highest	  Runx1	  expression	  among	  other	  sample	  clusters,	  together	  with	  other	  key	  hematopoietic	  markers	   (Sfpi1,	   Sla,	   Itgam,	   Ptprc)	   (Figure	   3.17.A).	   	   Those	   hematopoietic	   markers	  emphasize	   on	   the	   initiation	   of	   the	   EHT	   but	   there	   is	   not	   yet	   expression	   of	   mature	  hematopoietic	  markers.	  
It	  is	  interesting	  to	  observe	  no	  endothelial	  gene	  expression	  at	  all	  in	  SC_1	  population,	  while	  it	  is	  also	  sorted	  within	  VE-­‐Cadherin	  positive	  gate.	  SC_1	  cells	  are	  supposed	  to	  have	  the	  protein	  on	  the	  cell	  surface,	  but	  the	  VE-­‐Cadherin	  gene	  expression	  seems	  to	  be	  down	  regulated.	  Since	  there	  are	  93	  cells	  in	  SC_1,	  rather	  than	  a	  technical	  error,	  it	  might	  be	  due	  to	   recently	   switched	   off	   VE-­‐Cadherin	   gene	   expression.	   Indeed	   the	   previous	   studies	  supported	  the	   fact	   that	  some	  circulating	  cells	  at	  E10.5	  stage	  may	  have	  VE-­‐Cadherin	  on	  their	   membrane	   as	   a	   reminiscence	   of	   its	   endothelial	   origin	   (Taoudi	   2005)	   but	   not	  expressing	  the	  gene	  anymore	  (Zovein	  2008).	  
Among	  all	  sample	  clusters,	  SC_2	  is	  the	  smallest	  but	  also	  the	  most	  interesting	  sample	  cluster.	  It	  is	  surprising	  to	  see	  the	  expression	  of	  very	  mature	  erythroid	  cell	  type	  related	  genes	  (Hbb-­‐b1,	  Hbb-­‐bh1)	  coexpressed	  together	  with	  several	  endothelial	  genes	  but	  not	  with	  Runx1,	  which	  is	  the	  key	  regulator	  of	  EHT	  (Figure	  3.17.A).	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Figure	  3.0.17	  Single	  cell	  gene	  expression	  summary	  for	  in	  vivo	  sample	  clusters.	  A.	  Simplified	  gene	  
expression	  data	  for	  some	  endothelial	  (green	  tones)	  and	  hematopoietic	  (orange	  and	  red	  tones)	  genes	  
varying	  between	  sample	  clusters.	  The	  list	  of	  genes	  clustered	  closely	  (as	  in	  Figure	  3.10.B)	  shown	  within	  
the	  dark	  borders.	  Mark	  explanation:	  no	  expression	  (-­‐),	  low	  expression	  (+),	  intermediate	  expression	  
(++),	  high	  expression	  (+++),	  bimodal	  expression	  as	  the	  dominant	  expression	  sign	  is	  the	  first	  before	  the	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slash	  (+/)	  while	  it	  has	  some	  cells	  with	  very	  highly	  expression	  within	  the	  same	  sample	  cluster	  (+/+++	  or	  
-­‐/+++)	  B.	  Proposed	  model	  of	  sample	  cluster	  differentiation	  relations,	  according	  to	  their	  endothelial	  and	  
hematopoietic	  gene	  composition.	  EHT	  progression	  is	  shown	  as	  transition	  from	  SC_5	  to	  SC_6	  and	  then	  to	  
SC_1	  populations.	  Additional	  proposed	  differentiation	  relation	  is	  shown	  as	  dashed	  lines	  (a)	  between	  
SC_4	  and	  SC_5	  populations,	  (b)	  for	  differentiation	  of	  SC_5	  to	  SC_3,	  and	  (c)	  for	  differentiation	  of	  SC_4	  to	  
SC_2.	  	  	  
3.2.2. CD41	  protein	  is	  not	  the	  direct	  marker	  of	  cell	  progression	  during	  EHT	  Since	  CD41	  is	  the	  early	  hematopoietic	  marker	  expressed	  during	  EHT,	  we	  hypothesized	  that	  cells	  would	  express	  more	  CD41	  protein	  on	  the	  membrane	  as	  it	  goes	  through	  EHT.	  To	  test	  this	  hypothesis,	  we	  sorted	  VE-­‐Cadherin	  positive	  cells	  with	  CD41	  negative,	  intermediate	  or	  high	  gates	  and	  then	  check	  CD41	  annotation	  within	  the	  previously	  identified	  sample	  clusters.	  Unexpectedly,	  the	  CD41	  protein	  doesn’t	  increase	  gradually	  from	  endothelial	  to	  hematopoietic	  sample	  clusters	  (Figure	  3.13).	  	  It	  seems	  like	  CD41	  hi	  expression	  is	  more	  abundant	  in	  transiting	  SC_6	  cells	  (93%	  from	  CD41hi),	  while	  CD41	  mid	  expression	  is	  marking	  the	  more	  mature	  hematopoietic	  SC_1	  cells	  (58%	  from	  CD41mid).	  
Figure	  3.0.18	  The	  percentage	  of	  cells	  with	  hematopoietic	  profile	  among	  CD41mid	  and	  CD41hi	  
annotated	  cells.	  The	  hematopoietic	  profile	  is	  assessed	  such	  that	  the	  cells	  expressing	  (Ct	  value	  is	  lower	  
than	  24)	  at	  least	  2	  of	  the	  major	  hematopoietic	  genes	  (Sla,	  Itgam,	  Runx1,	  Sfpi1)	  are	  accepted	  
hematopoietic.	  The	  ratio	  of	  hematopoietic	  cell	  count	  within	  the	  total	  acquired	  cell	  count	  for	  each	  CD41	  
fraction	  is	  calculated	  and	  converted	  to	  a	  percentage.	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It	   is	   shown	   in	   Figure	   3.13	   that	   the	   endothelial	   sample	   clusters	   (SC_3,	   SC_4,	   SC_5)	  have	   contribution	   from	   all	   CD41	   annotations,	   although	   CD41	   negative	   is	   the	   most	  abundant	   for	   SC_3	   (57%	   from	   CD41neg)	   and	   SC_5	   (58%	   from	   CD41neg).	   SC_4	   is	   an	  exception	   as	   it	   is	   almost	   equally	   contributed	   from	   all	   CD41	   annotations.	   It	   might	   be	  explained	   by	   finding	   of	   SC_4	  mostly	   (92%)	   in	   YS	   derived	   cells,	   where	   the	   cells	   show	  more	   common	   features	   regardless	   of	   CD41	   annotation.	   As	   shown	   in	   figure	   3.18,	   we	  found	   that	   between	   60	   and	   90%	   of	   CD41+	   cells	   in	   the	   YS	   are	   not	   expressing	   any	  hematopoietic	  genes.	  This	  is	  very	  surprising,	  as	  CD41	  has	  so	  far	  always	  been	  considered	  as	   an	   exclusive	   hematopoietic	   marker.	   We	   can	   see	   that	   this	   non	   hematopoietic	  expression	  is	  mostly	  seen	  in	  the	  YS	  as	  in	  the	  AGM	  (apart	  from	  CD41mid	  at	  E9),	  between	  80	  and	  90	  %	  of	  CD41	  positive	  cells	  are	  also	  expressing	  hematopoietic	  genes.	  
3.2.3. Sample	  clusters	  show	  different	  abundance	  within	  AGM	  and	  YS	  Although	  most	   sample	   clusters	   are	   detected	   in	   the	   two	   tissues,	   the	   abundance	   of	  each	  cluster	  is	  changing	  (Figure	  3.14).	  For	  AGM,	  the	  most	  abundant	  endothelial	  cluster	  is	  SC_5	  (purple),	  which	   is	  decreasing	   from	  E9.0	  to	  E11.0	  (Figure	  3.16).	  At	   the	  same	  time,	  the	  SC_1	  (red)	  population	  is	  increasing	  from	  E9.0	  to	  E11.0	  and	  the	  transiting	  SC_6(pink)	  population	  is	  at	  the	  highest	  frequency	  at	  E10.5	  (Figure	  3.16).	  	  
The	  YS	  is	  in	  general	  showing	  more	  equilibrated	  and	  stable	  count	  for	  sample	  clusters,	  in	   comparison	   with	   AGM	   (Figure	   3.16).	   For	   YS,	   the	   most	   abundant	   endothelial	  population	   is	   SC_4	   (orange)	   (92%	   of	   SC_4	   is	   from	   YS)	   while	   the	   other	   SC_5	   (purple)	  exists	   (23%	  of	   SC_5	   is	   from	  YS)	   but	   not	   as	   high	   frequency	   as	   SC_4	   (Figure	   3.14).	   The	  frequency	   of	   both	   SC_4	   and	   SC_5	   drops	   from	   E10.5	   to	   E11.0.	   On	   the	   other	   hand,	  SC_1(red)	  hematopoietic	  population	   increases	  a	   lot	   from	  E10.5	   to	  E11.0	   (Figure	  3.16).	  SC_3	  (blue)	  population	  is	  also	  more	  abundant	  in	  YS	  as	  64%	  of	  it	  from	  YS	  (Figure	  3.14)	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In	  summary,	  SC_5,	  SC_6	  and	  SC_1	  have	  the	  highest	  contribution	  from	  AGM,	  although	  they	   exist	   also	   in	   YS.	   Interestingly	   SC_2(green)	   population	   is	   found	   only	   in	   YS	   at	   day	  E10.5.	  Moreover,	  SC_3	  and	  SC_4	  are	  highly	  abundant	  in	  YS	  (Figure	  3.16).	  
3.2.4. Detection	  of	  sample	  clusters	  within	  3	  time	  points	  revealed	  the	  
differentiation	  path	  For	   the	   in	   vivo	   analysis	   of	   EHT	   progress,	   the	   population	   abundance	   change	   can	  reflect	  the	  transition	  stage.	  If	  the	  sample	  cluster	  abundance	  is	  increasing	  or	  decreasing	  between	  time	  points	  E9.0	  to	  E10.5	  and	  E11.0,	  it	  may	  indicate	  that	  one	  type	  of	  cell	  giving	  rise	  to	  another	  one.	  	  By	  using	  this	  approach,	  here	  I	  propose	  a	  model	  for	  YS	  and	  AGM	  EHT	  process.	  
The	  SC_5	  (purple),	  SC_6	  (pink),	  SC_1	  (red)	  cells	  are	  found	  both	  in	  YS	  and	  AGM,	  SC_5	  cells	  have	  strong	  endothelial	  gene	  expression	  profile	  as	  well	  mild	  Kit	  and	  Erg	  expression,	  which	  might	  indicate	  hemogenic	  potential.	  Later,	  SC_6	  has	  very	  similar	  but	  less	  endothelial	  in	  addition	  to	  strong	  hematopoietic	  gene	  expression.	  SC_6	  is	  distinctive	  with	  highest	  Kit	  and	  Runx1	  expression,	  which	  suggests	  an	  already	  triggered	  EHT	  program.	  Lastly,	  SC_1	  has	  no	  endothelial	  gene	  expression,	  lower	  Runx1,	  Myb,	  Itgb3	  but	  strong	  hematopoietic	  gene	  expression	  related	  with	  blood	  maturation,	  such	  as	  Sfpi1,	  Sla,	  Ptprc.	  Within	  the	  SC_1,	  there	  are	  very	  few	  cells	  expressing	  mature	  erythroid	  markers	  Hbb-­‐b1.	  Since	  for	  both	  YS	  and	  AGM,	  the	  cell	  counts	  for	  SC_5	  decreases	  while	  SC_1	  is	  increasing	  from	  E9.0	  to	  E11.0,	  I	  propose	  the	  presentation	  of	  EHT	  as	  transition	  of	  SC_5	  to	  SC_6	  intermediate	  cells	  and	  then	  to	  SC_1	  more	  hematopoietic	  committed	  cells	  (Figure	  3.17.B).	  
Recently	   A.	   Medvinsky's	   group	   proposed	   a	   characterization	   of	   3	   different	   cell	  populations	   based	   on	   their	   marker	   expression.	   (Rybtsov	   2011,	   Rybtsov	   2014).	  According	  to	  that	  model,	  Pro-­‐HSC	  is	  the	  most	  immature	  cells	  with	  VE-­‐Cadherin,	  Runx1,	  CD41	   and	   C-­‐Kit	   expression.	   Pre-­‐HSC	   type	   I	   is	   one	   step	   further	   than	   Pro-­‐HSC	   by	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expressing	  CD41	   lower,	  and	  pre-­‐HSC	   type	   II	   is	  more	  mature	  with	  CD43	  and	  CD45	   low	  expression.	  When	  the	  pre-­‐HSC	  type	  II	  differentiate	  to	  HSC,	  it	  expresses	  CD45	  and	  CD43	  high	  but	  not	  CD41	  anymore.	   If	  we	  consider	  a	  direct	   relation	  with	   the	  gene	  expression	  and	  the	  availability	  of	  that	  protein	  on	  cell	  surface	  for	  labeling,	  we	  may	  refer	  to	  the	  model	  suggested	   by	   Medvinsky's	   group.	   With	   that	   approach,	   SC_5	   may	   include	   a	   small	  population	  of	   hemogenic	   endothelial	   cells	   due	   to	   the	  high	   endothelial	   profile	   but	   very	  few	  Runx1+	  cells.	  SC_6	  may	  include	  the	  pro,	  pre	  type	  I	  and	  pre	  type	  II	  HSCs	  depending	  on	   the	   tissue	   and	   the	   time	   point.	   SC_1	  may	  match	   with	   a	   population	   pre-­‐HSC	   type	   II	  because	   of	   high	   Ptprc	   (CD45)	   expression.	   However	   this	   interpretation	   needs	   to	   be	  confirmed	  by	  functional	  analysis	  for	  each	  population.	  
The	   SC_4	   and	   SC_5	   samples	   seem	   very	   similar	   in	   terms	   of	   endothelial	   gene	  expressions,	   yet	   there	   are	   some	   differences	   to	   make	   the	   clusters.	   Since	   SC_5	   has	   Kit	  expression	  and	  lower	  expression	  of	  endothelial	  genes	  Nrp1	  and	  Meis2	  than	  SC_4	  which	  might	   indicate	   that	   SC_5	   has	   capacity	   to	   become	   hematopoietic.	   However	   it	   does	   not	  eliminate	   the	  possibility	  of	  one	  giving	  rise	   to	   the	  other	  population	  as	  drawn	   in	  dashed	  lines	  in	  Figure	  3.17.B.a.	  
The	  SC_3	  (blue)	  population	  is	  identified	  as	  low	  endothelial	  gene	  expression	  and	  for	  both	  YS	  and	  AGM,	  the	  cell	  counts	   for	  SC_3	   increases	  gradually	   towards	  E11.0.	  Since	   its	  gene	  expression	  pattern	  looks	  similar	  to	  the	  pattern	  of	  SC_4,	  I	  proposed	  that	  SC_3	  cells	  might	  be	  derived	   from	  SC_4	   in	  a	   form	  of	   less	  endothelial	  gene	  expression	  as	  shown	   in	  dashed	  lines	  in	  Figure	  3.17.B.b.	  However,	  Ppia	  (the	  reference	  gene)	  expression	  level	  for	  some	  cells	  within	  the	  SC_3	  is	  un-­‐expectedly	  low.	  Such	  low	  expression	  have	  to	  be	  double	  checked	  in	  order	  to	  eliminate	  the	  possibility	  of	  a	  technical	  error,	  before	  inferring	  about	  the	  biological	  meaning	  of	  the	  SC_3	  cells.	  
The	  SC_2	  cells	  are	  very	  interesting	  with	  both	  strong	  endothelial	  and	  erythroid	  gene	  expression	   profile,	  which	  was	   never	   reported	   before.	   Those	   cells	   are	   detected	   only	   at	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E10.5	  of	  YS.	   	  The	  SC_2	  endothelial	  gene	  expression	  profile	   is	  similar	   to	  SC_4	  and	  there	  are	  very	  few	  cells	  within	  SC_4	  expressing	  Hbb-­‐b1	  and	  Hbb-­‐bh1	  erythroid	  genes	  like	  SC_2	  (Figure	  3.17.A).	   Considering	   these	   similarities	   in	   gene	   expression,	   I	   propose	   that	   SC_2	  cells	  might	  be	  derived	  from	  SC_4	  population	  only	  for	  very	  short	  time	  window	  between	  E9.0	  to	  E10.5	  of	  YS	  (Figure	  3.17.B.c).	  
4. Conclusion	  and	  Future	  directions:	  With	   the	   new	   advances	   on	   the	   microfluidics	   mechanical	   controlling	   units,	   it	   is	  possible	  to	  run	  mid-­‐throughput	  qPCR	  reactions	  on	  cDNA	  material	  harvested	  from	  single	  cells.	   (Ståhlberg,	  Rusnakova,	  Forootan,	  Anderova,	  &	  Kubista,	  2013).	  The	   technique	  has	  been	  used	  to	  perform	  an	  extensive	  gene	  expression	  profiling	  studies	  on	  blastocyst	  stage	  embryos	   to	   reveal	   fate	   decisions	   at	   single	   cells	   (Guo	   et	   al.,	   2010),	   	   early	   kidney	  development	  of	  mouse	  (Brunskill	  et	  al.,	  2014),	  and	  early	  emergence	  of	   lymphomyeloid	  restricted	  progenitors	   in	  mouse	  hematopoiesis	  (Böiers	  et	  al.,	  2013).	   It	  has	  been	  a	  very	  powerful	  technique	  also	  to	  reveal	  gene	  regulatory	  networks	  (Moignard	  et	  al.,	  2013)	  and	  cell	  surface	  repertoire	  (Guo	  et	  al.,	  2013)	  in	  adult	  mouse	  hematopoietic	  lineage,	  as	  well	  as	  the	   fate	   change	   profiling	   during	   EHT	   (Swiers	   et	   al.,	   2013).	   Recently	   it	   was	   used	   in	  combination	  with	  site	  specific	  transcriptional	  activators	  to	  reveal	  regulatory	  networks,	  to	  understand	  the	  role	  of	  Sfpi1	  in	  developmental	  hematopoiesis	  (Wilkinson	  et	  al.,	  2014).	  
The	   difference	   between	  AGM	   and	   YS	   hematopoiesis	   has	   been	   a	   debate	   topic	   for	   a	  long	   time	   (Lassila,	   Eskola,	   Toivanen,	  Martin,	   &	   Dieterlen-­‐Lievre,	   1978)	   (Tanaka	   et	   al.,	  2012).	  There	  is	  a	  consensus	  for	  AGM	  as	  the	  only	  site	  for	  generation	  of	  HSCs	  with	  long-­‐term	   functional	   repopulation	   capacity,	   in	   addition	   to	   the	   multi-­‐potent	   progenitors	  (Boisset	   et	   al.,	   2010;	   Chen	   et	   al.,	   2011;	   	   a	  Medvinsky	  &	  Dzierzak,	   1996).	  On	   the	   other	  hand	   YS	   is	   the	   site	   for	   the	   first	   HP	   emergence,	   forming	   the	   primitive	   erythroid	   cells,	  followed	  by	   erythroid	  myeloid	   and	   lymphoid	  progenitors	   (Lux	   et	   al.,	   2008;	  Palacios	  &	  Imhof,	  1993;	  Samokhvalov	  et	  al.,	  2007).	  Although	  the	  hematopoiesis	  at	  both	  AGM	  and	  YS	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depends	  on	  the	  transition	  of	  hemogenic	  endothelial	  cell	  to	  HSPC	  (Boisset	  et	  al.,	  2010;	  W.	  Li	   et	   al.,	   2005),	   the	   hematopoietic	   program	   at	   each	   site	   is	   initiated	   at	   different	   time	  during	   embryogenesis.	   YS	   hematopoiesis	   is	   initiated	   at	   around	   E7.5	   and	   actively	  generating	  HPs	  until	  E11.0,	  while	  AGM	  hematopoiesis	   is	   started	  at	  E9.5	  and	  continues	  until	  E12.0	  (Palis,	  Robertson,	  Kennedy,	  Wall,	  &	  Keller,	  1999).	  Despite	  all	   those	  studies,	  the	  difference	  of	  hematopoietic	  programs	  for	  both	  tissues	  could	  not	  be	  analyzed	  at	  the	  single	  cell	  level,	  until	  today.	  
In	   this	   project,	   we	   used	   the	   single	   cell	   qRT-­‐PCR	   technique	   to	   explore	   the	  hematopoietic	  program	  of	  AGM	  and	  YS	  at	  the	  single	  cell	  level.	  We	  aimed	  at	  identification	  of	  cell	  types	  during	  the	  course	  of	  EHT	  for	  both	  AGM	  and	  YS	  tissues.	  In	  order	  to	  capture	  all	   types	  of	  cell	  appearing	  during	  EHT,	  we	  chose	   to	  collect	  cells	   from	  time	  points	  E9.0,	  E10.5	   and	  E11.0.	   A	   similar	   study	   done	   previously	   by	   Swiers	  G.	   et	   al.,	  with	   single	   cells	  isolated	  from	  all	  big	  arteries	  (AGM,	  vitelline	  and	  umbilical	  arteries	  together)	  using	  a	  set	  of	  20	  endothelial	  and	  hematopoietic	  affiliated	  genes	   (and	  4	  reference	  genes)	  while	  we	  used	  a	  panel	  of	  96	  genes.	  With	  the	  help	  of	  Runx1	  +23	  GFP	  enhancer-­‐reporter	  transgenic	  mouse	  line,	  they	  separated	  the	  hemogenic	  endothelium	  (HE)	  from	  the	  other	  endothelial	  cells	  (NonHE).	  They	   isolated	  NonHE,	  HE,	  CD41+	  HP	  cells	  and	  CD45+	  HP	  cells	   to	   follow	  the	   EHT	   course	   (Swiers	   et	   al.,	   2013).	   However	   their	   study	   neglects	   the	   fact	   that	   even	  sorted	   populations	   have	   cellular	   heterogeneity,	   which	   is	   actually	   seen	   as	   sub-­‐populations	   within	   their	   hierarchical	   clustering	   of	   sorted	   populations.	   Also	   by	  combining	  the	  cells	  from	  AGM,	  umbilical	  and	  vitelline	  arteries,	  they	  lose	  the	  information	  about	  tissue	  specificity.	  In	  terms	  of	  expression	  change	  of	  certain	  genes	  (Gata2,	  Tal1,	  Gfi1,	  Sfpi1	  and	  Myb),	  our	  proposed	  model	  of	  EHT	  confirms	  the	  transition	  within	  their	  sorted	  populations.	  On	  top	  of	  it,	  our	  study	  provides	  data	  about	  YS	  hematopoiesis	  and	  makes	  it	  possible	   to	   compare	   the	   hematopoietic	   programs	   initiated	   within	   hemogenic	  endothelium	  of	  the	  two	  tissues.	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The	   transition	  model	   I	   proposed	   for	   EHT	   (SC_5	  à	   SC_6	  à	   SC_1)	   has	   shared	   gene	  expression	  profile	  with	  the	  populations	  introduced	  in	  Wilkinson	  et.	  al.	  and	  Swiers	  et.	  al.	  However,	   for	   all	   three	   studies,	   it	   is	   solely	   based	   on	   the	   gene	   expression	   data,	   whose	  biology	  needs	  to	  be	  confirmed.	  For	  future	  experiments,	  isolation	  of	  that	  populations	  and	  confirming	  the	  hematopoietic	  lineage	  commitment	  capacity	  will	  be	  precious	  to	  conclude	  about	   the	   initial	   cell	   identity.	   Finding	   the	   corresponding	   sample	   clusters	   within	   the	  embryo	   (AGM	  would	   have	   higher	   population	   frequencies)	  would	   be	   possible	   by	   using	  reporter	  cell/mouse	  lines	  for	  that	  gene.	  Alternatively,	  among	  96	  genes,	  some	  cell	  surface	  proteins	   (such	   as	   Itgb3)	   can	   be	   used	   for	   antibody	   labeling	   if	   the	   gene	   expression	   is	  directly	  correlated	  with	  protein	  expression.	  	  
Lastly,	  SC_2	  is	  an	  interesting	  sample	  cluster,	  which	  was	  not	  discovered	  before.	  Despite	  the	  fact	  that	  there	  are	  only	  9	  cells,	  all	  isolated	  from	  E10.5	  YS,	  it	  may	  still	  reflect	  a	  biologically	  relevant	  population.	  To	  confirm	  that	  cells	  co-­‐expressing	  endothelial	  and	  erythroid	  genes	  exist,	  we	  need	  to	  isolate	  it	  using	  another	  method.	  Following	  that	  approach,	  we	  used	  the	  mir144/451-­‐eGFP	  mouse	  line	  (Rasmussen	  et	  al.,	  2010),	  which	  expresses	  GFP	  specifically	  in	  the	  erythroid	  lineage.	  In	  the	  FACS	  analysis	  of	  E10.5	  YS	  derived	  cells	  from	  mir144/451+/GFP	  embryos,	  we	  found	  a	  very	  small	  VE-­‐Cadherin+	  GFP+	  population,	  which	  would	  fit	  the	  only	  9	  cells	  found	  in	  SC_2	  (Irina	  Pinheiro,	  data	  not	  shown).	  As	  a	  next	  step,	  we	  will	  run	  single	  cell	  qRT-­‐PCR	  of	  those	  isolated	  cells	  to	  check	  gene	  expression	  profile	  and	  see	  if	  it	  matches	  with	  the	  SC_2	  profile.	  In	  parallel,	  we	  will	  test	  its	  functional	  hematopoietic	  lineage	  potential	  by	  performing	  in	  vitro	  hematopoietic	  commitment	  assay	  with	  the	  sorted	  VE-­‐Cadherin+	  GFP+	  cells.	  If	  the	  results	  confirm	  the	  endothelial	  and	  erythroid	  function	  of	  these	  cells,	  it	  will	  be	  the	  first-­‐time	  identification	  of	  erythroid	  lineage	  commitment	  at	  endothelial	  stage.	  Under	  the	  circumstances	  that	  we	  confirm	  the	  existence	  of	  such	  rare	  population	  detectable	  only	  for	  a	  short	  time	  in	  the	  YS,	  one	  may	  speculate	  that	  these	  cells	  can	  be	  the	  endothelial	  cells	  already	  committed	  to	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erythroid	  lineage	  with	  previously	  proposed	  Runx1	  independent	  EHT	  program	  (Lacaud	  G.	  2002)	  
Single	  cell	  qRT-­‐PCR	  is	  a	  powerful	  technique	  to	  analyze	  the	  expression	  of	  96	  genes	  in	  the	   same	   cell,	   however	   some	   aspects	   of	   the	   results	   have	   to	   be	   confirmed	   by	   other	  methods.	  Since	  96	  genes	  are	  chosen	  in	  customized	  manner,	  there	  is	  a	  bias	  introduced	  by	  the	   choice	   of	   genes.	   Within	   the	   samples,	   there	   might	   be	   cells,	   which	   cannot	   be	  distinguished	  by	  the	  expression	  level	  of	  96	  chosen	  genes.	  Single	  cell	  mRNA	  sequencing	  would	  offer	  a	  great	  solution	  to	  get	  the	  un-­‐biased	  gene	  expression	  profiling.	  By	  aiming	  at	  identification	  of	  distinguished	  sub-­‐populations,	  we	  analyzed	  VE-­‐Cadherin	  positive	  cells	  isolated	  from	  AGM.	  Through	  collaboration	  with	  Sarah	  Teichmann’s	  lab	  in	  EMBL	  EBI,	  we	  followed	  the	  C1	  (Fluidigm)	  single	  cell	  mRNA	  sequencing	  protocol.	  The	  initial	  results	  are	  promising	  as	  we	  identified	  sub-­‐populations	  with	  distinctive	  gene	  expression	  profile.	   In	  the	   future,	  we	   are	  planning	   to	   compare	   those	   sub-­‐populations	  with	   the	   ones	   found	   in	  single	   cell	   qRT-­‐PCR.	   	   Furthermore,	   the	   distinctive	   genes	   of	   sub-­‐populations	   have	   a	  potential	  use	  as	  a	  marker	  gene	  related	  with	  that	  population.	  Therefore,	  identified	  genes	  will	  be	  confirmed	  for	  labeling	  specific	  cells	  in	  vivo	  and	  in	  vitro.	  
Gene	   expression	   can	   be	   a	   good	   indication	   of	   cell	   type,	   but	   sometimes	   the	   post-­‐transcriptional	   regulations	   and	   post-­‐translational	   modifications	   become	   the	  determining	   factor	   for	   having	   the	   functional	   protein	   in	   the	   cell.	   Therefore	   the	   protein	  expression	   analysis	   would	   be	   needed	   for	   population	   analysis	   during	   EHT.	   Lyoplate	  monoclonal	   antibody	  panel	   is	   the	   collection	  of	  176	  mouse	   antibodies	  provided	  by	  BD.	  This	   experiment	   would	   not	   have	   been	   possible	   using	   embryonic	   cells	   because	   of	   the	  small	  quantity	  of	  material	  per	  embryo.	  To	  bypass	  this	  problem,	  I	  used	  the	  in	  vitro	  ES	  cell	  differentiation	   system	   and	   I	   managed	   to	   generate	   a	   large	   cell	   numbers	   sufficient	   to	  screen	  these	  176	  antibodies	  on	  cells	  derived	  from	  blast	  day	  1.5	  culture.	  I	  selected	  the	  list	  of	  antibodies	  with	  overall	  labeling	  frequency	  within	  4-­‐80%.	  In	  order	  to	  focus	  on	  finding	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a	   marker	   for	   hemogenic	   endothelium,	   I	   chose	   15	   antibodies	   showing	   differential	  expression	   within	   VE-­‐Cadherin	   positive	   cells.	   Lastly	   I	   confirmed	   that	   13	   of	   them	   has	  similar	  expression	  pattern	  in	  AGM	  and	  YS	  derived	  cells	  at	  E10.5	  embryos.	  In	  the	  future,	  I	  will	   test	   the	  enrichment	  of	  hematopoietic	  commitment	  of	   the	  cells	   isolated	  from	  E10.5	  isolated	   AGM	   and	   YS	   samples.	   If	   any	   of	   the	   13	   antibodies	   show	   enrichment	   of	  hematopoietic	   potential,	   I	   will	   check	   the	   gene	   expression	   profile	   of	   those	   cells	   in	   the	  search	  of	  a	  match	  between	  the	  sample	  clusters	  discussed	  in	  this	  chapter.	  
In	   the	   future,	   by	   combining	   the	   information	   gained	   by	   C1	   single	   cell	   mRNA	  sequencing	  and	  lyoplate	  antibody	  screening,	  I	  aim	  to	  find	  a	  good	  marker	  for	  isolation	  of	  the	   sample	   clusters	   SC_5,	   SC_6	   and	   SC_1.	   After	   isolation	   of	   the	   corresponding	  populations,	   my	   ultimate	   aim	   is	   to	   confirm	   their	   lineage	   capacity	   in	   hematopoietic	  commitment	  assays.	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Chapter	  4:	  The	  role	  of	  TGFβ 	  Pathway	  in	  EHT	  
1. Introduction:	  
1.1. EndMT	  and	  its	  similarity	  with	  EHT	  Endothelial	   cells	   can	   have	   high	   plasticity	   during	   development	   and	   can	   transit	  through	  a	  migratory	  cell	  type.	  Endothelial	  to	  mesenchymal	  transition	  (EndMT)	  is	  a	  key	  developmental	   event,	  which	   is	   first	   identified	   in	  endocardial	   cushion	   formation.	   Initial	  studies	  with	  chicken	  and	  rat	  developing	  heart	  tissue	  suggested	  the	  endothelial	  cells	  are	  transforming	   into	  mesenchymal	   cells	   and	  migrating	   towards	   the	   region	   called	   cardiac	  jelly	   (Markwald,	   Fitzharris,	   &	   Manasek,	   1977).	   Formed	   cardiac	   jelly	   composed	   of	  extracellular	  matrix	  elements	  and	  mesenchymal	  cells	   surrounded	  by	  endothelial	   layer,	  which	  all	  together	  named	  as	  endocardial	  cushion.	  Endocardial	  cushion	  is	  preceding	  the	  heart	  valves	  (Maron	  &	  Hutchins,	  1974),	  therefore	  EndMT	  is	  vital	  for	  heart	  development.	  	  
On	  top	  of	   its	  essential	  role	  in	  development,	  the	  EndMT	  may	  also	  play	  an	  important	  role	  in	  tissue	  fibrosis	  and	  cancer	  metastasis	  in	  adult	  organism.	  The	  fibrotic	  diseases	  are	  due	  to	  accumulation	  of	   fibroblasts	  and	  extracellular	  matrix	   into	  the	  site	  of	   injury.	  Such	  as	   in	   cardiac	   fibrosis,	   endothelial	   origin	   cells	   are	   giving	   rise	   to	   fibroblasts	   thorough	  EndMT	   (Zeisberg,	   Tarnavski,	   et	   al.,	   2007).	   Similarly	   EndMT	   is	   found	   to	   contribute	   to	  kidney	   fibrosis	   (Zeisberg,	   Potenta,	   Sugimoto,	   Zeisberg,	   &	   Kalluri,	   2008),	   pulmonary	  fibrosis	   (Arciniegas,	   Neves,	   Carrillo,	   Zambrano,	   &	   Ramírez,	   2005)	   ,	   and	   intestinal	  fibrosis(Rieder	   et	   al.,	   2011).	   Similarly	   carcinoma	   associated	   fibroblasts	   can	   promote	  tumor	   progression	   and	   EndMT	   is	   claimed	   to	   have	   role	   in	   emergence	   of	   activated	  fibroblasts	   from	   nearby	   endothelial	   cells	   (Zeisberg,	   Potenta,	   Xie,	   Zeisberg,	   &	   Kalluri,	  2007).	  
Upon	   detection	   of	   the	   EndMT	   initiating	   signal,	   the	   cells	   are	   delaminated	   from	   the	  endothelial	  layer.	  Following	  this,	  the	  mesenchymal	  markers	  such	  as	  αSMA	  and	  FSP1	  are	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replacing	  the	  endothelial	  markers	  such	  as	  VE-­‐Cadherin,	  CD31.	  The	  endothelial	  cells	  are	  losing	   their	   apical-­‐basal	   polarity,	   endothelial	   marker	   expressions,	   tight	   junctions	   and	  adhesions	  within	  endothelial	  layer,	  resulting	  in	  a	  migratory	  cell	  type	  (Potenta,	  Zeisberg,	  &	  Kalluri,	  2008). 
1.2. General	  remarks	  of	  TGFB	  signaling	  Transforming	   growth	   factor	   beta	   (TGFβ)	   signaling	   pathway	   is	   the	   driver	   of	  many	  cellular	  events	  underlying	  various	  developmental	  regulations.	  The	  pathway	  consists	  of	  three	  main	  players:	  TGFβ	  superfamily	  ligands,	  cell	  membrane-­‐bound	  receptors	  and	  the	  effector	  molecules	  in	  the	  cell	  (SMAD	  transcription	  factors).	  The	  series	  of	  kinase	  event	  is	  initiated	  upon	  binding	  of	  a	  ligand	  on	  a	  homodimer	  of	  type	  II	  TGFβ	  receptor.	  This	  binding	  recruits	   a	   TGFβ	   receptor	   type	   I	   homodimer	   to	   form	   all	   together	   a	   hetero-­‐tetrameric	  complex	  and	   the	   type	   II	   receptors	  phosphorylate	   the	   type	   I	   receptors.	  Phosphorylated	  type	   I	   receptors	   become	   active	   and	   then	   they	   phosphorylate	   and	   activate	   a	   group	   of	  receptor	  regulated	  SMAD	  (R-­‐SMAD)	  proteins.	  The	  phosphorylated	  R-­‐SMADs	   later	   form	  heterodimers	   with	   common-­‐mediator	   SMAD	   proteins	   (Co-­‐SMADs)	   and	   localize	   into	  nucleus	  where	   they	   act	   on	   target	   genes	   in	  means	   of	   transcription	   activation.	   Another	  type	  of	  SMAD	  proteins,	  Inhibitory	  SMAD	  (I-­‐SMAD),	  can	  block	  the	  phosphorylation	  of	  R-­‐SMADs,	   which	   cuts	   off	   the	   down-­‐stream	   relay	   of	   the	   signal	   (Evangelia	   Pardali	   &	   Ten	  Dijke,	  2012)	  
The	  cellular	  response	  might	  be	  different	  depending	  on	  the	  types	  of	  ligand	  binding	  to	  receptors	   (Goumans	   et	   al.,	   2002;	   Evangelia	   Pardali	   &	   Ten	   Dijke,	   2012).	   TGFβ	  superfamily	   protein	   ligands	   include	   TGFβ	   isoforms,	   activins,	   bone	   morphogenetic	  proteins	  (BMPs).	  In	  endothelial	  cells,	  all	  TGFβ	  isoforms	  bind	  to	  TGFBR2	  (also	  known	  as	  TβRII),	  which	  then	  recruits	  TGFBR1	  (also	  known	  as	  ALK5).	  This	  receptor	  complex	  then	  phosphorylates	  Smad2	  and	  Smad3	  (Figure4.1.A).	  Instead	  of	  TGFβ,	  if	  BMP	  is	  available	  as	  a	   ligand,	   it	  binds	   to	  different	   type	   II	   receptors,	  BMPRII	  or	  ActRII;	   then	  different	   type	   I	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receptors,	   ALK1/2/3/6.	   These	   type	   I	   and	   type	   II	   receptors	   form	   a	   different	   complex,	  which	   relays	   the	   signal	   through	   Smad1/5/8	   (Figure4.1.B).	   The	   type	   of	   Smad	   proteins	  localized	   in	   the	   nucleus	  will	   determine	   the	   target	   gene	   for	   transcription.	   In	   summary	  two	  sets	  of	  signaling	  events	  can	  be	  activated	  depending	  on	  the	  ligand	  availability	  in	  the	  environment	  and	  receptor	  availability	  in	  the	  cell.	  	   
Figure	  4.0.1	  Simplified	  TGFβ 	  signaling	  pathway	  showing	  two	  sets	  of	  kinase	  reactions	  resulting	  in	  
different	  gene	  transcription	  initiation.	  Image	  is	  adapted	  from	  Pardali,	  E.,	  &	  Ten	  Dijke,	  P.	  (2012)	  
International	  Journal	  of	  Biological	  Sciences.	  A.	  TGFβ 	  family	  proteins	  trigger	  the	  signaling	  cascade	  
through	  TGFBR2,	  TGFBR1	  (ALK5),	  SMAD2/3.	  B.	  BMP	  family	  proteins	  trigger	  the	  signaling	  cascade	  
through	  BMPRII,	  ACTRII,	  ALK1/2/3/6,	  SMAD1/5/8.	   
1.3. TGFβ 	  pathway	  in	  EndMT	  There	   are	   several	   signaling	  mechanisms	   controlling	   EndMT	   and	   TGFβ	   pathway	   is	  one	  of	   the	   important	   regulators	   involved	   in	  both	  developmental	   and	  pathologic	   cases.	  TGFβ1,	   as	   a	   cardiac	   fibrosis	   promoting	   ligand,	   induces	   EndMT	   therefore	   increases	  
A  B  
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number	   of	   fibroblasts,	   whose	   effect	   can	   be	   reversed	   by	   introducing	   BMP-­‐7	   (Zeisberg,	  Tarnavski,	  et	  al.,	  2007).	  TGFβ1	  also	  increases	  the	  rate	  of	  EndMT	  in	  primary	  endothelial	  cell	  lines,	  generating	  more	  fibroblast	  cells.	  Similarly	  high	  TGFβ1	  labeling	  overlaps	  in	  the	  areas	   of	   FSP1	   expressing	   fibroblasts	   in	   tumor	   tissues	   (Zeisberg,	   Potenta,	   et	   al.,	   2007).	  Smad7,	  which	  is	  a	  negative	  regulator	  of	  TGFβ	  signaling,	  inhibits	  EndMT	  mediated	  renal	  fibrosis	   (Lan	   et	   al.,	   2003).	   Smad3,	   an	   R-­‐Smad	   family	   protein,	   deficiency	   on	   the	   other	  hand	  can	  be	  protective	  against	  renal	  fibrosis(Inazaki	  et	  al.,	  2004;	  Sato,	  Muragaki,	  Saika,	  &	  Roberts,	  2003).	  
A	  very	  comprehensive	  study	  of	  TGFβ	  pathway	  in	  regulation	  of	  EndMT	  was	  done	  on	  the	   fibrodysplasia	   ossificans	   progressiva	   (FOP)	   disease	   (Medici	   et	   al.,	   2010).	   FOP	  patients	  suffer	   from	  ectopic	  bone	   formation	   in	  soft	   tissues	  after	  acute	   inflammation.	  A	  genotypic	   study	   showed	   a	   mutation	   in	   Alk2	   (also	   known	   as	   Acvr1)	   gene	   causes	  constitutively	   active	   receptor	   type	   I	   for	   TGFβ	   signaling	   (Shore	   et	   al.,	   2006).	   Further	  Medici	  et	  al.	  confirmed	  the	  role	  of	  active	  Alk2	  on	  FOP	  disease	  by	  using	  either	  a	  mouse	  model	  with	   constitutively	   active	  Alk2	   or	   by	   treating	   the	   normal	   endothelial	   cells	  with	  TGFβ2	  or	  BMP4.	  The	  result	  is	  the	  same	  for	  both	  cases	  as	  the	  endothelial	  cells	  transited	  to	  mesenchymal,	  stem-­‐like	  cell	  phenotype,	   later	  they	  can	  differentiate	   into	  osteoblasts.	  In	   summary,	   this	   study	   links	   the	   TGFβ/Alk2	   signaling	   with	   activation	   of	   EndMT	  mechanism	  in	  a	  disease. 
1.4. TGFβ 	  pathway	  in	  hematopoiesis	  Mouse	  studies	  suggested	  that	  the	  loss	  of	  function	  of	  TGFB	  signaling	  (either	  ligand,	  or	  receptor,	   or	   the	   effector	   proteins)	   causes	   deficiencies	   in	   hematopoiesis.	   Two	   groups	  generated	  TGFB1	  null	  mouse	  and	  reported	  that	  rare	  viable	  TGFB1-­‐/-­‐	  mice	  have	  excess	  inflammatory	  response,	   leading	  to	  death	  within	  one	  month	  after	  birth.	  (Kulkarni	  et	  al.,	  1993;	   Shull	   et	   al.,	   1992).	  The	  deficient	  phenotype	   related	  with	   the	  hematopoiesis	  was	  noticed	  when	  TGFB1-­‐/-­‐	  mouse	  embryos	  are	   investigated	  prior	   than	  E10.5	   (Dickson	  et	  
	   	   	  124	  
al.,	  1995).	  At	  E9.5	  of	  TGFB1-­‐/-­‐	  embryos,	  endothelial	  cells	  are	  less	  adherent	  yet	  they	  can	  form	   the	   yolk	   sac	   and	   the	   embryo	   proper	   vasculature	   but	   not	   enough	   of	   capillary	  vessels.	   This	   can	   be	   interpreted	   as	   the	   initial	   emergence	   of	   vascular	   endothelial	  precursors	  from	  hemangioblast	  is	  intact,	  however	  further	  differentiation	  of	  endothelial	  cells	   to	   support	   the	   vasculature	   is	   disrupted	   in	   TGFB1-­‐/-­‐	   embryos.	   In	   parallel	   at	   E9.5	  there	  are	   less	   red	  blood	  cells	   in	  TGFB1-­‐/-­‐	  yolk	  sac	   then	   in	  a	  wild	   type	   littermate.	  This	  anemic	   phenotype	   is	   possibly	   caused	   by	   a	   deficiency	   in	   the	   yolk	   sac	   hematopoiesis.	  (Dickson	  et	  al.,	  1995).	  
Similar	   anemic	   phenotype	   is	   observed	   in	   other	   mouse	   knock-­‐out	   studies	   of	   the	  pathway.	  Deletion	  of	  either	  the	  type	  I	  receptor	  ALK1	  (Oh	  et	  al.,	  2000),	  or	  another	  type	  I	  receptor	  TGFBR1	  (Larsson	  et	  al.,	  2001)	  or	  type	  II	  receptor	  TGFBR2	  (Oshima,	  Oshima,	  &	  Taketo,	  1996)	  or	   their	  binding	  partner	  Endoglin	   (D.	  Y.	  Li	   et	   al.,	   1999)	  or	   the	   signaling	  transducer	  Smad5	  (Sankar	  et	  al.,	  1996)	  results	   in	  embryonic	   lethality	  with	  anemia.	  All	  these	   studies	   report	   the	   similar	   phenotype	   of	  weak,	   dilated	   vasculature	   that	   does	   not	  support	   a	   proper	   circulation,	   together	   with	   less	   blood	   cell	   emergence.	   In	   contrast	   to	  abnormal	  hematopoiesis	  phenotype,	  TGFBR1	  -­‐/-­‐	  mouse	  hematopoietic	  stem	  cells	  show	  a	   completely	   normal	   hematopoietic	   differentiation	   capacity	   in	   vitro	   (Larsson	   et	   al.,	  2001).	   Additionally,	   when	   TGFBR1	   is	   conditionally	   knocked	   out	   in	   adult	   mice;	   the	  isolated	   hematopoietic	   stem	   cells	   showed	   increased	   proliferation	   in	   vitro	   but	   normal	  self-­‐renewal	  and	  differentiation	  in	  vivo	  (Larsson	  et	  al.,	  2003).	  
Runx1	   protein,	   the	   key	   transcription	   factor	   of	   EHT,	   is	   interestingly	   found	   to	   be	  physically	  interacting	  with	  Smad	  proteins	  in	  various	  cell	  types.	  Affinity	  chromatography	  made	  from	  mouse	  megakaryoblastic	  cells	  revealed	  a	  physical	   interaction	  of	  Runx1	  and	  Smad2	   proteins	   (Yu	   et	   al.,	   2012)	   Another	   study	   reported	   that	   Smad3/4	   proteins	   and	  Runx1	   cooperatively	   bound	   on	   target	   DNA	   site	   to	   trigger	   transcription	   from	  immunoglobulin	  α	  constant	  region	  during	  B	  cell	  maturation	  (Y.	  Zhang	  &	  Derynck,	  2000).	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Similar	  interaction	  of	  Smad3/4	  proteins	  with	  Runx1	  plays	  the	  role	  of	  regulating	  human	  germ	   line	   IgA	   gene	   expression	   (E.	   Pardali	   et	   al.,	   2000)	   and	   induction	   of	   germline	  immunoglobulin	  Cα	  promoter	  (Hanai	  et	  al.,	  1999). 
1.5. Hypothesis:	  Considering	   the	   valuable	   findings	   from	   knock-­‐out	   studies	   showing	   TGFβ	   signaling	  involvement	  in	  early	  hematopoiesis,	  we	  investigated	  the	  possible	  role	  of	  TGFβ	  pathway	  in	   the	   regulation	  of	  EHT.	  Furthermore,	  Runx1	   interaction	  with	  Smad	  proteins	   in	  adult	  hematopoiesis	   may	   suggest	   a	   similar	   developmental	   regulation	   of	   Runx1	   binding	   to	  target	  DNA	  during	  EHT.	  Putting	  together	  the	  previous	  findings	  about	  TGFβ	  signaling	  and	  hematopoiesis	  might	  suggest	  a	  regulatory	  mechanism	  of	  EHT.	  
The	  regulatory	  role	  of	  TGFβ	  signaling	  in	  EndMT	  is	  well	  studied	  and	  the	  recognition	  of	  TGFβ	  ligand	  in	  endothelial	  cells	  triggers	  a	  set	  of	  events	  activating	  EndMT.	  The	  loss	  of	  their	   endothelial	   phenotype	   and	   the	   gain	   of	   migratory	   features	   are	   the	   shared	  morphological	   changes	   between	   EndMT	   and	   EHT.	   Yet	   the	   resulting	   phenotype	   is	  mesenchymal	   cells	   in	   EndMT	   and	  hematopoietic	   cells	   in	   EHT.	  Due	   to	   the	   similarity	   in	  endothelial	   phenotype	   loss,	   I	   hypothesized	   that	  TGFβ	   signaling	   could	   be	   involved	   in	   a	  common	   molecular	   mechanism	   to	   regulate	   the	   initial	   endothelial	   phenotype	   loss	   in	  EndMT	  and	  EHT.	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2. Results:	  
2.1. Expression	  analysis	  of	  TGFβ 	  pathway	  related	  genes	  during	  EHT	  If	   TGFβ	   signaling	   has	   a	   role	   in	   EHT	   regulation,	   the	   cells	   undergoing	   EHT	   should	  express	   the	   elements	   of	   the	   cascade.	   In	   order	   to	   check	   the	   expression	   level	   of	   TGFβ	  signaling	  related	  genes,	  we	  decided	  to	  analyze	  EHT	  populations	  isolated	  from	  embryos	  or	   in	   vitro	   culture.	   As	   we	   discussed	   in	   the	   previous	   chapter,	   there	   is	   cellular	  heterogeneity	   for	   rare	   cell	   types	   appearing	  within	   a	   short	   time	  window,	   therefore	  we	  decided	  to	  use	  single	  cell	  qRT-­‐PCR	  technique	  instead	  of	  the	  conventional	  one.	  Among	  the	  96	   genes	   (Table	   3.1)	   to	   be	   used	   in	   BioMark	   96	   x	   96	   microfluidics	   platform,	   22	   are	  TGFβ/BMP	  pathway	  related	  genes	  (Table	  4.1).	  	  
Table	  7.4.1	  List	  of	  TGFβ 	  pathway	  related	  genes	  with	  their	  role	  in	  the	  pathway.	  The	  official	  names	  are	  
in	  the	  second	  column	  and	  the	  alternative	  names	  in	  the	  third.	  
To	  recapitulate	  EHT	   in	  vitro,	   I	  used	  a	  well-­‐established	  mESC	  protocol	   (Sroczynska,	  Lancrin,	  Pearson,	  &	  Lacaud,	  2009).	   In	  this	  protocol,	   first	  mES	  cells	  were	  cultured	  for	  3	  days	   to	   generate	   embryoid	   bodies	   and	   the	   hemangioblast	   equivalent	   cells	   defined	   by	  Flk1	   expression	   were	   sorted	   to	   start	   blast	   culture.	   By	   day	   1.5	   of	   blast	   culture,	   the	  NonHE,	  HE,	  Pre-­‐HP	  and	  HP	  populations	  characterized	  by	  the	  combined	  staining	  pattern	  of	  VE-­‐Cadherin,	  hCD4/Runx1	  and	  CD41	  (see	  Figure	  3.3).	  The	  FACS	  isolated	  populations	  
Function Name Alternative names Long name Ensembl 
Receptor Type I 
Acvrl1 Alk1; Acvrlk1 activin A receptor, type II-like 1 ENSMUSG00000000530 
Acvr1 Alk-2; Acvr; Alk8; SKR1 activin A receptor, type 1 ENSMUSG00000026836 
Bmpr1a ALK3; Bmpr; BMPR-IA bone morphogenetic protein receptor, type 1A ENSMUSG00000021796 
Acvr1b Alk4; SKR2 activin A receptor, type 1B ENSMUSG00000000532 
Tgfbr1 Alk-5; TbetaRI transforming growth factor, beta receptor I ENSMUSG00000007613 
Receptor Type II 
Bmpr2 BMP-2, BMPRII bone morphogenic protein receptor, type II ENSMUSG00000067336 
Acvr2a ActRIIa, Acvr2, tActRII activin receptor IIA ENSMUSG00000052155 
Tgfbr2 TbetaRII, TbetaR-II transforming growth factor, beta receptor II ENSMUSG00000032440 
Acvr2b ActRIIB activin receptor IIB  ENSMUSG00000061393 
Ligand 
Bmp4 Bmp-4; Bmp2b; Bmp2b1 bone morphogenetic protein 4 ENSMUSG00000021835 
Tgfb1 Tgfb; Tgfb-1; TGFbeta1 transforming growth factor, beta 1 ENSMUSG00000002603 
Tgfb2 Tgfb-2; BB105277 transforming growth factor, beta 2 ENSMUSG00000039239 
Tgfb3 Tgfb-3 transforming growth factor, beta 3 ENSMUSG00000021253 
Signal transducer 
Smad1 Madh1, Madr1, Smad 1 SMAD family member 1 ENSMUSG00000031681 
Smad2 Madh2, Madr2, Smad 2 SMAD family member 2 ENSMUSG00000024563 
Smad3 Madh3; AU022421 SMAD family member 3 ENSMUSG00000032402 
Smad4 DPC4; Madh4 SMAD family member 4 ENSMUSG00000024515 
Smad5 Dwf-C; Madh5 SMAD family member 5 ENSMUSG00000021540 
Smad6 Madh6 SMAD family member 6 ENSMUSG00000036867 
Smad7 Madh7 SMAD family member 7 ENSMUSG00000025880 
Smad9 Madh8; Madh9; Smad8 SMAD family member 9 ENSMUSG00000027796 
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can	   be	   further	   tested	   for	   hematopoietic	   differentiation	   capacity	   in	   hemogenic	  endothelium	  culture.	  
As	   it	   is	   explained	   in	   detail	   in	   chapter	   3,	   to	   analyze	   the	   EHT	   in	   vivo,	   I	   decided	   to	  isolated	   VE-­‐Cad+	   cells	   expressing	   different	   levels	   of	   CD41	   from	   AGM	   and	   YS	   tissues,	  which	  are	  the	  main	  EHT	  sites	   in	  the	  embryo.	  In	  order	  to	  collect	  cells	   from	  all	  stages	  of	  EHT	  within	  VE-­‐Cadherin+	  and	  CD41	  negative/intermediate/high	  gates	  (Figure	  3.9),	  the	  AGM	  and	  YS	  tissues	  of	  embryos	  at	  E9.0,	  E10.5	  and	  E11.0	  time	  points	  was	  sorted	  by	  FACS	  at	  the	  single	  cell	  level.	  The	  single	  cell	  qRT-­‐PCR	  was	  run	  and	  the	  raw	  data	  results	  of	  the	  AGM	   and	   YS	   tissues	   for	   all	   time	   points	   are	  merged	   for	   the	   combined	   analysis	   (Figure	  3.10).	  Also	  only	  for	  this	  chapter,	  the	  raw	  data	  of	  AGM	  samples	  from	  different	  time	  points	  are	  merged.	  The	   same	   sample	   clusters	   characterized	   in	   the	   chapter	  3	   are	  kept	   for	   the	  analysis	   in	   this	   chapter.	   According	   to	   the	   proposed	  model	   in	   chapter	   3,	   the	   SC_4	   and	  SC_5	   are	   the	   main	   endothelial	   populations,	   while	   the	   SC_5	   includes	   hemogenic	  endothelial	   cells.	   SC_6	   has	   shared	   endothelial	   phenotype	   with	   SC_5	   but	   also	   express	  some	   hematopoietic	   genes	   like	   Runx1.	   Lastly	   the	   SC_1	   is	   the	   population	   with	   no	  endothelial	   expression	  but	   genes	   related	  with	  more	  mature	  hematopoietic	   phenotype.	  In	  summary,	  the	  SC_4	  and	  SC_5	  might	   include	  the	  non-­‐hemogenic	  endothelial	  cells	  and	  the	  EHT	  process	  is	  expected	  to	  be	  from	  hemogenic	  endothelial	  cells	  of	  SC_5	  to	  SC_6	  and	  then	  to	  SC_1.	  It	  is	  noteworthy	  that,	  since	  we	  did	  not	  sort	  VE-­‐Cadherin-­‐,	  CD41+	  cells	  from	  the	  embryo	  derived	  samples,	  for	  the	  in	  vivo	  analysis	  we	  do	  not	  expect	  to	  have	  a	  sample	  cluster	  corresponding	  to	  HP	  from	  the	  in	  vitro	  data	  set.	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Figure	  4.0.2	  Single	  cell	  gene	  expression	  analysis	  of	  TGFβ 	  pathway	  elements.	  A.	  Cells	  isolated	  from	  
blast	  day	  1.5	  culture	  as	  it	  is	  explained	  in	  chapter	  3	  B.	  Cell	  isolated	  from	  AGM	  of	  3	  time	  points	  (E9.0,	  
E10.5,	  E11.0)	  with	  the	  sample	  clusters	  identified	  in	  chapter	  3.	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First	  of	  all,	  we	  checked	  if	  we	  can	  detect	  the	  expression	  of	  the	  TGFβ	  pathway	  genes	  in	  NonHE,	   HE,	   Pre-­‐HP	   and	   HP	   population	   isolated	   from	   in	   vitro	   blast	   day	   1.5	   culture	  (Figure	   4.2.A)	   and	   previously	   identified	   endothelial	   populations	   from	   AGM	   section	   of	  E10.5	  embryo	  (Figure	  4.2.B).	  We	  observed	  that	  most	  of	  the	  TGFβ	  pathway	  related	  genes	  are	  expressed	  either	  at	   low	   level	  or	  not	  showing	  variance	  between	  populations.	  When	  we	   compare	   the	   populations	   in	   the	   direction	   of	   EHT,	  we	   saw	   a	   consistent	   pattern	   for	  both	  in	  vitro	  and	  in	  vivo	  of	  down-­‐regulation	  of	  Acvrl1(ALK1),	  Tgfbr2,	  Eng,	  Bmp4	  genes	  but	   no	   differential	   expression	   of	   Tgfbr1	   (Alk5)	   (Figure	   4.2).	   Previously	   it	   has	   been	  shown	  that	  both	  ACVRL1	  (Alk1)	  and	  TGFBR1	  (Alk5)	  are	  binding	  to	  TGFBR2	  on	  human	  umbilical	   vessel	   endothelial	   cells	   (HUVEC).	   They	   suggested	   a	   model	   of	   angiogenesis	  control	  either	  via	  activation	  of	  Alk1	  Smad1/5	  signal	  transduction	  or	  via	  Alk5	  activation	  triggering	  Smad2/3	  signal	  transduction	  (Oh	  et	  al.,	  2000).	  We	  thought	  a	  similar	  balance	  could	  play	  role	  in	  endothelial	  cell	  differentiation	  towards	  hematopoiesis.	  
Since	  the	  expression	  of	  receptor	  type	  I	  and	  II	  is	  necessary	  for	  the	  signaling	  activity,	  we	   focused	  on	  the	  expression	  pattern	  of	  Acvrl1	  (Alk1),	  Tgfbr1	  (Alk5),	  and	  Tgfbr2.	  The	  box	   plot	   representation	   of	   gene	   expression	   values	   showed	   high	   Acvrl1	   and	   Tgfbr1	  expression,	   coupled	   with	   lower	   expression	   of	   Tgfbr2	   on	   the	   cells	   with	   endothelial	  phenotype	  (NonHE,	  HE	   in	  Figure	  4.3.A	  and	  SC_4,	  SC_5	   in	  Figure	  4.3.B).	  However	  when	  we	   cultured	   these	   endothelial	   cells	   isolated	   from	   blast	   day	   1.5	   in	   hemogenic	  endothelium	  culture	  for	  2	  days,	  we	  see	  dramatically	  decreased	  expression	  of	  Acvrl1	  and	  obvious	   down-­‐regulation	   of	   Tgfbr2	   but	   almost	   no	   change	   of	   Tgfbr1	   expression	   in	  descendent	   HP	   cells	   (Figure	   4.3.C).	   Because	   it	   is	   technically	   challenging	   to	   trace	   the	  clonal	   progeny	   of	   hemogenic	   endothelial	   cells	   after	   EHT,	   we	   checked	   the	   gene	  expression	  level	  of	  AGM	  isolated	  cells	  with	  the	  previously	  identified	  sample	  clusters	   in	  the	   direction	   of	   EHT	   (SC_5	   to	   SC_6	   to	   SC_1	   but	   no	   sample	   cluster	   equivalent	   of	   HP).	  Similar	  to	  in	  vitro	  results,	  SC_6	  and	  SC_1	  populations	  have	  lower	  Acvrl1	  expression	  than	  SC_5	  but	  there	  is	  no	  difference	  in	  Tgfbr1	  and	  Tgfbr2	  expression	  (Figure	  4.3.D).	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Figure	  4.0.3	  Box	  plot	  representation	  of	  single	  cell	  qRT-­‐PCR	  results	  with	  log2	  expression	  values	  of	  
Acvrl1	  (Alk1),	  Tgfbr1	  (Alk5),	  Tgfbr2	  genes.	  A.	  Populations	  from	  in	  vitro	  blast	  day1.5	  culture	  were	  
sorted	  as	  explained	  previously	  in	  Figure	  3.6.	  B.	  Endothelial	  populations	  isolated	  from	  AGM	  of	  E10.5	  
embryos,	  sorted	  as	  explained	  previously	  in	  Figure	  3.9	  and	  populations	  are	  identified	  in	  Figure	  3.10.	  	  C.	  
NonHE+HE	  population	  isolated	  from	  blast	  day1.5	  culture	  and	  HP	  population	  derived	  from	  the	  
NonHE+HE	  population	  after	  the	  in	  vitro	  hematopoietic	  differentiation	  culture.	  D.	  	  In	  vivo	  YS	  and	  AGM	  
derived	  populations	  according	  to	  the	  proposed	  model	  of	  EHT.	  The	  arrow	  indicates	  the	  expected	  EHT	  
direction.	  
2.2. Testing	  the	  effect	  of	  TGFβ 	  activation	  and	  inhibition	  on	  EHT	  EndMT	  can	  be	  triggered	  by	   ligand	  TGFβ2	  (Medici	  et	  al.,	  2010).	   In	  order	   to	  activate	  the	   TGFβ	   signaling	   cascade,	   I	   added	   5ng/ml	   of	   human	   recombinant	   TGFβ2	   into	   the	  culture	  medium;	  or	   to	   inhibit	   the	  cascade,	   I	   added	  10nM	  SB-­‐431542,	  a	   small	  molecule	  inhibitor	  of	  ALK5.	  As	  a	  control,	  I	  used	  normal	  culture	  medium	  with	  the	  same	  amount	  of	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suspension	   liquid	   0.1%BSA	  +	   4mM	  HCl	   for	   TGFβ2	   or	  DMSO	   for	   SB431542	   or	  without	  any	   addition.	   Since	  we	  did	  not	   acquire	   a	  different	   result	  with	   these	  3	   conditions,	   only	  DMSO	  added	  control	  was	  kept	  afterwards.	  
The	  cells	  were	  re-­‐plated	  in	  hemogenic	  endothelium	  mix	  with	  either	  DMSO	  or	  10nM	  SB431542	  or	  5ng/ml	  TGFβ2	   for	   3	   days.	   The	   time-­‐lapse	   images	  were	   taken	   for	   3	  days	  every	  15	  minutes.	  After	  three	  days	  of	  culture,	  the	  cells	  were	  examined	  for	  VE-­‐Cadherin	  and	  CD41	  expression	  by	  flow	  cytometry	  analysis.	  The	  harvested	  cells	  were	  also	  frozen	  to	  extract	  total	  RNA	  and	  perform	  mRNA	  microarray	  analysis	  (Figure4.4.A).	  Surprisingly,	  at	  the	  end	  of	  3	  days,	  there	  were	  more	  round	  cells	  in	  the	  condition	  with	  SB431542.	  On	  the	  other	  hand,	  in	  the	  presence	  of	  TGFβ2,	  there	  were	  very	  few	  round	  cells	  but	  more	  flat	  cells	  of	   mesenchymal	   morphology	   (Figure	   4.4.B).	   The	   number	   of	   round	   cells	   during	   the	   3	  days	   of	   culture	  was	   quantified	   based	   on	   the	   live-­‐cell	   imaging.	   The	   control	  with	  DMSO	  doesn’t	   seem	   different	  morphologically	   (Figure	   4.4.B)	   and	   also	   reflected	   in	   quantified	  number	  of	  round	  cells	  (Figure	  4.4.C).	  It	  shows	  that	  there	  is	  a	  striking	  increase	  of	  round	  cells,	  presumably	  HP	  cells,	  in	  TGFβ	  inhibited	  condition	  compared	  to	  DMSO	  treated	  cells.	  On	  the	  contrary,	  TGFβ	  activation	  results	  in	  almost	  no	  round	  cells	  (Figure	  4.4.C).	  
After	  3	  days	  of	  hemogenic	  endothelium	  culture,	  the	  cells	  are	  expected	  to	  have	  higher	  frequency	   of	   CD41+,	   VE-­‐Cadherin-­‐	   cells	   as	   in	   DMSO	   culture	   (Figure	   4.5.A).	   The	   FACS	  analysis	  done	  after	  3	  days	  are	  showing	  a	  significant	  increase	  in	  CD41	  positive	  frequency	  in	   condition	  with	   inhibitor	   while	   with	   the	   TGFβ	   activator	   CD41	   positive	   frequency	   is	  dramatically	   lower.	   In	   contrast,	   VE-­‐Cadherin	   frequency	   is	   significantly	   higher	   in	   TGFβ	  activator	  added	  condition	  than	  the	  control	  (Figure4.5.A&B).	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Figure	  4.0.4	  Culture	  of	  sorted	  Pre-­‐HP	  population	  for	  3	  days	  in	  hemogenic	  endothelium	  culture.	  A.	  The	  
graphical	  representation	  of	  experimental	  flow.	  The	  samples	  are	  used	  for	  time-­‐lapse	  imaging,	  FC	  
analysis	  and	  mRNA	  microarray	  analysis.	  B.	  The	  last	  image	  is	  taken	  with	  the	  incucyte	  microscope	  of	  
each	  condition	  after	  3	  days	  of	  culture.	  The	  scale	  bar	  corresponds	  to	  0.2µm.	  The	  green	  pseudo-­‐color	  is	  
indicating	  the	  round	  cells	  detected	  by	  the	  Cell	  Profiler	  software.	  C.	  Number	  of	  round	  cells	  quantified	  
based	  on	  the	  time-­‐lapse	  imaging	  for	  3	  days.	  Nine	  images	  per	  culture	  condition	  were	  taken	  every	  15	  
minutes	  over	  3	  days.	  Later	  round	  cell	  count	  was	  quantified,	  averaged	  for	  all	  9	  frames	  and	  error	  bars	  
calculated	  as	  standard	  deviation	  of	  counts	  from	  9	  frames	  per	  condition. 
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Figure	  4.0.5	  Flow	  cytometry	  result	  of	  cells	  after	  3	  days	  of	  culture	  in	  hemogenic	  endothelium	  medium	  
with	  corresponding	  compound.	  A.	  Representative	  FC	  staining	  with	  VE-­‐Cadherin	  and	  CD41	  of	  samples	  
harvested	  after	  3	  days	  of	  culture.	  B.	  Average	  CD41	  and	  VE-­‐Cadherin	  frequencies	  of	  FC	  results	  calculated	  
from	  3	  independent	  experiments.	  The	  error	  bars	  represent	  standard	  deviation.	  Indicated	  p	  values	  are	  
calculated	  with	  student	  t	  test.	  Non-­‐indicated	  p	  values	  are	  higher	  than	  0.05. 
 
2.3. TGFβ 	  is	  promoting	  mesenchymal	  fate  Since	   the	  TGFβ2	   treatment	  of	  Pre-­‐HP	   cells	   give	   rise	   to	   a	  more	   smooth	  muscle	   like	  cell	  morphology	  dominance	  in	  the	  culture	  (Figure	  4.4.B),	  we	  wanted	  to	  understand	  the	  resulting	   expression	   pattern	   after	   inhibiting	   the	   TGFβ	   pathway	   and	   activating	   it.	   We	  analyzed	  the	  mRNA	  microarray	  of	   the	  3	  sets	  of	   treated	  cells	   (Figure	  4.4.A)	  with	  DMSO	  (control),	   with	   SB431542	   (inhibitor)	   and	   with	   TGFβ2	   (activator)	   as	   it	   is	   labeled	   in	   3	  different	  colors	  in	  Figure	  4.6.A.	  We	  performed	  principal	  component	  analysis	  to	  compare	  the	   overall	   expression	   pattern	   after	   normalization.	   The	   control	   and	   inhibitor	   samples	  cluster	  very	  closely;	  on	  the	  other	  hand	  activator	  replicates	  cluster	  separately	  from	  them	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(Figure	   4.6.B),	   which	   suggests	   a	   completely	   different	   expression	   profile	   on	   TGFβ2	  treatment	  versus	  control.	  Focusing	  on	   the	  comparison	  of	  activation	  versus	  control,	  we	  did	   hierarchical	   clustering	   of	   all	   9	   sample	   sets	   with	   the	   top	   250	   genes	   significantly	  changed	  expression	   in	  activation	  versus	  control.	  Figure	  4.6.C	  shows	  close	  clustering	  of	  the	   samples	   from	   the	   same	   groups.	   It	   also	   depicts	   very	   similar	   expression	   pattern	  between	   control	   and	   inhibitor	   groups	   but	   the	   opposite	   pattern	   in	   activator	   group	  (Figure	  4.6.C).	  
Figure	  4.0.6	  Microarray	  results	  of	  3	  days	  treated	  with	  DMSO,	  10nM	  SB431542	  (inhibitor),	  5ng/ml	  
TGFB2	  (activator)	  as	  it	  is	  depicted	  in	  figure4.2.A.	  A.	  The	  sample	  annotation	  of	  3	  biological	  replicates	  of	  
control	  (blue)	  ,	  inhibitor	  (red),	  activator	  (yellow)	  samples	  shown.	  B.	  Principal	  component	  analysis	  is	  
run	  for	  all	  samples	  after	  normalization.	  C.	  The	  hierarchical	  clustering	  of	  9	  samples	  based	  on	  the	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Figure	  4.0.7	  Gene	  Ontology	  (GO)	  analysis	  of	  biological	  processes	  for	  activator	  versus	  control	  sample	  
set.	  The	  raw	  data	  is	  cleaned	  from	  the	  samples	  with	  adjusted	  p	  value	  lower	  than	  0.01	  and	  log2	  fold	  
change	  in	  between	  -­‐1	  and	  1.	  The	  GO	  analysis	  is	  done	  with	  the	  shortened	  list	  in	  comparison	  with	  the	  
background	  list	  from	  the	  raw	  data.	  Selection	  of	  significantly	  enriched	  biological	  process	  GO	  terms	  
based	  on	  A.	  the	  up-­‐regulated	  genes	  and	  B.	  the	  down-­‐regulated	  genes	  on	  activator	  versus	  control.	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To	   understand	   the	   nature	   of	   the	   resulting	   cells	   upon	   treatment	   with	   TGFβ2,	   we	  analyzed	   the	   significantly	   up-­‐regulated	   and	   down-­‐regulated	   genes	   for	   gene	   ontology	  association	  with	  biological	  process	  terms.	  The	  top	  GO	  terms	  with	  high	  enrichment	  in	  up-­‐regulated	   gene	   list	   seems	   to	   be	   associated	   with	   increased	   mesenchymal	   cell	  development,	  angiogenesis	  and	  endothelial	  cell	  migration	  (Figure	  4.7.A).	  In	  contrast,	  the	  down-­‐regulated	   gene	   list	   indicates	   GO	   terms	   related	   with	   decreased	   hematopoiesis,	  blood	  and	  immune	  cell	  differentiation,	  cell	  adhesion	  (Figure	  4.7.B).	  
To	  conclude	  about	  the	  resulting	  cell	  phenotype	  after	  treatment,	  we	  checked	  the	  fold	  changes	  in	  sets	  known	  cell	  type	  related	  genes	  in	  microarray	  analysis.	  In	  general	  we	  see	  an	  increased	  expression	  of	  cardiac	  and	  muscle	  fate,	  mesenchymal	  fate,	  endothelial	   fate	  related	   genes	   after	   treatment	   with	   TGFβ2	   (Figure	   4.8.A).	   On	   the	   other	   hand,	  hematopoietic	   fate	   related	   genes	   are	   down-­‐regulated	   after	   TGFβ2	   treatment	   (Figure	  4.8.B).	  The	  combination	  of	  the	  gene	  lists	  (Figure4.8.A&B)	  and	  GO	  terms	  (Figure4.7)	  for	  all	  3	  conditions;	  control	  versus	  inhibitor	  and	  control	  versus	  activator;	  gives	  a	  simplified	  view	   of	   gene	   expression	   pattern.	   The	   inhibition	   of	   TGFβ	   pathway	   with	   SB431542	  treatment	  doesn’t	  seem	  very	  different	   than	  control	  except	   for	  a	  higher	  expression	  of	  a	  short	  list	  of	  hematopoietic	  genes.	  On	  the	  other	  hand,	  activation	  by	  treating	  with	  TGFβ2	  seems	   to	   promote	   a	   down-­‐regulation	   of	   hematopoietic	   genes	   and	   an	   up-­‐regulation	   of	  endothelial,	  mesenchymal,	  cardiac/muscle	  differentiation	  genes	  (Figure4.8.C).	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Figure	  4.0.8	  Cell	  type	  specific	  genes	  expression	  in	  microarray	  analysis.	  The	  bar	  plots	  of	  log2	  fold	  
change	  (higher	  then	  1)	  in	  activator	  TGFβ2	  versus	  control	  conditions	  .A.	  Selection	  of	  cardiac,	  muscle,	  
mesenchyme,	  endothelium	  related	  genes	  are	  up	  regulated	  in	  activator	  and	  B.	  hematopoietic	  genes	  are	  
down	  regulated	  in	  activator.	  C.	  Overview	  of	  expression	  of	  hematopoietic,	  endothelial,	  cardiac	  and	  
mesenchymal	  fate	  related	  genes	  in	  3	  conditions. 
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   Lastly	   we	   decided	   to	   analyse	   EndMT	   related	   gene	   expression	   by	   using	   single	   cell	  qRT-­‐PCR	   on	   the	   cells	   treated	  with	   DMSO,	   SB431542	   and	   TGFβ2.	   These	   genes	   (Acta2,	  Cdh2,	   Snai1,	   Snai2,	   Serpine1)	   are	   markers	   of	   mesenchymal	   phenotype,	   which	   is	  expected	   to	   have	   increased	   expression	   as	   a	   result	   of	   EndMT.	   The	   analysis	   was	   done	  before	   and	   after	   the	   2	   days	   of	   hemogenic	   endothelium	   culture	   with	   sorted	   cell	  populations	   from	  day1.5	  blast	   culture.	  The	  gene	  expression	  values	   are	  plotted	  as	   log2	  expression	   values	   and	   box	   plots	   for	   each	   cell	   population.	   Treated	   endothelial	   and	  hemogenic	   endothelial	   cells	   with	   TGFβ2	   showed	   higher	   expression	   of	   Acta2,	   Cdh2,	  Serpine1	  genes	  in	  comparison	  with	  pre-­‐culture	  cells	  and	  also	  with	  control	  or	  SB431542	  treated	  cells.	  The	  Snai1	  gene	  expression	  remains	  similar	  between	  samples	  while	  Snai2	  expression	  is	  mostly	  not	  detected	  (Figure4.9).	  
Figure	  4.0.9	  Single	  cell	  qPCR	  analysis	  of	  EndMT	  genes	  on	  samples	  after	  treatment	  with	  control,	  
inhibitor,	  and	  activator.	  Before	  and	  after	  culture	  log2	  expression	  values	  are	  shown	  as	  box	  plot	  graph.	  
Sorted	  VE-­‐Cadherin+,	  CD41-­‐	  endothelial	  and	  hemogenic	  endothelium	  population	  is	  treated	  with	  DMSO,	  
SB	  and	  TGFB2	  for	  2	  days.	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3. Discussion:	  	  Considering	  the	  similar	  loss	  of	  endothelial	  phenotype	  in	  EHT	  and	  EndMT,	  one	  could	  think	   of	   common	   signalling	   mechanisms	   regulating	   both	   endothelial	   transitions	  important	   during	   vertebrate	   development.	   The	   promoting	   role	   of	   TGFβ	   signalling	   in	  EndMT	   is	   a	   well-­‐studied	   cellular	   regulation.	   Knowledge	   about	   TGFβ	   signalling	   in	  developmental	   hematopoiesis	   was	   promising	   for	   the	   idea	   of	   a	   possible	   role	   of	   this	  pathway	  in	  the	  regulation	  of	  EHT,	  but	  not	  specific	  enough	  to	  argue	  about	  regulation	  at	  the	   cell	   level.	   Here	   I	   hypothesized	   that	   TGFβ	   pathway	   is	   regulating	   the	   transition	   of	  endothelial	   cells	   towards	   hematopoiesis.	   I	   studied	   the	   cell	   type	   specific	   reaction	   for	  TGFβ	  signalling	  and	  combined	  the	  conventional	  molecular	  biology	  protocols	  with	  single	  cell	  gene	  expression	  techniques.	  
3.1. TGFβ 	  receptors	  are	  expressed	  differentially	  during	  EHT	  Firstly,	   we	   wanted	   to	   investigate	   if	   the	   cells	   going	   through	   EHT	   express	   the	  receptors	   of	   the	   TGFβ	   signaling,	   as	   it	   will	   be	   the	   first	   step	   to	   be	   responsive	   for	   the	  pathway	  activation.	  Considering	  the	  existence	  of	  the	  cellular	  heterogeneity	  even	  within	  sorted	  populations	  and	  the	  rareness	  of	  hemogenic	  endothelial	  cells	  we	  decided	  to	  study	  the	   gene	   expression	   at	   single-­‐cell	   level	   to	   reveal	   TGFβ	   responsive	   cell	   type.	   By	   using	  single	   cell	  qPCR	  approach,	  we	  checked	   the	  gene	  expression	  of	  many	  signal	   transducer	  Smad	   proteins,	   type	   I	   and	   type	   II	   receptors	   (Table	   4.1).	   Among	   them,	   the	   expression	  pattern	  of	  Acvrl1	  (Alk1),	  Tgfbr1	  (Alk5)	  and	  Tgfbr2	  gave	  interesting	  results	  (Figure4.3).	  The	  endothelial	  cells	  isolated	  from	  both	  in	  vitro	  culture	  system	  (Figure4.3.A)	  and	  in	  vivo	  E10.5	   AGM	   region	   (Figure4.3.B)	   showed	   high	   expression	   for	   Acvrl1,	   Tgfbr1	   and	   mid	  expression	  of	  Tgfbr2.	  Interestingly,	  their	  expression	  levels	  change	  when	  the	  endothelial	  cells	  go	  through	  EHT,	  either	  after	  culture	  of	  those	  cells	  (Figure4.3.C)	  or	  only	  comparing	  the	  different	  subsets	  of	  endothelial	  cells	  going	  through	  EHT	  in	  vivo	  (Figure4.3.D).	  Both	  in	  vivo	  and	  in	  vitro	  experiments	  conclude	  that	  the	  receptor	  type	  I,	  Acvrl1	  expression	  is	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dramatically	   decreasing,	   and	   its	   binding	   partner	   type	   II	   receptor,	   Tgfbr2	   is	   slightly	  reduced	  in	  cells	  going	  towards	  EHT.	  However,	  the	  other	  type	  I	  receptor,	  Tgfbr1	  doesn’t	  show	  an	  apparent	  gene	  expression	  change	  in	  the	  course	  of	  EHT.	  This	  result	  may	  indicate	  an	   initial	   role	   of	  Acvrl1	   gene	   in	   endothelial	   cells	   but	   then	   it	   is	   down-­‐regulated	  during	  EHT.	   This	   would	   reduce	   the	   TGFβ	   ligand	   binding	   to	   Acvrl1	   while	   the	   cells	   would	  respond	  mostly	  via	  the	  Tgfbr1	  changing	  the	  type	  of	  TGFβ	  response.	  While	  the	  inhibition	  of	  the	  pathway	  is	  positively	  regulating	  the	  EHT	  as	  we	  concluded	  in	  the	  first	  part,	  down-­‐regulation	   of	   the	   crucial	   Acvrl1	   gene	   might	   be	   a	   part	   of	   TGFβ	   pathway	   inhibitory	  program	  in	  the	  course	  of	  normal	  EHT.	  
3.2. TGFβ 	  pathway	  activation	  is	  inhibiting	  EHT	  Secondly,	   we	   tested	   the	   activation	   of	   TGFβ	   pathway	   by	   adding	   TGFβ2	   ligand	   and	  inhibition	   by	   adding	   SB431542,	   an	   inhibitor	   of	   ALK5	   receptor	   function	   (Figure4.4.A).	  Upon	  TGFβ2	  treatment	  for	  3	  days,	  it	  resulted	  in	  a	  dramatic	  decrease	  of	  CD41	  expressing,	  round,	  hematopoietic	  progenitor	  cell	  population	  (Figure	  4.4	  and	  Figure	  4.5).	  Combining	  the	   same	   experiments	   with	   3	   biological	   replicates	   confirmed	   the	   results	   that	   TGFβ2	  treatment	   is	   inhibiting	   EHT.	   On	   the	   other	   hand,	   treatment	   with	   inhibitor	   SB431542	  gives	   rise	   to	   more	   round	   cells	   with	   CD41	   expression	   (Figure	   4.4	   and	   Figure	   4.5).	   All	  together,	   our	   data	   indicates	   that	   TGFβ	   inhibition	   is	   promoting	   EHT	   and	   resulting	   in	  more	  HP	  cells.	  A	  study	  done	  on	  human	  ES	  cell	   in	  vitro	  differentiation	  culture	  came	  up	  with	   the	   same	   results.	   When	   TGFβ	   inhibitor	   SB431542	   is	   added,	   they	   observed	  generation	  of	  more	  HP	  cells	  (C.	  Wang	  et	  al.,	  2012).	  As	  an	  exploitation	  of	  these	  findings,	  the	  Alk5	  inhibitor,	  SB431542,	   is	  also	  added	  into	  the	  culture	  medium	  to	   improve	  the	   in	  vitro	  hematopoietic	  differentiation	  system.	  
3.3. TGFβ 	  pathway	  activation	  on	  endothelial	  cells	  promotes	  mesenchymal	  fate	  Finally	  we	   analyzed	   the	   resulting	   gene	   expression	  pattern	   after	   cells	   are	   activated	  for	  TGFβ	  signaling,	  to	  get	  better	  understanding	  of	  the	  nature	  of	  TGFβ	  activated	  cells	  with	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flat,	  adherent	  cell	  morphology.	  The	  microarray	  results	  of	  TGFβ	  activated	  versus	  control	  experiment	   indicates	   cardiac/muscle,	   mesenchymal,	   and	   endothelial	   cell-­‐like	   gene	  expression	  profile	   (Figure	  4.6,	  4.7	  and	  4.8).	  Similar	  profile	   is	  also	  supported	  by	  higher	  expression	  of	  EndMT	  related	  Acta2,	  Cdh2,	  Serpine1	  gene	  expressions	  in	  single	  cell	  qRT-­‐PCR	  experiment	  (Figure4.9).	  	  
4. Conclusion	  and	  Future	  Directions	  Our	  findings	  in	  general	  are	  indicating	  an	  inhibitory	  effect	  of	  TGFβ	  pathway	  in	  EHT,	  actually	   opposing	  our	   initial	   hypothesis.	  Here	  we	  provide	   evidence	   that	   actually	  TGFβ	  activation	  in	  endothelial	  cells	  through	  Tgfbr1	  (Alk5)	  is	  giving	  rise	  to	  mesenchymal-­‐like	  cell	   fate.	   On	   the	   other	   hand,	   inhibition	   of	   the	   pathway	   through	   Tgfbr1	   (Alk5)	   is	  promoting	  EHT	  (Figure	  4.10).	  	  
	  
	  
Figure	  4.10	  The	  proposed	  model	  about	  the	  regulatory	  role	  of	  TGFβ 	  signaling	  on	  EHT	  and	  EndMT.	  
For	   future	   directions,	   better	   understanding	   of	   the	   down-­‐stream	   targets	   of	   the	  pathway	   inhibition	  and	  activation	   is	  needed.	  Specifically,	  a	  Western	  Blot	  and	   immuno-­‐fluorescent	  staining	  for	  Smad	  proteins	  would	  be	  informative.	  Also	  a	  different	  inhibition	  system	   might	   be	   useful	   to	   eliminate	   possible	   un-­‐specific	   binding	   effects	   of	   small	  molecule	  inhibitor	  SB431542.	  Finally	  it	  would	  be	  interesting	  to	  see	  the	  TGFβ	  inhibition	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effect	  on	  EHT	  happening	  in	  vivo	  tissues.	  Triggering	  the	  pathway	  in	  a	  short	  time	  window	  for	   only	   hemogenic	   endothelial	   cells	   with	   no	   exclusive	   cell	   marker	   would	   be	   very	  challenging.	  An	  alternative	  test	  would	  be	  ex	  vivo	  AGM	  explant	  culture	  with	  the	  inhibitor	  SB431542	  and	  testing	  the	  emergence	  of	  hematopoietic	  progenitors.	  
Activation	   of	   the	   mesenchymal	   cell	   fate	   through	   Alk5	   would	   be	   interesting	   to	  investigate.	   Additional	   experiments	   to	   explore	   the	   cell	   fate	   decision	   upon	  TGFβ	   signal	  activation	  would	  enlighten	  the	  molecular	  mechanism	  of	  EndMT.	  With	   that	  aim,	  we	  are	  planning	   to	   explore	   the	   direct	   protein	   synthesis	   targets	   of	   TGFβ2	   treatment	   after	  6hours.	   Through	   a	   collaboration	   with	   Dr.	   Jeroen	   Krijsveld	   (EMBL	   Heidelberg)	   we	  successfully	   identified	   secreted	  proteins	  upon	  TGFβ	   activation	  and	  we	  are	  planning	   to	  identify	   the	   proteins	   changing	   after	   TGFβ	   activation	   in	   the	   intracellular	   compartment.	  The	   technique	  developed	   in	  Dr.	  Krijgsveld’s	   lab	  made	   it	  possible	   to	   label	   the	  complete	  set	   of	   synthesized	   and	   secreted	   proteins	   by	   using	   amino-­‐acids	   with	   different	   weight	  isotopes(Hughes	   &	   Krijgsveld,	   2012).	   The	   comparison	   between	   proteome	   and	   cDNA	  microarray	  data	  would	  allow	  us	  to	  identify	  the	  direct	  targets	  of	  TGFβ	  activation.	  	  
Our	   study	   is	   putting	   forward	   the	   notion	   of	   exquisite	   regulation	   of	   endothelial	   cell	  transitions	   by	   TGFβ	   signaling	   towards	   mesenchymal	   or	   hematopoietic	   fate.	   Several	  articles	   in	   the	   literature	   have	   shown	   that	   the	   balance	   between	  which	   type	   I	   receptor	  activations	   seems	   to	   be	   a	   very	   delicate	   regulatory	   switch	   during	   development.	  Specifically	  for	  hematopoieisis,	  the	  role	  of	  Endoglin	  (Eng),	  the	  ancillary	  receptor	  of	  TGFβ	  family,	  has	  been	  studied	  widely.	  Eng	  -­‐/-­‐	  mESCs	  showed	  reduced	  hematopoiesis	  in	  the	  EB	  and	   blast	   culture	   (Perlingeiro,	   2007),	   as	   well	   as	   in	   hematopoietic	   progenitor	   culture	  (Baik,	  Borges,	  Magli,	  Thatava,	  &	  Perlingeiro,	  2012).	   	  This	  decreased	  hemangioblast	  and	  hematopoietic	  development	  of	  Eng-­‐/-­‐	  cells	  can	  be	  rescued	  by	  activation	  of	  Acvrl1	  (Alk1),	  on	  the	  other	  hand	  Alk5	  activation	  leads	  to	  the	  inhibition	  of	  hematopoiesis	  (L.	  Zhang	  et	  al.,	   2011)	   .	   As	   it	   was	   reported	   previously	   (Oh	   et	   al.,	   2000),	   different	   type	   I	   receptors	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function	   through	   specific	   R-­‐Smad	   transduction,	  which	   result	   in	   distinct	   differentiation	  programs.	  Another	  study	  on	  in	  vitro	  cultured	  mES	  cells	  showed	  the	  inhibitory	  effect	  of	  TGFβ1	  and	  promoting	  effect	  of	  Activin	  A	  (another	  TGFβ	  family	  ligand)	  on	  hematopoiesis	  (Park	  et	  al.,	  2004).	  All	  together,	  our	  study	  confirm	  that	  TGFβ	  signalling	  through	  Alk5	  is	  inhibiting	   hematopoiesis	   but	   our	   data	   is	   novel	   for	   showing	   the	  Alk5	   inhibition	   during	  EHT	   with	   specifically	   on	   HE	   cells	   and	   its	   promoting	   effect	   toward	   mesenchymal	  phenotype.	   Here	   we	   also	   provide	   detailed	   gene	   expression	   when	   the	   down-­‐stream	  mesenchymal	  or	  hematopoietic	  differentiation	  programs	  are	  triggered.	  This	  knowledge	  not	  only	  reveals	  a	  developmental	  mechanism	  but	  also	  hold	  a	  promise	  for	  future	  usage	  in	  stem	  cell	  manipulations.	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General	  Conclusion	  and	  Future	  Perspectives	  In	   the	  mouse	  development,	   the	   first	   hematopoietic	   progenitors	   are	   detected	   at	   E8	  yolk	   sac.	   Those	   progenitor	   cells	   can	   only	   differentiate	   into	   primitive	   erythroid	   cells	  (Palis	  et	  al.,	  1999).	  Later	  during	  the	  development,	  at	  E10	  stage,	  definitive	  hematopoietic	  progenitor	   cells	   with	   myeloid	   and	   lymphoid	   potential	   arise	   from	   the	   aorta-­‐gonad-­‐mesonephros	   (AGM)	   region	   (	   Medvinsky	   &	   Dzierzak,	   1996).	   Cell	   tracing	   experiments	  show	   that	   both	   primitive	   and	   definitive	   hematopoietic	   progenitors	   are	   actually	  differentiated	   from	   endothelial	   cells	   (Jaffredo	   et	   al.,	   1998).	   These	   special	   endothelial	  cells	   bear	   not	   only	   endothelial	   markers	   and	   morphology	   but	   they	   also	   express	   early	  hematopoietic	  genes.	  Due	  to	  their	  distinctive	  features	  from	  other	  endothelial	  cells,	  they	  have	   been	   named	   hemogenic	   endothelium	   (HE)	   (Eilken	   et	   al.,	   2009).	   To	   become	  hematopoietic	   progenitors	   (HP),	   HE	   cells	   lose	   their	   endothelial	   features,	   while	  expressing	   hematopoietic	  markers	   coupled	  with	   some	  morphological	   changes	   such	   as	  detaching	  from	  the	  endothelial	  layer	  and	  having	  small	  and	  round	  shape.	  It	  is	  now	  well-­‐accepted	   concept	   that	   the	   endothelial	   to	   hematopoietic	   transition	   (EHT)	   is	   a	   key	  developmental	  event	  leading	  to	  the	  formation	  of	  blood	  stem	  and	  progenitor	  cells	  during	  embryogenesis	  (Lancrin	  et	  al.,	  2009).	  
Understanding	   the	   cellular	   heterogeneity	   of	   cells	   during	   EHT	   is	   very	   important	   to	  decipher	   its	   molecular	   program.	   To	   achieve	   that	   aim,	   we	   used	   the	   single	   cell	   gene	  expression	   analysis	   approach.	   This	   technique	   allowed	   us	   to	   see	   the	   heterogeneity	   in	  transcriptional	  level.	  	  Such	  a	  detailed	  gene	  expression	  profiling	  on	  the	  EHT	  populations	  have	   never	   been	   achieved,	   due	   to	   the	   technical	   obstacles.	   Here	   we	   identified	   6	  populations	   in	   the	   embryonic	   hematopoiesis	   by	   using	   single	   cell	   qRT-­‐PCR	   technique,	  which	  put	  forward	  exciting	  information	  about	  the	  cell	  characteristics.	  Based	  on	  the	  gene	  expression	   signature	   of	   those	   populations,	   in	   the	   future,	   we	   will	   identify	   definitive	  markers	   for	   isolation	   those	   populations.	   Moreover,	   by	   applying	   reverse	   genetic	  approach	   such	   as	   CRISPR/Cas9	   (H.	   Wang	   et	   al.,	   2013),	   we	   can	   study	   the	   biological	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functions	  of	   these	  genes	  during	  EHT.	  Ultimately,	  we	  aim	  to	  define	   those	  6	  populations	  and	  their	  relevant	  function	  in	  the	  mouse	  hematopoiesis.	  
Understanding	   the	   mechanism	   of	   endothelial	   to	   hematopoietic	   transition	   is	  interesting	  not	  only	  it	  generates	  one	  of	  the	  vital	  tissues	  of	  mammals,	  but	  it	  also	  holds	  a	  great	   potential	   of	   use	   in	   therapeutic	   applications,	   such	   as	   blood	   generation	   by	  differentiating	  induced	  pluripotent	  stem	  cells	  based	  on	  the	  information	  gathered	  about	  mechanism	   of	   EHT.	   Considering	   the	   fact	   that	   TGFβ	   signaling	   triggers	   a	   similar	   event	  during	   heart	   development	   called	   endothelial	   to	  mesenchymal	   transition	   (EndMT),	   we	  hypothesized	   that	   TGFβ	   activity	   should	   play	   a	   similar	   role	   in	   EHT	   as	   well.	   Our	   data	  suggest	   that	   the	  activation	  of	   the	  TGFβ	  pathway	  via	  Tgfbr1	  (Alk5)	   is	  blocking	   the	  EHT	  but	   it	   is	   promoting	   the	   differentiation	   towards	   mesenchymal	   cell	   type,	   so	   it	   favors	  EndMT.	  Although	  both	  EndMT	  and	  EHT	  lead	  to	  a	  loss	  of	  endothelial	  cell	  identity	  and	  the	  generation	  of	  mobile	  cells,	  our	  study	  suggests	  that	  the	  TGF	  signaling	  has	  opposite	  effects	  on	  both.	  
Current	  literature	  defines	  the	  HE	  and	  PreHP	  cells	  roughly	  depending	  on	  a	  couple	  of	  surface	   markers	   and	   inform	   only	   about	   the	   role	   of	   a	   few	   transcriptional	   regulators	  during	   EHT.	   Yet,	   there	   are	   a	   lot	   of	   important	   scientific	   questions	   about	   the	   precise	  identity	  of	  the	  cells	  during	  EHT	  and	  their	  mechanism	  left	  un-­‐answered.	  	  During	  my	  PhD	  period	   I	   sought	   out	   answers	   of	   these	   questions.	   I	   have	   searched	   for	   a	   connection	  between	   functional	  heterogeneity	   and	  heterogeneous	  gene	  expression	  patterns,	  which	  may	  reveal	   the	  stringent	  EHT	  program.	  Additionally,	   I	  have	   investigated	  the	  molecular	  mechanism	  through	  TGFβ	  signaling	  in	  terms	  of	  cell	  fate	  decision	  towards	  hematopoietic	  or	  mesenchymal	  cell	  type.	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Appendix 
Table	  5.8.	  	  The	  list	  of	  96	  genes	  used	  to	  see	  in	  single	  cell	  qPCR	  expression.	  The	  classification	  
indicates	  the	  reason	  to	  be	  selected.	  
Gene	  name	   ENSEMBL	  Gene	  ID	   Long	  Gene	  Name	   Classification	  PPIA	   ENSMUSG00000071866	   peptidylprolyl	  isomerase	  A	   Reference	  gene	  ACTA2	   ENSMUSG00000035783	   actin,	  alpha	  2,	  smooth	  muscle,	  aorta	   EMT	  related	  ACVR1	   ENSMUSG00000026836	   activin	  A	  receptor,	  type	  1	   TGFB	  or	  BMP	  pathway	  ACVR1B	   ENSMUSG00000000532	   activin	  A	  receptor,	  type	  1B	   TGFB	  or	  BMP	  pathway	  ACVR2A	   ENSMUSG00000052155	   activin	  receptor	  IIA	   TGFB	  or	  BMP	  pathway	  ACVR2B	   ENSMUSG00000061393	   activin	  receptor	  IIB	   TGFB	  or	  BMP	  pathway	  ACVRL1	   ENSMUSG00000000530	   activin	  A	  receptor,	  type	  II-­‐like	  1	   TGFB	  or	  BMP	  pathway	  ADCY4	   ENSMUSG00000022220	   adenylate	  cyclase	  4	   common	  target	  of	  Runx1	  and	  Gfi1	  ATP2A3	   ENSMUSG00000020788	   ATPase,	  Ca++	  transporting,	  ubiquitous	   common	  target	  of	  Runx1	  and	  Gfi1	  BMP4	   ENSMUSG00000021835	   bone	  morphogenetic	  protein	  4	   TGFB	  or	  BMP	  pathway	  BMPR1A	   ENSMUSG00000021796	   bone	  morphogenetic	  protein	  receptor,	  type	  1A	   TGFB	  or	  BMP	  pathway	  BMPR2	   ENSMUSG00000067336	   bone	  morphogenic	  protein	  receptor,	  type	  II	  (serine/threonine	  kinase)	   TGFB	  or	  BMP	  pathway	  
CACNA2D1	   ENSMUSG00000040118	   calcium	  channel,	  voltage-­‐dependent,	  alpha2/delta	  subunit	  1	   common	  target	  of	  Runx1	  and	  Gfi1	  CDH2	   ENSMUSG00000024304	   cadherin	  2	   EMT	  related	  CDH5	   ENSMUSG00000031871	   cadherin	  5	   Endothelial	  gene,	  common	  target	  of	  Runx1	  and	  Gfi1	  CLDN5	   ENSMUSG00000041378	   claudin	  5	   Endothelial	  genes	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COL4A2	   ENSMUSG00000031503	   collagen,	  type	  IV,	  alpha	  2	   common	  target	  of	  Runx1	  and	  Gfi1	  COL4A5	   ENSMUSG00000031274	   collagen,	  type	  IV,	  alpha	  5	   common	  target	  of	  Runx1	  and	  Gfi1	  CTNNB1	   ENSMUSG00000006932	   catenin	  (cadherin	  associated	  protein),	  beta	  1	   EMT	  related	  DCAF12L1	   ENSMUSG00000045284	   DDB1	  and	  CUL4	  associated	  factor	  12-­‐like	  1	   common	  target	  of	  Runx1	  and	  Gfi1	  DPYSL3	   ENSMUSG00000024501	   dihydropyrimidinase-­‐like	  3	   common	  target	  of	  Runx1	  and	  Gfi1	  ENG	   ENSMUSG00000026814	   Endoglin	   Endothelial	  gene,	  TGFB	  or	  BMP	  pathway	  ENPP1	   ENSMUSG00000037370	   ectonucleotide	  pyrophosphatase/phosphodiesterase	  1	   common	  target	  of	  Runx1	  and	  Gfi1	  EPO	   ENSMUSG00000029711	   Erythropoietin	   Hematopoietic	  genes	  EPOR	   ENSMUSG00000006235	   erythropoietin	  receptor	   Hematopoietic	  genes	  EPS8	   ENSMUSG00000015766	   epidermal	  growth	  factor	  receptor	  pathway	  substrate	  8	   common	  target	  of	  Runx1	  and	  Gfi1	  ERG	   ENSMUSG00000040732	   avian	  erythroblastosis	  virus	  E-­‐26	  (v-­‐ets)	  oncogene	  related	   Endothelial	  gene,	  Transcription	  factors	  ESAM	   ENSMUSG00000001946	   endothelial	  cell-­‐specific	  adhesion	  molecule	   Endothelial	  genes,	  common	  target	  of	  Runx1	  and	  Gfi1	  FAM122B	   ENSMUSG00000036022	   family	  with	  sequence	  similarity	  122,	  member	  B	   common	  target	  of	  Runx1	  and	  Gfi1	  FBN1	   ENSMUSG00000027204	   fibrillin	  1	   Endothelial	  genes,	  common	  target	  of	  Runx1	  and	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Gfi1	  
FLI1	   ENSMUSG00000016087	   Friend	  leukemia	  integration	  1	   Transcription	  factors	  FLRT2	   ENSMUSG00000047414	   fibronectin	  leucine	  rich	  transmembrane	  protein	  2	   common	  target	  of	  Runx1	  and	  Gfi1	  FMO1	   ENSMUSG00000040181	   flavin	  containing	  monooxygenase	  1	   common	  target	  of	  Runx1	  and	  Gfi1	  GATA1	   ENSMUSG00000031162	   GATA	  binding	  protein	  1	   Hematopoietic	  genes,	  Transcription	  factors	  GATA2	   ENSMUSG00000015053	   GATA	  binding	  protein	  2	   Hematopoietic	  genes,	  Transcription	  factors	  GDPD5	   ENSMUSG00000035314	   glycerophosphodiester	  phosphodiesterase	  domain	  containing	  5	   common	  target	  of	  Runx1	  and	  Gfi1	  GFI1	   ENSMUSG00000029275	   growth	  factor	  independent	  1	   Hematopoietic	  genes,	  Transcription	  factors	  GFI1B	   ENSMUSG00000026815	   growth	  factor	  independent	  1B	   Hematopoietic	  genes,	  Transcription	  factors	  GPR126	   ENSMUSG00000039116	   G	  protein-­‐coupled	  receptor	  126	   Endothelial	  genes,	  common	  target	  of	  Runx1	  and	  Gfi1	  GRIA4	   ENSMUSG00000025892	   glutamate	  receptor,	  ionotropic,	  AMPA4	  (alpha	  4)	   common	  target	  of	  Runx1	  and	  Gfi1	  HBB-­‐B1	   ENSMUSG00000073940	   hemoglobin,	  beta	  adult	  major	  chain	   Hematopoietic	  genes	  HBB-­‐BH1	   ENSMUSG00000052217	   hemoglobin	  Z,	  beta-­‐like	  embryonic	  chain	   Hematopoietic	  genes	  ITGA2B	   ENSMUSG00000034664	   integrin	  alpha	  2b	   Hematopoietic	  genes	  ITGAM	   ENSMUSG00000030786	   integrin	  alpha	  M	   Hematopoietic	  genes	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ITGB3	   ENSMUSG00000020689	   integrin	  beta	  3	   Endothelial	  genes	  KDR	   ENSMUSG00000062960	   kinase	  insert	  domain	  protein	  receptor	   Hematopoietic	  genes	  KIT	   ENSMUSG00000005672	   kit	  oncogene	   Hematopoietic	  genes	  LAD1	   ENSMUSG00000041782	   Ladinin	   common	  target	  of	  Runx1	  and	  Gfi1	  LAT	   ENSMUSG00000030742	   linker	  for	  activation	  of	  T	  cells	   common	  target	  of	  Runx1	  and	  Gfi1	  LGR5	   ENSMUSG00000020140	   leucine	  rich	  repeat	  containing	  G	  protein	  coupled	  receptor	  5	   common	  target	  of	  Runx1	  and	  Gfi1	  LMO2	   ENSMUSG00000032698	   LIM	  domain	  only	  2	   Transcription	  factors	  LYL1	   ENSMUSG00000034041	   lymphoblastomic	  leukemia	  1	   Hematopoietic	  genes,	  Transcription	  factors	  MEIS2	   ENSMUSG00000027210	   Meis	  homeobox	  2	   Endothelial	  genes,	  Transcription	  factors,	  common	  target	  of	  Runx1	  and	  Gfi1	  MET	   ENSMUSG00000009376	   met	  proto-­‐oncogene	   common	  target	  of	  Runx1	  and	  Gfi1	  MPO	   ENSMUSG00000009350	   myeloperoxidase	   Hematopoietic	  genes	  MYB	   ENSMUSG00000019982	   myeloblastosis	  oncogene	   Hematopoietic	  genes,	  Transcription	  factors,	  common	  target	  of	  Runx1	  and	  Gfi1	  MYOM1	   ENSMUSG00000024049	   myomesin	  1	   common	  target	  of	  Runx1	  and	  Gfi1	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NOTCH1	   ENSMUSG00000026923	   Notch	  1	   Endothelial	  genes,	  common	  target	  of	  Runx1	  and	  Gfi1	  NPR1	   ENSMUSG00000027931	   natriuretic	  peptide	  receptor	  1	   Endothelial	  genes,	  common	  target	  of	  Runx1	  and	  Gfi1	  PALLD	   ENSMUSG00000058056	   palladin,	  cytoskeletal	  associated	  protein	   common	  target	  of	  Runx1	  and	  Gfi1	  PECAM1	   ENSMUSG00000020717	   platelet/endothelial	  cell	  adhesion	  molecule	  1	   Endothelial	  genes	  PCDH12	   ENSMUSG00000024440	   protocadherin	  12	   Endothelial	  genes,	  common	  target	  of	  Runx1	  and	  Gfi1	  PDZD2	   ENSMUSG00000022197	   PDZ	  domain	  containing	  2	   common	  target	  of	  Runx1	  and	  Gfi1	  PLCD1	   ENSMUSG00000010660	   phospholipase	  C,	  delta	  1	   common	  target	  of	  Runx1	  and	  Gfi1	  PPP1R16B	   ENSMUSG00000037754	   protein	  phosphatase	  1,	  regulatory	  (inhibitor)	  subunit	  16B	   common	  target	  of	  Runx1	  and	  Gfi1	  PTPRB	   ENSMUSG00000020154	   protein	  tyrosine	  phosphatase,	  receptor	  type,	  B	   Endothelial	  genes,	  common	  target	  of	  Runx1	  and	  Gfi1	  PTPRC	   ENSMUSG00000026395	   protein	  tyrosine	  phosphatase,	  receptor	  type,	  C	   Hematopoietic	  genes	  
PTPRM	   ENSMUSG00000033278	   protein	  tyrosine	  phosphatase,	  receptor	  type,	  M	   Endothelial	  genes,	  common	  target	  of	  Runx1	  and	  Gfi1	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RAMP2	   ENSMUSG00000001240	   receptor	  (calcitonin)	  activity	  modifying	  protein	  2	   Endothelial	  genes	  RUNX1	   ENSMUSG00000022952	   runt	  related	  transcription	  factor	  1	   Hematopoietic	  genes,	  Transcription	  factors	  SAMD4	   ENSMUSG00000021838	   sterile	  alpha	  motif	  domain	  containing	  4	   common	  target	  of	  Runx1	  and	  Gfi1	  SASH1	   ENSMUSG00000015305	   SAM	  and	  SH3	  domain	  containing	  1	   common	  target	  of	  Runx1	  and	  Gfi1	  SERPINE1	   ENSMUSG00000037411	   serine	  (or	  cysteine)	  peptidase	  inhibitor,	  clade	  E,	  member	  1	   EMT	  related	  
SFPI1	   ENSMUSG00000002111	   SFFV	  proviral	  integration	  1	   Hematopoietic	  genes,	  Transcription	  factors	  SHE	   ENSMUSG00000046280	   src	  homology	  2	  domain-­‐containing	  transforming	  protein	  E	   common	  target	  of	  Runx1	  and	  Gfi1	  SLA	   ENSMUSG00000022372	   src-­‐like	  adaptor	   Hematopoietic	  genes,	  common	  target	  of	  Runx1	  and	  Gfi1	  SMAD1	   ENSMUSG00000031681	   SMAD	  family	  member	  1	   TGFB	  or	  BMP	  pathway	  SMAD2	   ENSMUSG00000024563	   SMAD	  family	  member	  2	   TGFB	  or	  BMP	  pathway	  SMAD3	   ENSMUSG00000032402	   SMAD	  family	  member	  3	   TGFB	  or	  BMP	  pathway	  SMAD4	   ENSMUSG00000024515	   SMAD	  family	  member	  4	   TGFB	  or	  BMP	  pathway	  SMAD5	   ENSMUSG00000021540	   SMAD	  family	  member	  5	   TGFB	  or	  BMP	  pathway	  SMAD6	   ENSMUSG00000036867	   SMAD	  family	  member	  6	   TGFB	  or	  BMP	  pathway	  SMAD7	   ENSMUSG00000025880	   SMAD	  family	  member	  7	   TGFB	  or	  BMP	  pathway	  SMAD9	   ENSMUSG00000027796	   SMAD	  family	  member	  9	   TGFB	  or	  BMP	  pathway	  SNAI1	   ENSMUSG00000042821	   snail	  family	  zinc	  finger	  1	   Transcription	  factors,	  EMT	  related	  SNAI2	   ENSMUSG00000022676	   snail	  family	  zinc	  finger	  2	   Transcription	  factors,	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EMT	  related	  
SOX7	   ENSMUSG00000063060	   SRY	  (sex	  determining	  region	  Y)-­‐box	  7	   Endothelial	  genes,	  Transcription	  factors	  TAL1	   ENSMUSG00000028717	   T-­‐cell	  acute	  lymphocytic	  leukemia	  1	   Hematopoietic	  genes,	  Transcription	  factors	  TEK	   ENSMUSG00000006386	   endothelial-­‐specific	  receptor	  tyrosine	  kinase	   Endothelial	  genes	  TGFB1	   ENSMUSG00000002603	   transforming	  growth	  factor,	  beta	  1	   TGFB	  or	  BMP	  pathway,	  EMT	  related	  TGFB2	   ENSMUSG00000039239	   transforming	  growth	  factor,	  beta	  2	   TGFB	  or	  BMP	  pathway,	  EMT	  related	  TGFB3	   ENSMUSG00000021253	   transforming	  growth	  factor,	  beta	  3	   TGFB	  or	  BMP	  pathway,	  EMT	  related	  TGFBR1	   ENSMUSG00000007613	   transforming	  growth	  factor,	  beta	  receptor	  I	   TGFB	  or	  BMP	  pathway,	  EMT	  related	  TGFBR2	   ENSMUSG00000032440	   transforming	  growth	  factor,	  beta	  receptor	  II	   TGFB	  or	  BMP	  pathway,	  EMT	  related	  THPO	   ENSMUSG00000022847	   Thrombopoietin	   Hematopoietic	  genes	  UPP1	   ENSMUSG00000020407	   uridine	  phosphorylase	  1	   common	  target	  of	  Runx1	  and	  Gfi1	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